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Practical approaches for the treatment of chronic heart failure: 
Frequently asked questions, overlooked points and
controversial issues in current clinical practice
Heart failure (HF) is a progressive disorder associated with impaired quality of life, high morbidity, mortality and frequent hospitalization and 
affects millions of people from all around the world. Despite further improvements in HF therapy, mortality and morbidity remains to be very 
high. The life-long treatment, frequent hospitalization, and sophisticated and very expensive device therapies for HF also leads a substantial 
economic burden on the health care system. Therefore, implementation of evidence-based guideline-recommended therapy is very important 
to overcome its worse clinical outcomes. However, HF therapy is a long process that has many drawbacks and sometimes HF guidelines cannot 
answers to every question which rises in everyday clinical practice. In this paper, commonly encountered questions, overlooked points, contro-
versial issues, management strategies in grey zone and problems arising during follow up of a HF patient in real life clinical practice have been 
addressed in the form of expert opinions based on the available data in the literature. (Anatol J Cardiol 2015: 15 Suppl 2; 1-60)
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1.0 Introduction – Lale Tokgözoğlu
Heart failure (HF) is one of the most common causes of mor-
tality and hospitalizations in adults and is gradually becoming 
a global epidemic. Currently, approximately 26 million adults 
live with HF in the world. It is estimated that this number will 
increase substantially with aging populations. Even though the 
prevalence is not clearly known in our country, absolute HF 
prevalence in adults was found to be 2.9% in the HAPPY Study 
(1) which is higher than Western countries. 85% of HF patients 
in the U.S. and Europe are 65 years of age or over. The average 
age of HF in our country is lower than that of Europe (2). It is 
estimated that these numbers will rise with our aging population.
Heart failure causes major costs to the healthcare economy 
owing to life-long treatment, frequent hospitalization, and so-
phisticated and very expensive device therapies. Almost 1-3% 
of total healthcare costs are spent for the management of HF in 
Western Europe.
ABSTRACT
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Heart failure is a progressive and irreversible disorder. 
Therefore, prevention of HF is of great importance. Primarily, 
it is required to control the risk factors of HF and the leading 
underlying causes. If the disease has settled in, it is important 
to implement the guidelines recommended therapy. Inadequate 
treatment or incompliance with treatment increases mortality. 
Almost 17-45% of hospitalized HF patients die within one year. 
It is possible to increase survival with compliance to guideline 
recommendations and the right treatment. In these patients, 
treatment is a long process that has many difficulties. The guide-
lines sometimes cannot answers to every question which rises 
in everyday clinical practice regarding problems, controversial 
issues and managing complications. In this grey zone, clinical 
experience comes into prominence in decision-making.
In this paper, we aimed to adress controversial issues, com-
monly encountered questions, overlooked points, new drugs, 
management strategies in grey zone and problems arising dur-
ing follow up of a HF patient in real life clinical practice in the 
form of expert opinions based on the available data in the lit-
erature.
2.0 What are the targets of therapy in heart
failure? – Yüksel Çavuşoğlu
Basic treatment targets in chronic HF are reducing mortality 
and re-hospitalization, relieving symptoms and signs, increasing 
functional capacity and improving quality of life (3, 4). In most of 
the major HF trials, all-cause mortality, mortality from HF, cardio-
vascular mortality and sudden deaths are targeted as primary 
and secondary mortality outcomes. Similarly, in these major HF 
trials, in addition to HF re-hospitalization, cardiovascular hospi-
talization and all-cause hospitalizations were investigated. Al-
though symptom control, functional capacity and quality of life 
have been evaluated as secondary endpoints in many studies, 
they are referred as basic treatment targets in the follow-up of 
these cases. In addition to these basic targets, slowing, stop-
ping or reversing disease progression, controlling congestion, 
reducing the levels of natriuretic peptide levels, increasing peak 
oxygen consumption, providing an increase in a 6-min walk 
distance, providing a decrease in left ventricular systolic and 
diastolic volumes, reducing the emergency service and hospi-
tal admissions are among the targets to be achieved in clinical 
follow-up (Table 1).
3.0 General recommendations – Mehdi Zoghi
3.1 Is salt restriction necessary? If so, how much? 
There is no strong evidence regarding the benefit of salt re-
striction in HF based on randomized, controlled trials. There are 
studies showing that salt restriction is necessary (5), however, 
there is also data showing that it has no benefit. It is suggested 
that a salt-free diet may cause neurohormonal activation in HF. A 
normal salt diet has not been shown to be harmful. However, it is 
generally accepted that excess sodium intake increases hospi-
talization by causing fluid retention in the body.
In a meta-analysis in which six randomized trials were evalu-
ated, very low-sodium diet (1.8 gr/day) was reported to increase 
the rate of all-cause mortality (RR 1.95, 1.66 vs. 2.29) and hos-
pitalization (RR 2.10, 1.67 vs. 2.64). Even though studies in this 
aspect mainly include patients with systolic HF, there are also 
observational studies reporting favorable effects of DASH diet 
on diastolic functions in hypertensive patients who have HF with 
preserved ejection fraction (6).
There is data showing that in patients presenting with acute 
decompensated HF, fluid (maximum 800 mL/day) and sodium 
(maximum 800 mg/day) restriction has no effect on weight-loss 
or clinical improvement (7). Acute HF is a clinical syndrome in 
which various neurohormonal and triggering factors are involved 
in the pathophysiology and salt restriction should not be gener-
alized in all groups in acute HF.
Clinical effect of sodium amount in diet in HF shows a U-
shape curve effect (excess consuming and excess restriction 
are harmful) rather than linear relationship (8). A low salt diet 
is represented by daily sodium consumption of 2-3 grams (1-2 
flat teaspoon of salt). HF guidelines recommend that HF patients 
consume less salt than the normal population (Table 2). Recom-
mendations for the daily amount of sodium consumption vary de-
pending on the type of HF (systolic or diastolic), accompanying 
diseases, New York Heart Association (NYHA) functional class 
and severity of the disease (3). In patients with systemic conges-
tion, salt restriction is strongly recommended.
The American Heart Association restricts daily sodium in-
take with 1.5 gr/day in asymptomatic stage A and B HF patients 
in which hypertension and cardiovascular disease usually play 
a role in etiology. In symptomatic stage C and D HF patients, 
daily sodium intake is recommended to be <3 gr/day (4). Guide-
lines recommendations for daily sodium restriction are shown 
in Table 2.
Table 1. Targets of therapy in heart failure
Basic targets
Controlling symptoms and signs 
Reducing mortality
Reducing re-hospitalization
Increasing functional capacity
Improving quality of life
Clinical targets
Slowing, stopping or reversing disease progression 
Controlling congestion 
Decreasing natriuretic peptide levels
Increasing peak oxygen consumption 
Providing an increase in a 6-min walk distance
Providing a decrease in systolic/diastolic ventricle volumes
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3.2 Daily weight monitoring: How should it be performed? 
In HF patients, ensuring and preserving dry body weight are 
essential in the management of clinical course of the disorder. 
Weight gain due to fluid overload has a special clinical impor-
tance in terms of gradual worsening of symptoms and frequent 
hospitalization. Weight gain is known to increase the risk of hos-
pitalization by 2.77 fold. Therefore, in the course of HF treatment, 
daily weight monitoring (in the morning, after going to the toilet, 
at the same morning hour and with the same weighing scale) 
should be performed; and in patients who have weight gain more 
than 2 kg in 3 days, the diuretic dose should be increased and/
or they should refer to their doctor. Well-educated patients with 
good treatment compliance can maintain their dry body weight 
by increasing and decreasing the diuretic doses according to 
their daily weight monitoring. In HF patients monitoring their 
daily weight regularly, annual hospitalization was shown to have 
decreased significantly (9-11).
3.3 Should fluid restriction be performed? 
There is no data regarding the clinical benefit of routine 
fluid restriction in all patients with HF. Therefore, it is generally 
accepted that there is no need for fluid restriction, except for 
Stage D HF patients, particularly, with hyponatremia, refractory 
congestion or diuretic resistance. In patients in whom fluid re-
striction is considered, daily fluid intake is generally restricted to 
1.5 L/day. However, in patients with hypervolemic hyponatremia, 
daily fluid intake can be restricted up to 0.5-1 L/day. It is also re-
ported that fluid restriction performed based on the body weight 
(30 ml/kg/day in patients <85 kg and 35 ml/kg/day in patients >85 
kg) can prevent the development of thirst sensation (3, 4).
3.4 Regular exercise training programs: How should they 
be performed? 
Regular exercise training programs for 30 minutes a day and 
5 days in a week accompanied by optimal medical therapy have 
favorable effects on HF-related symptoms and survival. In the 
HF-ACTION trial, it was reported that an 11% decrease in all-
cause mortality or hospitalization and a 15% decrease in cardio-
vascular death or HF hospitalization were observed in patients 
who were on aerobic exercise training program 5 days a week. 
Cardiac rehabilitation programs implemented in clinically stable 
patients improve NYHA functional capacity, exercise duration 
and quality of life as well as mortality (4, 12).
4.0 Evidence-based drug therapy – 
Sanem Nalbantgil, Yüksel Çavuşoğlu
4.1 What should the basic drugs and treatment algorithm be?
Drugs that are used in the treatment of HF with reduced ejec-
tion fraction (HF-REF), the efficacy of which has been proven, 
are angiotensin converting enzyme inhibitors (ACEIs)/ARBs, 
BBs, mineralocorticoid receptor antagonists (MRA), ivabradine, 
diuretics, hydralazine and isosorbide dinitrate (H-ISDN) combi-
nation and digoxin (Table 3). It is expected that angiotensin re-
ceptor neprilysin inhibitors (ARNI) will replace ACEIs in the near 
future, based on the strong evidence in reducing mortality and 
re-hospitalization compared to ACEIs.
Angiotensin converting enzyme inhibitors and BBs are drugs 
that have been proven to definitely reduce the mortality and mor-
bidity rates in patients with systolic HF, regardless of HF etiology. 
ARBs are recommended as an alternative in patients who have 
contraindication or intolerance to ACEIs. MRAs, added to the 
ACEI and BB treatments, reduce mortality and hospitalization 
further in patients with NYHA Class II-IV HF. Even though there 
is no evidence showing that they decrease mortality, diuretics 
are basic agents that are used in the treatment of symptomatic 
cases with systemic and pulmonary congestion. Adding MRA to 
the treatment is recommended in patients having uncontrolled 
symptoms despite optimal ACEI and BB treatments. It has been 
shown that adding ivabradine to the treatment in patients with 
ongoing symptoms who are in sinus rhythm with a heart rate 
Anatol J Cardiol 2015; 15 Suppl 2: 1–60
Table 2. Guidelines recommendations for daily sodium restriction
2013 ACCF/AHA <3 gr/day
HFSA 2010 2 gr/day
AHA General <1.4 gr/day
Canadian Cardiovascular Society HF 2012 No recommendation
ESC-HFA 2012 May be beneficial in NYHA Class III and IV patients
ACCF – American College of Cardiology Foundation; AHA – American Heart Association; HFSA – Heart Failure Society of America; HF – Heart failure; ESC – European Society of 
Cardiology, HFA – Heart Failure Association
Table 3. Basic drugs in HF-REF
ACEI* (ARBs)*†
Beta blockers*
MRAs*
Ivabradine*
Hydralazine+isosorbide dinitrate*
Diuretics
Digoxin
ARNIs*
*Proven to have decreased mortality in randomized clinical trials
†ACEIs are the first choice. ARBs are recommended in the case of ACEI inhibitor 
intolerance
ACEIs – angiotensin converting enzyme inhibitors; ARBs – angiotensin receptor block-
ers; ARNIs – angiotensin receptor neprilysin inhibitors; HF-REF – heart failure with 
preserved ejection fraction; MRAs – mineralocorticoid receptor antagonists
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of ≥70 b.p.m reduced cardiovascular mortality or, in particular, 
re-hospitalization. In patients who are still symptomatic, adding 
H-ISDN combination to the treatment is known to provide ben-
efit, particularly in African-Americans. Digoxin which has been 
shown to have no beneficial effect on mortality is used in the 
treatment of HF, mainly in patients with atrial fibrillation (AF), with 
the goal of reducing hospitalizations, relieving symptoms and im-
proving quality of life (Figure 1). ACEIs/ARBs, BBs and MRAs, 
which have been proven to decrease mortality in HF with reduced 
ejection fraction, are recommended as Class I indication by the 
guidelines (3, 4). It has been shown that all these three groups 
of drugs relieve symptoms and improve quality of life, reduce re-
hospitalizations, delay, prevent or reverse the progression of left 
ventricle systolic dysfunction. In patients who have intolerance 
or contraindication to ACEIs/ARBs, H-ISDN is recommended as 
an alternative. Also, in patients who have intolerance or contra-
indication to BBs, ivabradine or digoxin can be used as an alter-
native therapy. In this case, choice of ivabradine in patients with 
elevated heart rate and in sinus rhythm and digoxin in patients 
with normal heart rate or AF seems to be reasonable.
4.2 Which drugs are effective in reducing mortality?
In patients with HF with reduced ejection fraction (HF-REF), 
ACEIs or ARBs, beta-blockers (BBs) and MRAs have been prov-
Çavuşoğlu et al.
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+ +/–
ARNI (LCZ696)
In place of ACEI or ARB in 
patients with NYHA Class 
II-IV and EF <40% to provide 
more clinical benefit vs 
ACEİ in reducing mortality, 
rehospitalization and 
symptoms
ACEI (ARBs in case of 
intolerance to ACEI) 
If there is 
contraindication/
intolerance to ACEI/
ARB, give hydralazine 
and/or nitrate
Beta-blocker
If there is contraindication or 
intolerance to beta-blockers
*If sinus rhythm + heart rate >70 
b.p.m, give ivabradine
* If sinus rhythm + heart rate <70 
b.p.m or AF, give digoxin
Diuretics 
if there are symptoms 
or signs of congestion
Heart failure with reduced ejection fraction
(EF ≤40%)
Symptomatic, NYHA Class II-IV and EF ≤35%
Symptomatic, NYHA Class II-IV and EF ≤35%
If sinus rhythm + heart rate >70 b.p.m
Add ivabradine
Consider digoxin and/or hydralazine and/or nitrate
Evaluate considering CRT-P/CRT-D
If end-stage HF, LVAD and/or transplantation
Symptomatic, NYHA Class II-IV and EF ≤45%
Add an MRA
Figure 1. Treatment algorithm in chronic heart failure
ACEI – angiotensin converting enzyme inhibitor; AF – atrial fibrillation; ARBs – angiotensin receptor blocker; ARNIs – angiotensin receptor neprilysin inhibitors; CRT - cardiac resynchronisation 
therapy; D – defibrillator; EF – ejection fraction; LVAD – left ventricular assist device; MRAs – mineralocorticoid receptor antagonist; NYHA – New York Heart Association; P – pacemaker
en to reduce mortality. ACEIs reduce both mortality and re-hos-
pitalization and have been shown to be effective in all patients 
who have mild, moderate or severe HF with or without coro-
nary artery disease (CAD). Candesartan, valsartan and losartan 
among the ARBs were shown to reduce cardiovascular death or 
hospitalization significantly. However, their efficacy on all-cause 
mortality alone has not been clear (3, 4).
In the BB group; bisoprolol, carvedilol and extended-release 
metoprolol succinate have been demonstrated to decrease all-
cause mortality, cardiovascular mortality, HF-related mortality or 
sudden deaths. Their clinical benefits are observed in female and 
male patients with or without CAD and with or without diabetes 
mellitus (DM). Nebivolol was shown to reduce all-cause mortal-
ity or hospitalization in elderly population (>70 years). However, 
its effect on mortality alone has not been demonstrated (13).
MRAs are the third drug group which is effective on mortality. 
In the RALES Trial (14), spironolactone reduced all-cause mor-
tality, sudden cardiac death and hospitalization. Eplerenone was 
shown to reduce all-cause mortality in patients with both post-
MI HF (15) and NYHA Class II-IV HF-REF (16).
Ivabradine provides a reduction in heart rate by exerting its 
effect through the inhibition of If channels located in the sinus 
node. In patients who have NYHA Class II-IV HF with EF <35%, 
resting heart rate >70 b.p.m. and in sinus rhythm, ivabradine 
treatment added to standard background HF therapy including 
BB, ACEI, MRA and diuretic was shown to significantly reduce 
cardiovascular death or HF hospitalization as well as death from 
HF alone and HF hospitalization alone.
Hydralazine + isosorbide dinitrate combination has been 
shown to reduce mortality and hospitalization in African-Ameri-
cans with NYHA Class III-IV HF and EF ≤45%, who were receiv-
ing diuretic, digoxin, ACEI (ARB), BB and spironolactone therapy. 
In order to reduce the risk of death in patients with left ventricu-
lar EF ≤45% who cannot tolerate ACEIs/ARBs, hydralazine + ni-
trate combination is recommended as Class IIa indication by the 
American College of Cardiology Foundation (ACCF) / American 
Heart Association (AHA) guidelines and Class IIb indication by 
the European Society of Cardiology (ESC) guidelines (3, 4). In the 
ACCF/AHA guidelines, this combination is given as Class I rec-
ommendation to reduce mortality in symptomatic African-Amer-
icans in functional NYHA Class III-IV despite optimal medical 
treatment (4). Drugs with proven effect on mortality are shown 
in Table 4.
In the recent PARADIGM-HF Trial, the ARNI LCZ696 consist-
ing of a new molecule sacubitril (neprilysin inhibitor) and valsar-
tan (ARB) was compared with the enalapril therapy in patients 
with HF-REF. Patients with left ventricular EF ≤40% in NYHA Class 
II-IV were included in this trial and randomized to receive LCZ696 
200 mg b.i.d. or enalapril 10 mg b.i.d.. Due to the favorable ef-
fect of LCZ696 on mortality, the trial was terminated prematurely. 
When compared to enalapril, ARNI was shown to significantly 
reduce primary end-points of cardiovascular (CV) mortality or HF 
hospitalization by 20%, CV mortality alone by 20%, HF hospital-
ization alone by 21% and all-cause mortality by 16%. The most 
frequent side effect was hypotension (17).
No group of drugs has been shown to have significant effect 
on mortality in patients with HF with preserved ejection fraction 
(HF-PEF) to date.
4.3 Does beta-blocker therapy have any effect on mortality 
in atrial fibrillation?
Both ESC and ACCF/AHA guidelines recommend BB therapy 
as Class I recommendation in HF-REF patients. This group of 
drugs reduces both mortality and morbidity. There is no specific 
clinical trial evaluating mortality benefit of beta blocker treat-
ment in patients with AF. However some meta-analyses pub-
lished in literature examined mortality benefit of BB in this group 
of patients. In a meta-analysis in 8,500 HF patients, BB therapy 
was found to have no effect on mortality and much less benefi-
cial effect on re-hospitalization in patients with AF compared 
to patients in sinus rhythm (18). Also, in a recent meta-analysis 
including more than 18,000 patients, BB therapy was shown to 
have no effect on all-cause mortality in HF patients with AF (19). 
Randomized, prospective trials are needed to elucidate the ef-
fect of BBs on mortality in this group of patients. However, in all 
patients who have HF-REF with or without AF, BB therapy should 
be used and continued until this matter is clarified with random-
ized, prospective trials.
4.4 Which drugs are effective on symptoms, quality of life 
and re-hospitalization?
The favorable effects of ACEIs/ARBs, BBs and MRAs on sur-
vival as well as on symptoms, quality of life and hospitalization 
have been proven in major clinical trials. Hydralazine and nitrate 
combination has been shown to be very effective particularly in 
patients who cannot receive ACEIs/ARBs. This beneficial effect 
is more prominent in African-Americans. However, favorable ef-
Table 4. Drug groups in HF-REF and their effects on mortality/morbidity
Drug group Efficacy in mortality / morbidity
  (based on major studies)
ACEIs + (CONSENSUS, SOLVD, SAVE, AIRE, TRACE)
ARBs + (CHARM Alternative, Val-HEFT)
BBs + (US Carvedilol, CIBIS II, MERIT HF,
  COPERNICUS, CAPRICORN)
MRAs + (RALES, EMPHASIS HF)
Ivabradine + (SHIFT)
LCZ 696 + (PARADIGM-HF)
Digoxin ± Hospitalization (DIG)
H + ISDN + (V-HeFT I, V-HeFT II, A-HeFT)
Diuretics ?
ACEIs – angiotensin converting enzyme inhibitors; ARBs – angiotensin receptor
blockers; BBs – beta blockers; H – hydralazine; HF-REF – heart failure with reduced 
ejection fraction; ISDN – isosorbid dinitrate; MRAs – mineralocorticoid receptor 
antagonists
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fects of adding H-ISDN to the current ACEI/ARB therapy are not 
clear in other American populations (20, 21).
Diuretics are also very effective agents in the improvement of 
symptoms and quality of life. All patients with congestion and flu-
id retention should receive diuretic therapy. Even though digoxin 
has no effect on mortality, it is known to be an effective agent 
in symptoms and re-hospitalization. In the DIG Trial, digoxin has 
been demonstrated to reduce the frequency of hospitalization in 
symptomatic HF patients in sinus rhythm (22).
Ivabradine in patients with EF <35%, in sinus rhythm and with 
heart rate >70 b.p.m was not found effective in reducing cardio-
vascular death alone or all-cause mortality alone, however, it 
was shown to reduce cardiovascular death or HF hospitalization 
and also incidence of recurrent hospitalization (23).
4.5 How to select evidence-based drugs in terms of NYHA, 
EF and heart rate? 
According to the ESC and ACCF/AHA guidelines, drug choice 
should be ACEIs/ARBs and BBs in patients with NYHA Class I-IV 
with left ventricular dysfunction, MRAs in patients with NYHA 
Class II-IV, ivabradine in patients with NYHA Class II-IV who are 
in sinus rhythm, with a heart rate >70 b.p.m. and symptomatic 
despite optimal therapy, hydralazine+nitrate combination in Afri-
can-Americans with NYHA Class III-IV who are symptomatic de-
spite optimal treatment, diuretics in patients with NYHA Class II-
IV who have volume overload, and digoxin in patients with NYHA 
Class II-IV who are still symptomatic despite optimal treatment 
(3, 4) (Table 5). Drug selection according to the ejection fraction 
is similar in both guidelines. ACEI/ARB and BB therapy should be 
initiated in every patient with left ventricular EF ≤40%. MRAs can 
be scheduled to be used in patients with EF ≤35%. In patients in 
sinus rhythm with elevated heart rate and EF ≤35% despite the BB 
therapy, the ESC guidelines state that ivabradine therapy can be 
added whereas American guidelines have no recommendation 
about this drug. In patients with EF ≤45% who are symptomatic 
despite optimal treatment, adding digoxin or hydralazine+nitrate 
combination can be considered (3, 4).
ACEIs/ARBs have no effect on heart rate. BB use and dose 
adjustment according to heart rate are important. If the heart 
rate is <60 b.p.m., initiating BB therapy should be avoided. When 
the heart rate becomes <50 b.p.m. during BB use, the drug should 
be discontinued or the dose reduced to half. Adding ivabradine 
should be considered in patients with a heart rate >70 b.p.m. de-
spite optimal BB dose to decrease the heart rate below 70 b.p.m. 
(3). In patients with AF, BBs and, if necessary, digoxin should be 
given to control heart rate (3, 4).
In patients with systolic blood pressure below 80 mm Hg, 
ACEIs/ARBs, BBs and hydralazine-nitrate combination should 
not be given. Ivabradine has no effect on blood pressure. MRAs 
rarely cause a reduction in blood pressure when used in anti-
fibrotic doses used in HF. When adjusting the doses of these 
drugs according to the blood pressure, not only the blood pres-
sure levels but also the symptoms of hypotension should be 
considered.
4.6 Is it possible to discontinue drug therapy if EF improves 
along with symptoms? 
In HF patients in which EF improves along with symptoms, 
there is not enough evidence regarding the management of drug 
therapy. There is limited data concerning drug discontinuation 
after the improvement of ventricular functions in patients with 
acute myocarditis and peripartum cardiomyopathy. Discontinua-
tion of ACEI and BB therapy in chronic HF patients was reported 
to have unfavorable effects on cardiac functions, symptoms and 
end-points (24). In selected patients in whom symptoms and EF 
completely improved, discontinuation of BB and ACEI therapy 
step by step can be reasonable approach by decreasing the dos-
es gradually and monitoring cardiac functions closely.
4.7 Are dose titration intervals and duration the same for 
every drug and patient?
Generally guidelines recommend that ACEI, ARB, BB and 
MRA dose titrations should be performed as doubling the doses 
every 2-4 weeks and initiating with 1/8 of the dose (3, 4). How-
Table 5. Drug therapy according to New York Heart Association functional classification
  Heart failure with reduced ejection fraction
  NYHA I NYHA II NYHA III NYHA IV
ACEI + + + +
ARBs + + + +
BBs + + + +
MRAs – + + +
Ivabradine – + + +
Digoxin – + + +
Diuretics – – + +
Hydralazine+nitrate – – + +
ACEI – angiotensin converting enzyme inhibitor; ARBs – angiotensin receptor blocker; BBs – beta-blockers; MRAs – mineralocorticoid receptor antagonists; NYHA – New York Heart 
Association
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ever, this general recommendation should not be considered as 
an absolute rule to be adhered to for every patient and every 
drug. In clinical trials, generally, the duration of reaching the tar-
get dose or tolerated dose had taken 4 weeks on average with 
ACEIs/ARBs, approximately 6 weeks with BBs and 4-6 weeks 
with MRAs for stable patients. A slower up-titration with BBs 
and slightly faster up-titration with ACEIs/ARBs depending on 
blood pressure and renal functions can be considered. A slightly 
faster up-titration of MRA can be performed according to the 
creatinine and potassium levels tested every 3-7 days. It may be 
appropriate to initiate in a level of 1/4 of the target dose of drugs 
in patients with normal or mildly elevated blood pressure, normal 
renal functions and normal potassium levels. A faster up-titration 
can be considered in NYHA Class I-II patients who are clinically 
stable and asymptomatic. In case of adverse effects, switching 
to one or two previous doses and subsequent up-titration in a 
longer period of time can be considered.
Initial dose of digoxin should be decided according to age, 
weight and renal functions. Loading dose of digoxin is not rec-
ommended. Ideal dose adjustment should be performed with 
plasma digoxin level measurements, if possible. Hydralazine 
and/or nitrate combination is initiated at a very low dose and up-
titration is performed according to the blood pressure response. 
In clinical trials, the decision for up-titration of the hydralazine 
and/or nitrate dose has been left to the discretion of the physi-
cian and when the side effects resolved and blood pressure was 
controlled, the dose was up-titrated (25).
It is recommended to initiate ivabradine as 5 mg b.i.d. and, 
according to the protocol of its clinical trial, to increase to 7.5 
mg b.i.d. depending on the heart rate and side effects of the drug 
after 15 days (26).
4.8 Is it necessary to achieve the target dose for mortality 
benefit?
The basic rule in treatment is to start ACEI/ARB, BB and MRA 
therapies with the lowest dose and to increase to the target dose 
the benefit of which was shown in the clinical trials. The second 
basic rule is to increment the dose to the maximum tolerated 
dose in patients who cannot tolerate the target dose. Another 
important rule is to use these drugs even if in low doses rather 
than not using them at all. There are subgroup analyses support-
ing that mortality benefit is observed even 6.25 mg daily dose of 
carvedilol and 1.25-3.75 mg daily dose of bisoprolol. After initiat-
ing ACEI/ARB therapy, adding BB therapy before achieving the 
target dose is important in terms of mortality and morbidity (27). 
In a clinical trial conducted in Austria, it was demonstrated that 
adjusting treatment in accordance with the guidelines reduced 
all-cause mortality in patients with HF-REF (27). When the study 
group is examined, the percentage of patients who received 
ACEI/ARB, BB and MRA therapies were 90.5%, 87.8% and 42.7%, 
respectively and the percentage of patients receiving drugs in 
target doses was less than 50%. The majority of patients who 
could not achieve target doses with an adjustment of the treat-
ment in accordance with the guidelines at the end of follow-up 
could receive more than 50% of the target doses. Even under 
these circumstances, the favorable effects of therapy were dem-
onstrated. In patients with recurrent hospitalization, ischemic 
cardiomyopathy, renal disorder and advanced age, it was less 
possible to achieve the target doses. Target doses were more 
easily achieved in patients with elevated natriuretic peptide 
levels and hypertensive patients. In another trial conducted in 
Spain, target doses were achieved with ACEI, ARB, BB and MRA 
therapies in 16.2%, 23.3%, 13.2% and 23.5% of the HF patients, 
respectively (28). Even though target doses were not achieved 
after CRT, use of higher doses of neurohumoral blockers had fa-
vorable effects on survival (29). Use of basic drugs even in low 
doses is expected to have favorable effects despite having less 
effect on mortality and morbidity (4).
5.0 Angiotensin converting enzyme inhibitors/
Angiotensin receptor blockers –
Mehmet Eren
5.1 Which ACEIs/ARBs should be chosen?
Although angiotensin converting enzyme inhibitors are ac-
cepted to have a class efficacy in HF, all ACEIs individually do not 
have enough evidence in terms of their effectiveness and safe 
doses supported by randomized-controlled trials. Therefore, it 
is recommended that ACEIs proven to be effective in HF trials 
should be used in HF therapy (Table 6).
It has been demonstrated that morbidity significantly re-
duced with the use of both candesartan (36, 37) and valsartan 
(38) when angiotensin receptor blockers (ARBs) were added 
to the treatment of HF patients with symptomatic reduced left 
ventricular ejection fraction (LVEF) who are intolerant to ACEIs. 
Table 6. ACEIs and their doses with proven efficacy in patients with HF in randomized, controlled trials
ACEIs Patient characteristics Trial Starting dose (mg) Target dose (mg)
Captopril AMI SAVE (30) 3x6.25 3x50
Enalapril CHF CONSENSUS (31), SOLVD (32) 2x2.5 2x10-20
Lisinopril CHF ATLAS (33) 1x2.5-5 1x30-35
Ramipril AMI AIRE (34) 1x2.5 2x5/1x10
Trandolapril AMI TRACE (35) 1x1 1x4
ACEIs – angiotensin converting enzyme inhibitors; AMI – acute myocardial infarction; CHF – chronic heart failure
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Although candesartan has been shown to reduce mortality in 
major trials (36, 37) the mortality effect of valsartan was dem-
onstrated in a small subgroup of Val-HeFT Trial (38) (Table 7). In 
the ELITE-II Trial, the only trial in which ARBs were directly com-
pared to ACEIs in HF, losartan was not found as effective as cap-
topril on mortality and morbidity (39). In this trial, losartan was 
suggested to be less effective than captopril because of its low 
dose. Indeed, in the HEAAL Trial, (40) 150 mg losartan was found 
to be more effective compared to 50 mg losartan in terms of pri-
mary end-point (41). However, there is no comparative trial of 
losartan versus ACEIs or placebo. Therefore, current guidelines 
recommend the use of losartan with a careful consideration.
5.2 Does the history of myocardial infarction affect the 
selection of ACEIs/ARBs? 
It is not known whether ACEIs initiated in the first week af-
ter AMI have class efficacy regarding their clinical benefit. Thus, 
ACEIs proven to be beneficial in clinical trials should be used in 
these patients following myocardial infarction (Table 8).
In the OPTIMAAL (42) which is one of the two trials conduct-
ed with ARB in patients in whom HF developed after myocardial 
infarction, the mortality effect of losartan was lower than capto-
pril whereas in the VALIANT (41), valsartan was found to be as 
effective as captopril. When the valsartan arm in the VALIANT 
Trial was compared to the placebo arm of other trials, the results 
were found to be similar to those of ACEIs. Valsartan is therefore 
a good alternative to ACEIs after myocardial infarction (41, 43).
5.3 What are the alternative therapies if ACE inhibitor/
ARB is contraindicated? 
The contraindications of ACEI and ARB are given in Table 9. 
The side effects of ACEIs are related to either suppression of an-
giotensin or quinine elevation (Table 10). In the cases of quinine 
elevation, ARBs can be a good alternative to ACEIs (36, 38). In 
the cases of angiotensin suppression and pregnancy (44), ARBs 
cannot be prescribed either. In this case a hydralazine-nitrate 
combination can be used (25, 44-46). In non-severe aortic steno-
sis, ACEIs, ARBs and a hydralazine-nitrate combination can be 
used (47). H-ISDN combination is initiated with 37.5/20 mg tid and 
70/40 mg tid target dose is achieved. None of these agents are 
given in the presence of severe aortic stenosis because severe 
hypotension and syncope may develop. In severe aortic stenosis 
with asymptomatic left ventricular dysfunction or symptomatic 
HF, percutaneous or surgical valve replacement or balloon val-
vuloplasty is performed and then ACEIs/ARBs can be used. Oth-
erwise, vasodilator should not be used in severe aortic stenosis.
Table 7. ARBs and their doses with proven efficacy in patients with HF in randomized, controlled trials
ARBs Patient characteristics Trial Starting dose (mg) Target dose (mg)
Candesartan CHF CHARM (36,37) 1x4-8 1x32
Valsartan CHF Val-HeFT (38) 2x40 2x160
Valsartan AMI VALIANT (41) 2x20 2x160
AMI – acute myocardial infarction; ARBs – angiotensin receptor blockers; CHF – chronic heart failure
Table 9. Contraindications for ACEI and ARB use
Contraindications for ACEI Contraindications for ARBs
Bilateral renal artery stenosis Bilateral renal artery stenosis
Pregnancy Pregnancy
Serum creatinine >2.5 mg/dL Serum creatinine >2.5 mg/dL
Serum potassium >5 mEq/L Serum potassium >5 mEq/L
Severe aortic stenosis Severe aortic stenosis
History of angioedema 
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker
Table 8. Randomized ACEI or ARB trials conducted in symptomatic or asymptomatic patients with reduced ejection fraction after myocardial 
infarction
Class Trial Comparison Effect on primary results
ACEI  SAVE (30) Captopril-Placebo 19% reduction
ACEI TRACE (35) Trandolapril-Placebo 22% reduction
ACEI  AIRE (34) Ramipril-Placebo 27% reduction
ARB OPTIMAAL (42) Losartan-Captopril Captopril is better
ARB VALIANT (41) Valsartan-Captopril Captopril and valsartan are similar
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker
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6.0 Beta-blockers – Mehmet Eren
6.1 Which one of the 4 beta-blockers recommended in the 
treatment is better? 
Four BBs (metoprolol succinate, bisoprolol, carvedilol and 
nebivolol) are recommended based on data from major trials 
conducted for the treatment of HF. Since there are no random-
ized trials comparing the BBs used in HF, no superiority can be 
suggested. However, based on the results (Table 11) obtained 
from the trials and on the pharmacological properties of beta-
blockers (Table 12), in certain conditions, some beta-blockers 
may be preferred to others.
Cardioselectivity: Cardioselectivity shows that the drug 
blocks beta-1 receptors primarily. It should be kept in mind that 
all BBs also block beta-2 receptors in high doses. Bisoprolol, 
metoprolol, and nebivolol are less effective on beta-2 receptors. 
Bisoprolol has the highest cardioselectivity. Cardioselective BBs 
are preferred over non-selective ones in chronic bronchitis, DM 
and peripheral arterial disease. It should not be given to patients 
with bronchospasm, however, if it is mandatory, they should be 
used in low doses and very cautiously.
Lipid solubility: Hydrophilic BBs without lipid solubility (e.g. 
atenolol, nadolol and sotalol) cause less side-effects related to 
the central nervous system, such as nightmares, depression, fa-
tigue and impotence since their passage across the blood-brain 
barrier is low. However, agents like carvedilol and metoprolol with 
high lipid solubility are considered more effective in preventing 
cardiac deaths with better blockade of sympathetic discharge 
formed in the hypothalamus (48). Lipophilic BBs are metabolized 
via the liver whereas hydrophilic BBs are renally excreted. The 
beta-blocker with the highest lipophilicity is carvedilol.
Hepatic metabolism: Since lipophilic BBs undergo first-pass 
metabolism in the liver, different blood concentrations may occur 
among patients who receive the same dose and degradation of 
the drug reduces with the use of drugs which reduce the he-
patic blood flow (such as cimetidine) or with liver diseases (such 
Table 10. Main side effects of ACEIs
Side effects related to angiotensin suppression Side effects related to quinine elevation
1. Hypotension 1. Cough
2. Worsening of renal functions 2. Angioedema
3. Hyperkalemia
Table 11. Favorable clinical outcomes obtained from clinical trials on beta-blockers use in HF
Effect Trials Beta-blocker
Reduction in total mortality MERIT-HF (51, 52), CIBIS-II (53), Metoprolol CR/XL, bisoprolol, carvedilol
 COPERNICUS (54) 
Reduction in cardiovascular mortality MERIT-HF, CIBIS-II, COPERNICUS,  Metoprolol CR/XL, bisoprolol, carvedilol
Reduction in cardiovascular mortality  MDC (55), CIBIS-II, MERIT-HF, COPERNICUS, Metoprolol tartrate, Metoprolol CR/XL,
or HF hospitalization US Carvedilol (56), SENIORS (57) bisoprolol, carvedilol, nebivolol
Reduction in HF symptoms CIBIS-II, MERIT-HF, US Carvedilol Metoprolol CR/XL, bisoprolol, carvedilol
Table 12. Pharmacological properties of beta-blockers used in heart failure and their doses
Properties Metoprolol Bisoprolol Carvedilol Nebivolol
B1-blockade ++++ ++++ ++++ ++++
B2-blockade ++ ++ +++ +
A1-blockade 0 0 ++++ 0
ISA 0 0 0 0
Lipid solubility ++ ++ +++ +++
Hepatic elimination ++++ ++ ++++ ++
Half-life 2-6 hours 9-12 hours 6 hours 10 hoursa
Peripheral vasodilation  0 0 + + (with NO)
Anti-oxidant 0 0 + 0
Starting dose (mg) 1x12.5-25 1x1.25 2x3.125 1x1.25
Target dose (mg) 1x200 1x10 2x25-50 1x10
aHalf-life of nebivolol metabolites is 24 hours
ISA – intrensic sympatomimetic activity; NO – nitric oxide
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as cirrhosis). In these cases, dose adjustment of carvedilol and 
metoprolol in particular may be necessary.
Effect on oxidative stress: Another toxic effect of increase in 
catecholamine is the formation of free radicals and damage due to 
oxidative stress (49). In HF, free radicals in circulation contribute 
to the progression of the disease and probably cause apoptosis. 
Carvedilol is known to have antioxidant properties (50). Beta-
blockers except carvedilol should therefore be preferred in severe 
Chronic Obstructive Pulmonary Disease. Since carvedilol provided 
a better improvement in clinical results than metoprolol tartrate in 
the COMET Trial, carvedilol should be used instead of metoprolol 
tartrate (58). As the SENIORS Trial examined the efficacy of nebivo-
lol in elderly patients, nebivolol is a BB which can be preferred in 
the population >70 years (57). The CIBIS-III Trial examined which 
one of the BB (bisoprolol) and ACEI (enalapril) treatments should 
be initiated first in the form of a single drug therapy, and then used 
as a combination. No difference was determined in the results 
(59). If ACEIs are to be added later, bisoprolol is the BB of choice. 
In one meta-analysis, in patients with HF of ischemic origin, meto-
prolol succinate was found to be superior to carvedilol; whereas in 
HF of non-ischemic origin, carvedilol was found to be superior (60).
6.2 How can we determine whether fatigue and exercise 
intolerance are caused by beta-blockers or HF? 
In a meta-analysis examining the side effects of BB use in 
patients with HF, myocardial infarction or hypertension; fatigue 
and exercise intolerance related to BBs were observed in 1.8% 
of patients and 1 in 57 patients treated with BBs for one year 
(61). These side effects were observed less with last generation 
BBs (61). The mechanism of fatigue and exercise intolerance as-
sociated with BB therapy is not fully known. In patients with HF 
receiving BB therapy, development of fatigue or exercise intoler-
ance may originate from the disease itself or the effect of BB 
therapy. In this case, the BB dose should be reduced to half. If 
symptoms improve, the reason is BB and the treatment is con-
tinued with the dose the patient can tolerate. If the symptoms do 
not improve, they are related to the disease and the HF treatment 
should be optimized.
6.3 How should beta-blocker therapy be managed in case 
of impotence?
Normal sexual function occurs as a result of the interaction 
of psychological, hormonal, vascular and neurological factors. 
On the other hand, erection is a vascular phenomenon and nitric 
oxide (NO) plays an important role in this phenomenon (62). Im-
pairment of vascular smooth muscle relaxation developing as a 
result of the NO-cGMP pathway being affected is the final com-
mon pathway leading to erectile dysfunction (63).
It was reported that libido and erectile function are affected 
in three fourths of patients with HF (64). The causes and mecha-
nisms that may lead to erectile dysfunction in HF patient are sum-
marized in Table 13 (65). Erectile dysfunction in patients treated 
with BBs is only 0.5%, not as high as it was believed before (61). 
Although the mechanism of erectile dysfunction with BBs is not 
Table 13. Causes of erectile dysfunction in patients with HF
Causes of HD Mechanisms
Psychological
 Depression Reduced libido
 Performance anxiety Increased sympathetic tonus
 Anti-psychotic drugs Selective serotonin reuptake inhibitors
 Fear
Atherosclerosis Reduced penile artery flow
  Endothelial dysfunction
Cardiovascular exercise intolerance Heart rate incompetence
  Reduced stroke volume
Impaired vessel tonus response  Impaired endothelial independent vasodilation 
  Endothelial dysfunction 
  Elevated endothelin-1
  Elevated noradrenaline
  Reduced prostacycline
HF drugs
 Beta-blockers (some) Not known
 Digoxin Corporal smooth muscle sodium pump inhibition
 Spironolactone Androgen suppression
 Diuretics Not known
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fully known, potentializing corporal smooth muscle contraction 
via alpha-1 receptor may lead to this condition. Carvedilol and 
nebivolol have some advantages in this regard.
The first step in the treatment of HF patients with erec-
tile dysfunction is to optimize HF treatment. If possible, drugs 
causing sexual dysfunction should either be discontinued or 
switched. Digoxin and thiazide diuretics should be discontinued 
and carvedilol or nebivolol should be preferred among BBs. As 
an aldosterone antagonist, eplerenone, which is more selective 
with less androgenic effect, is preferred over spironolactone. If 
complaints continue after these measures, phosphodiesterase-5 
(PDE-5) inhibitors (sildenafil, vardenafil and tadalafil), which is the 
main treatment for erectile dysfunction, should be administered. 
Before initiating these drugs, the patients should be classified as 
mild-, moderate- and high-risk regarding the risks that they may 
experience during sexual intercourse. Most low-risk patients 
have NYHA Class I functional capacity, and PDE-5 inhibitors can 
be safely given. Whereas high-risk patients are NYHA Class III-IV 
or decompensated patients, and sexual intercourse is forbidden 
in this group. After the patients are stabilized, they are reevaluated 
in terms of erectile dysfunction treatment. Moderate-risk patients 
(in NYHA Class II or with asymptomatic left ventricular systolic 
dysfunction) should be evaluated with additional stress tests.
It was demonstrated that sildenafil has been well tolerated 
and improved erectile dysfunction in 25-100 mg doses in patients 
with mild to moderate HF (66). Although such safety or efficacy 
has not been shown with vardenafil and tadalafil, vardenafil can 
be used in solving the problem. However, tadalafil should not be 
used in these patients due to its long half-life.
As a result, sildenafil should be initiated in 25-50 mg doses 
and incremented to 100 mg for the treatment of erectile dysfunc-
tion in patients with HF. These drugs are contraindicated in com-
bination with nitrate or NO donors (nitroprusside, molsidomine) 
as they increase the hypotensive effects of nitrates.
6.4 What are the alternative therapies in the presence of 
beta-blocker contraindication?
Beta-blocker contraindications and adverse events during 
their use are shown in Table 14.
In patients with HF who have contraindication or intolerance 
for BBs, ivabradine or digoxin can be given as an alternative. If 
the patient has AF, only digoxin can be used to slow ventricular 
rate. If the patient is in sinus rhythm, primarily ivabradine and as 
a second alternative digoxin can be given (Table 15) (3).
7.0 Mineralocorticoid receptor antagonists –
Mehmet Eren
7.1 What are the antifibrotic and diuretic doses of MRAs? 
Mineralocorticoid receptor antagonists have both antifi-
brotic and diuretic effects. Spironolactone is used more as a di-
uretic. The doses of 25-50 mg spironolactone used in the RALES 
Trial have a more antifibrotic effect and their diuretic effect is 
minimum at these doses (67). The diuretic effect of spironolac-
tone is observed in doses above 100 mg a day (68).
In HF, there is a reduction in cardiac output, and this leads to 
the activation of renin angiotensin aldosterone system (RAAS), 
sympathetic nervous system and arginine vasopressin and even-
tually volume and salt retention in the body. Therefore, there is a 
hyperaldosteronism in HF. 
Hyperaldosteronism is also present in hepatic cirrhosis. In 
the treatment of ascites in patients with cirrhosis, a primarily 
high dose of spironolactone (200 mg bid) is used; whereas in 
HF, loop diuretics are used primarily for pre-existing congestion. 
However, loop diuretics cause more elevation in hyperaldoste-
ronism. Hyperaldosteronism is known as a risk factor for myo-
cardial and vascular fibrosis. Similar to cirrhosis, high doses of 
spironolactone are expected to be beneficial in HF. In a HF trial 
including a low number of patients, spironolactone treatment at 
doses of 200 mg b.i.d. caused a significant increase in sodium 
elimination with a nonsignificant increase in potassium levels. 
However, more trials are needed on the antifibrotic and clinical 
effects of diuretic doses of spironolactone in HF.
Table 15. Drugs recommended as the alternative therapy of beta-blockers in HF according to the ESC 2012 HF guidelines (3)
Drug Indication Recommendation and evidence level
Ivabradine Can be considered to reduce hospitalization in patients with BB intolerance, IIb-C
 receiving ACEIs (ARBs) and MRAs (ARBs), who are in sinus rhythm,
 with LVEF ≤35%, HR ≥70 b.p.m. 
Digoxin In order to reduce hospitalizations in patients receiving ACEIs (ARBs)+ IIb-B
 MRAs (ARBs), who are in sinus rhythm, with LVEF ≤45%
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Table 14. Beta-blocker contraindications and adverse events during 
their use
Contraindications Adverse events with use
Asthma Hypotension
Sinus bradycardia (<50 b.p.m) Bradycardia
Sick sinus syndrome Fluid accumulation
Second or third degree AV block Worsening of HF
Bronchospasm
Severe claudication
Decompensated HF- in acute phase
7.2 What are the cautions in the dose management of 
MRAs?
The most important risk of MRA treatment in patients with HF 
is the development of hyperkalemia (14, 16). The risk of severe 
hyperkalemia in patients with HF receiving MRA is approximate-
ly 2-3% (14, 16). This risk is higher in patients with renal failure. 
Because of the risk of hyperkalemia, both the patient selection 
and the treatment follow-up should be performed carefully. In 
this case, renal functions and serum potassium levels of patients 
are helpful markers in guiding MRA therapy. What to do to re-
duce the risk of severe hyperkalemia is summarized in Table 16. 
7.3 Can MRA be used every other day?
According to the RALES Trial protocol, if potassium had in-
creased while receiving 25 mg spironolactone, 25 mg every other 
day protocol was used instead of half the dose (14). In the EM-
PHASIS-HF Trial, in patients with an estimated glomerular filtra-
tion rate (eGFR) value of 30-49 mL/min/1.73 m2, eplerenone was 
initiated at 25 mg every other day instead of daily use and sub-
sequently the dose was up-titrated to 25 mg daily after 4 weeks 
(69). In the same trial, in patients receiving 25 mg daily doses of 
eplerenone, when renal dysfunction and potassium elevations 
were observed, the dose was adjusted to 25 mg every other day.
Based on the results of these two trials, in clinical practice, 
low doses of MRA can be used every other day in patients with 
HF who have developed (serum K+=5.5-5.9 mmol/L) or at risk of 
developing hyperkalemia (particularly, in elderly patients or in 
patients with eGFR=30-49 mL/min/1.73 m2).
7.4 What are the alternative therapies in the presence of 
MRA contraindication?
In Table 17, contraindications and conditions requiring cau-
tion are given. Since eplerenone is a specific MRA, it is preferred 
for the anti-androgenic side effects of spironolactone (e.g. gy-
necomastia). In cases where both of MRAs are not used, there 
is no agent to be given for mineralocorticoid blockage. In HF 
treatment, if the patient is still symptomatic despite ACEI+BB 
therapy, in patients who have contraindication or intolerance 
to MRA, ARBs can be added (37, 70). In patients receiving ACEI, 
adding ARB to the ACEI therapy has been primarily shown to pro-
Table 16. Recommendations related to the use of MRAs in patients with HF (3)
Condition What to do
Serum K+ >5 mEq/L MRAs use is contraindicated
Serum creatinine >2.5 mg/dL (221 mmol/L)
eGFR <30 mL/min/1.73 m2
In ACEI+ARB users MRAs use is contraindicated
Concurrent with potassium-sparing diuretics
Concurrent with potassium supplement
Should be initiated in a low dose and up-titrated to the target Initial dose; Spironolactone 25 mg daily
dose in 4-8 weeks  Eplerenone 25 mg daily
 25 mg every other day in elderly patients or in patients with
 eGFR=30-49 mL/min/1.73 m2
 Target dose; Spironolactone 25-50 mg daily
                             Eplerenone 50 mg daily
Follow-up intervals after initiating the drug At 1, 4, 8 and 12 weeks
 At 6, 9 and 12 months
 Subsequently every 4 months
Markers to be measured during follow-up Serum K+, Na+2 and creatinine
 eGFR
During follow-up; Serum K+ = 5.5-5.9 mEq/L Reduce the dose to 25 mg if 50 mg is used
Serum creatinine = 2.5-3.5 mg/dL (221-310 mmol/L) Reduce the dose to 25 mg every other day if 25 mg is used
eGFR <30 mL/min/1.73 m2 Discontinue if 25 mg is used every other day
During follow-up; Serum K+ >6 mEq/L Drug should be discontinued and potassium lowering therapy
Serum creatinine >3.5 mg/dL (310 mmol/L) should be initiated
eGFR <20 mL/min/1.73 m2
ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; eGFR – estimated glomerular filtration rate; K – potassium; Na – sodium
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vide morbidity benefit but also the combined endpoints of mortality 
and morbidity have been improved. In the Val-Heft Trial, valsartan, 
which was added to the treatment of patients receiving ACEIs, im-
proved morbidity with no effect on mortality (70). In the CHARM-
Added Trial, both mortality and morbidity reduced with the addition 
of candesartan to the treatment of patients receiving ACEIs (37). 
In these trials, adding ARB to the ACEI therapy caused more side 
effects (dizziness, hypotension, renal dysfunction and hypercalce-
mia). So, patients should be closely monitored if ARB will be added 
to their ACEI therapy.
There are controversial findings regarding ACEI+BB+ARB 
triple combination. In the Val-HeFT Trial, valsartan included in this 
combination has been found to increase mortality and morbid-
ity (70) whereas this negative outcomes were not confirmed in 
the VALIANT Trial in post-MI patients (41). This triple combination 
with candesartan in the CHARM-Added Trial provided a reduc-
tion in the combined endpoints of mortality and morbidity (37).
8.0 Diuretic treatment – Dilek Yeşilbursa
8.1 Which diuretic should be administered to which patient 
and how?
Unlike BBs, ACEIs and MRAs, the effects of diuretics on 
mortality and morbidity were not investigated. However, their 
use in relieving shortness of breath and edema is recommend-
ed regardless of ejection fraction in HF patients with signs and 
symptoms of congestion (Class I, Evidence B) (3). After evaluat-
ing the renal functions and serum electrolytes, the diuretic treat-
ment is initiated in a low dose and the dose is incremented until 
the clinical signs and symptoms regress. In patients with mild 
congestion, 2 or 3 times weekly use of thiazide diuretics may 
be enough in the maintenance of normal intravascular volume. 
Furthermore, thiazides can be preferred in hypertensive HF pa-
tients with mild fluid retention due to their antihypertensive ef-
fects. However, daily use of a loop diuretic such as furosemide is 
necessary in patients with severe congestion or reduced renal 
function that decreases the effect of thiazides (if GFR is <30-40 
mL/min., thiazides are ineffective). Loop diuretics are more po-
tent natriuretics than the other diuretics, particularly in patients 
with reduced GFR.
In patients without significant signs of congestion, a single 
daily dose of a loop diuretic is generally enough. 2-3 doses may 
be required in patients with more severe congestion. In patients 
whose congestive symptoms persist despite loop diuretics and 
salt restriction, thiazides or diuretics with similar effects but 
showing their activity in different localizations on renal tubule 
(sequential nephron blockade) may be effective. In patients re-
ceiving this treatment strategy, serum potassium levels should 
be monitored carefully and, if necessary, potassium replace-
ment should be performed. Use of thiazide diuretics is limited 
in the elderly, because glomerular filtration rate (GFR) reduces 
with age. Loop diuretics are preferred over thiazides in elderly 
patients.
The guidelines recommend intravenous (IV) treatment in pa-
tients with decompensated HF requiring hospitalization (3). IV 
administration shows a more rapid effect than oral administra-
tion. Furthermore, the problem of absorption in oral administra-
tion due to intestinal edema is not observed with IV administra-
tion. Practically, it is recommended that the IV dose should be 
twice more than the dose the patient usually receives. However, 
the ideal dose of treatment and route of administration (bolus or 
continuous infusion) is not clear. In a trial conducted in patients 
Table 17. Contraindications and cautions in MRA use
Contraindications Conditions requiring caution
Hyperkalemia (initial Serum K+ >5 mEq/L) Porphyria (only for spironolactone)
Anuria Pregnancy and lactation
Acute or severe renal failure (serum creatinine >2.5 mg/dL-221 mmol/L Child Pugh A or B hepatic failure (electrolytes should be closely 
or eGFR <30 mL/min/1.73 m2) monitored)
Addison’s Disease Moderate to severe renal failure (serum creatinine >1.8 mg/dL-150  
 mmol/L or eGFR=30-49 mL/min/1.73 m2)
Hyponatremia (Na+ <135 mmol/L) Diabetic microalbuminuria
Hypersensitivity to MRAs
Concurrent use with potassium-sparing diuretics Elderly patients (potassium levels should closely be monitored)
Concurrent use with potassium supplement Some drugs and food intake
Concurrent use with ACEI+ARB combination
Concurrent use of eplerenone with strong cytochrome P450 3A4
inhibitors (ketoconazole, itraconazole, nefazodone, troleandomycin,
clarithromycin, ritonavir, and nelfinavir) 
Severe hepatic failure (Childs Pugh-C)
ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; eGFR – estimated glomerular filtration rate; K – potassium; Na – sodium
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hospitalized for reduced ejection fraction and acute decompen-
sation, low dose and high dose administration of furosemide as 
IV bolus or continuous infusion were compared (71). No differ-
ence was observed between the administration of furosemide 
as intermittent IV bolus and IV continuous infusion. It was ob-
served that a high dose was more effective in symptom relief 
and regression of congestion signs. Before the patients are dis-
charged, symptoms and signs of congestion should disappear 
completely and the patients should have been receiving stable 
oral diuretic therapy for at least 48 hours.
8.2 Can patients self-manage their diuretic dose?
How?
Self-adjusting of diuretic dose by patients can be a suitable 
approach since the requirement of diuretics varies depending on 
the diet, activity level, NYHA Class and HF Stage. 
The aim of diuretic use is to achieve and maintain euvolemia 
(patient’s dry weight) with the lowest dose possible (3). This is 
possible by adjusting the diuretic dose according to needs. In 
particular, after achieving dry body weight, dehydration should 
be avoided as it may cause hypotension or worsening kidney 
functions (3). Dehydration can reduce cardiac output in pa-
tients with HF-PEF and, in HF-REF patients, it may unnecessarily 
prevent to reach the target dose of other drugs such as ACEIs 
(or ARBs) and MRAs that may change the course of the disease. 
Most patients can be educated regarding self-adjusting their 
diuretic doses by monitoring their congestive symptoms and 
signs as well as daily body weights. They should be informed 
that they can increase their diuretic dose if they experience 
shortness of breath and increase in edema or in >2 kg. weight 
gain in 3 days and decrease the dose again once the symptoms 
regress.
8.3 Should diuretic therapy be continued in patients in 
whom congestion improves?
In HF patients without signs and symptoms of congestion, 
diuretics have no place in treatment. In this case, their use 
may be harmful by increasing neurohumoral activation. Di-
uretics must be used in patients with symptoms and signs of 
congestion (4). Diuretic therapy should not be discontinued un-
til the signs of congestion resolve. After the patient becomes 
euvolemic, diuretic therapy may be completely discontinued 
and the clinical course can be monitored by considering the 
severity of HF. If congestion does not develop again in clinical 
follow-up, the patient can be monitored only by basic therapy 
(ACEI, BB, MRA). However, if congestion signs and symptoms 
recur in clinical follow-up, continuous diuretic therapy should 
be continued in doses that can prevent the redevelopment of 
fluid retention after the patient is brought to euvolemic state 
again. In patients in whom diuretic therapy is discontinued de-
spite recurrent congestion, frequent hospitalizations related to 
acute HF manifestation are observed.
8.4 Combinations in diuretic therapy: Which combination 
for which patient?
Diuretics which are used in the treatment of HF are divided 
into three main groups according to their mechanisms of action: 
1) Loop diuretics: They act by inhibiting Na-K-2Cl channel at the 
ascending limb of the loop of Henle. 2) Thiazides: They act by 
inhibiting NaCl reabsorption in the distal tubule. Their strength of 
effect is less compared to loop diuretics. 3) Potassium-sparing 
diuretics: They have a weak diuretic effect, in which amiloride 
and triamterene inhibit Na absorption in distal tubule and col-
lecting ducts, and aldosterone antagonists act by binding to al-
dosterone receptors. They have a particular place in HF because 
of reducing mortality. This effect is related to their favorable 
roles in neurohormonal activation, the diuresis they promote is 
quite low compared to other diuretics.
Each type of diuretics acts on different parts of the 
nephron. In combination therapy, furosemide+thiazide, 
furosemide+spironolactone, thiazide+spironolactone and 
furosemide+metolazone combinations are considered as useful.
Metolazone is not available in our country. Single prepara-
tions of other thiazides except indapamide are also not available. 
Thiazides are available as combination preparations.
A combination of different diuretic drugs is a method used in 
overcoming diuretic resistance in patients with refractory ede-
ma (4). The combination of thiazide or potassium-sparing diuret-
ics with loop diuretics exerts effect through sequential nephron 
blockade in diuretic resistance. While diuretic effect increases 
with the combination of loop diuretics and thiazides, since the 
combination also increases the risk of hypokalemia, hypona-
tremia and renal dysfunction, close monitoring of the patient is 
required (3).
Loop diuretics and thiazides cause severe reductions in 
potassium levels and may consequently cause lethal arrhyth-
mias. In order to prevent this, potassium-sparing diuretics can 
be used as an add-on therapy to the other diuretics. Generally, 
these agents have a weak diuretic effect. They are usually in-
sufficient in controlling congestion symptoms when used alone. 
If the symptoms cannot be controlled despite ACEI and diuretic 
therapy or hypokalemia persists despite ACEI therapy, potassi-
um-sparing diuretics are recommended to be added to the treat-
ment. Aldosterone antagonists should be preferred over other 
potassium-sparing diuretics.
8.5 Do low dose combinations have an advantage over high 
dose single use?
Diuretics should be used in the lowest dose that can improve 
fluid and sodium retention. This dose is generally determined for 
each patient by slowly incrementing the dose. Loop diuretics 
are the most preferred agents because of their fast and potent 
effects. High-dose diuretic use may lead to excess diuresis. In 
this case, hypotension and renal dysfunction related to a reduc-
tion in intravascular volume may develop. Diuretics are known 
to cause activation of both renin-angiotensin-aldosterone sys-
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tem and sympathetic nervous system. These agents may reduce 
cardiac output by causing loss of fluid and sodium and they may 
cause an increase in renin and aldosterone levels in peripheral 
circulation.
Thiazides and spironolactone are frequently used in combi-
nation with loop diuretics. If needed, a combination in low doses 
is more effective compared to high-dose single use and causes 
less side effects.
Although thiazides have insufficient diuretic effect when 
used alone in HF, if administered in combination with loop di-
uretics, a significant increase in urine output may be provided 
with significant reduction in complaints. Thus, post-diuretic so-
dium retention which is observed with loop diuretic therapy is 
prevented due to the long half-life of thiazides, and structural 
changes developing in distal tubule cells (cellular hypertrophy 
and hyperplasia) are avoided. To avoid hypokalemia caused by 
loop diuretics and thiazides, potassium-sparing diuretics can 
be added to the combination. However, since most of the pa-
tients with HF receive ACEIs or ARBs, it is recommended that the 
dose should be carefully titrated and potassium levels should be 
closely monitored.
8.6 What should be done in case of diuretic resistance? 
Diuretic resistance is considered in the case of a lack of ex-
pected response to the standard diuretic therapy. Diuretic resis-
tance may develop in 20-30% of patients with HF.
A reduction in the absorption of drugs in the gastrointestinal 
system, increased salt intake, the disruption of renal perfusion 
(low flow rate), a reduction in the secretion of diuretics from the 
kidneys, use of nonsteroidal anti-inflammatory drugs (NSAIDs), 
an increase in neurohormonal activity, hypertrophy and hyper-
plasia in distal tubules are the reasons for a reduction in the re-
sponse to diuretics and for diuretic resistance.
In patients in whom the response to diuretic therapy reduc-
es, the diet, dosage and administration of diuretics and concur-
rent use of other drugs should be reviewed. The patients’ daily 
consumption of salt (<2 gr) and water intake (1-1.5 L) should be 
restricted. Use of NSAIDs reducing the efficacy of diuretics 
should be avoided. Electrolytes and renal functions should be 
monitored and fluid should be given in hypovolemic patients.
After all these causes are eliminated, increasing the diuretic 
dose can initially be favorable. Thus, the reduction in active se-
cretion of loop diuretics into the tubule due to disrupted renal 
blood flow can be prevented. The dosing intervals of loop diuret-
ics can be shortened due to their short half-life (2-3 times/day). 
Administering these agents with frequent intervals can prevent 
post-diuretic sodium retention. IV administration of loop diuret-
ics increases bioavailability. Administering with continuous in-
fusion can also be beneficial in improving diuretic resistance 
(Table 18).
In the DOSE Trial, administration of furosemide in bolus or 
continuous infusion and also low-dose or high-dose administra-
tion were compared in patients with acute decompensated HF 
(71). No difference was found between intermittent IV bolus ad-
ministration and IV continuous infusion of furosemide. High-dose 
was observed to be superior in improving symptoms, weight loss 
and regression of congestions signs.
A combination of different diuretic drugs is another method 
in overcoming diuretic resistance (4). Concurrent administration 
of thiazides and potassium-sparing diuretics can be effective 
through sequential nephron blockade in diuretic resistance.
Dopamine infusion in low doses can be used to increase the 
efficacy of diuretics (3).
Adding vasopressin antagonists (tolvaptan, conivaptan) to 
the treatment can also be considered. Vasopressin antagonists, 
particularly used in the treatment of hypervolemic hyponatremia, 
are known to increase pure water elimination via the kidneys 
without showing a natriuretic or kaliuretic effect. In the EVER-
EST Trial, it was shown that routine tolvaptan administration to 
the patients with acute decompensated HF provided significant 
improvement in edema, body-weight and dyspnea although it 
had no effect on mortality and hospitalization (3, 4).
In order to reduce the fluid overload, ultrafiltration can be 
applied in patients who are unresponsive to the aforementioned 
precautions and administrations (3, 4).
ACEIs and ARBs decrease blood pressure and a reduction 
in blood pressure in HF increases the risk of diuretic resistance. 
However, due to their proven benefits in cardiovascular dis-
eases, discontinuing these treatments or decreasing their doses 
should be the last resort.
8.7 How much can the diuretic dose be increased? 
The ideal dose of diuretics to be used is not clear. The gen-
eral approach is to adjust the dose according to the clinical con-
dition of the patient.
Treatment with loop diuretics should be initiated at a low 
dose. The dose is titrated according to the diuresis response 
received and the symptomatic improvement. The initial dose of 
furosemide is 20-40 mg, PO or IV. Incrementing to high-doses 
may be required in patients with renal dysfunction. Even doses 
higher than 500 mg may be required depending on the condition 
Table 18. Approach to diuretic resistance
Recommendations
Sodium and fluid restriction
Discontinuing NSAIDs
Volume replacement in hypovolemia
Increasing the dose and frequency of loop diuretics
Administration of diuretic therapy in IV bolus or continuous infusion
Combination of loop diuretics with thiazides or spironolactone
Adding dopamine to the treatment with the renal vasodilator dose 
(2-5 µg/kg/min)
Adding vasopressin antagonists to the treatment
Ultrafiltration
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of the patient. Switching to continuous IV infusion in these kinds 
of patients may be appropriate. Although the infusion dose of fu-
rosemide varies between 3 mg/hour and 200 mg/hour, generally 
5-40 mg/hour is accepted as the sufficient dose. High-dose di-
uretic use should be avoided due to hypovolemia, hyponatremia, 
activation of renin angiotensin-aldosterone system and increase 
in the risk of mortality. Autotoxicity may develop in high doses. 
Total furosemide dose should be <100 mg in the first 6 hours and 
<240 mg in the first 24 hours.
Thiazides (25 mg hydrochlorothiazide, PO) and MRAs (25-
50 mg spironolactone, PO) can be concurrently used with loop 
diuretics in HF patients with volume overload or diuretic resis-
tance. The patients should be closely monitored in terms of hy-
povolemia, hyponatremia and hypo/hyperkalemia. Urine output 
and congestion signs should be closely monitored and the treat-
ment should be planned accordingly.
Commonly used diuretic doses in HF are given in the Table 
19 (3, 4).
9.0 Ivabradine, digoxin, hydralazine,
and/or nitrate treatment – Yüksel Çavuşoğlu
9.1 Which one should be chosen in patients with heart 
rate of >70 bpm? Is it ivabradine or beta-blocker dose 
uptitration? 
Elevated heart rate is associated with poor clinical outcomes 
in HF. The analyses of BB trials demonstrated that the mortality 
benefit of BB therapy correlated with the reduction in heart rate. 
Meta-analysis of 23 trials with BBs, including 19,000 cases, indi-
cates that the benefits of BBs on mortality rates are strongly as-
sociated with a reduction in heart rate, rather than with dosage 
(72). The results of the SHIFT Study have shown that the reduc-
tion in heart rate achieved by adding ivabradine to the standard 
therapy including BBs, ACEIs/ARBs, MRAs, diuretics and digoxin 
in HF patients in sinus rhythm, with an EF <35% and a heart rate 
>70 b.p.m, significantly decreased cardiovascular death or HF 
hospitalization and HF-related death alone, HF hospitalization 
alone, all-cause hospitalization alone and cardiovascular hospi-
talization (23). These results show that reducing elevated heart 
rate in chronic HF-REF provided clinical benefit.
Beta-blockers are drugs which have proven to reduce mor-
tality in HF in many major studies and, according to the guide-
lines, should be given to all patients (3). In patients in sinus rhythm 
with elevated heart rate (>70 b.p.m), ivabradine treatment should 
be added for heart rate control. In patients with elevated heart 
rate, the BB dose should primarily be up-titrated to the target or 
maximum tolerated dose. In patients with a heart rate >70 b.p.m 
despite the target or maximum tolerated dose of BBs, ivabradine 
should be added. In many studies, it is reported that the heart rate 
remains at >70 b.p.m in 50-70% of cases despite a BB use and that 
there is not a very good correlation between BB dose and heart 
rate control. It can be said that >50% of HF cases in sinus rhythm 
require ivabradine treatment considering that the rate of achieve-
ment of BB target dose is only 17% in real life or, despite the BB 
treatment, the heart rate is >70 b.p.m in many cases. BB and iv-
abradine treatments should not be considered alternatives for 
one another but complementary treatment forms. Also, European 
HF guidelines recommend ivabradine as an alternative of BBs in 
patients who have a contraindication for beta blocker therapy.
9.2 Which one should be chosen in a symptomatic patient? 
Ivabradine or digoxin?
The ESC guidelines for HF recommend ivabradine treatment 
primarily in cases with EF ≤35%, in sinus rhythm and at a heart 
rate ≥70 b.p.m who are symptomatic (NYHA Class II-IV) despite 
the maximum tolerated dose of BB, ACEI/ARB, MRA and diuretic 
treatment (3). Since the DIG Trial, which studied digoxin and 
demonstrated no mortality benefit, was conducted in the 1990s, 
the subjects in DIG had received only diuretics and ACEIs as a 
HF therapy (22). Therefore, the favorable efficacy of digoxin on 
hospitalizations, symptoms and quality of life has been proven in 
HF patients receiving ACEIs and diuretics. There is no evidence 
Table 19. Commonly used diuretic doses in heart failure
Diuretics Initial dose (mg) Routine daily dose (mg) Maximum dose (mg)
Loop diuretics
Furosemide 20-40 40-240 600
Bumetanide 0.5-1 1-5 10
Torasemide 5-10 10-20 200
Thiazides
Hydrochlorothiazide 25 12.5-100 200
Metolazone 2.5 2.5-10 20
Indapamide 2.5 2.5-5 5
Potassium-sparing diuretics
Spironolactone/eplerenone 12.5-25 25-50 100
Amiloride 5 10 20
Triamterene 50-75 100 200
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as to whether digoxin provides an additional clinical benefit 
in patients receiving current modern therapy (e.g. BBs, ACEIs, 
MRAs, diuretics). However, ivabradine has been demonstrated 
to reduce the primary outcome of cardiovascular death or HF 
hospitalization and to reduce HF-related death alone, HF hospi-
talization alone, all-cause hospitalization alone and cardiovas-
cular hospitalization significantly when added to the standard 
treatment comprised of BB, ACEI/ARB, MRA, diuretic and even 
digoxin (23). These results pointed out that ivabradine has a pri-
ority over digoxin. However, it should be kept in mind that that 
despite ivabradine treatment, digoxin can still be added to the 
ivabradine-based treatment in NYHA Class II-IV HF patients and 
concurrent use of these two drugs is not contraindicated.
9.3 What are the selection criteria for digoxin and 
ivabradine?
Ivabradine is indicated in patients with EF ≤35% and a heart 
rate ≥70 b.p.m who are still symptomatic (NYHA Class II-IV) de-
spite maximum tolerated doses of BB, ACEI/ARB, MRA and di-
uretic treatment (3). As ivabradine exerts its effect through the 
inhibition of If channels located in the sinus node, the patient has 
to be in sinus rhythm (23). It is not used in AF. Therefore, the pa-
tient should be in sinus rhythm with a heart rate ≥70 b.p.m for the 
initiation of ivabradine treatment. These conditions are not appli-
cable for digoxin. Digoxin can be used in sinus rhythm as well as 
in AF. There is no certain heart rate limit for digoxin use. Digoxin is 
known to be a quite effective drug in ventricular rate control in AF. 
Therefore, its use in AF is particularly recommended for rate con-
trol. There is a limitation of digoxin use in chronic renal failure due 
to intoxication. Ivabradine use is effective and safe in these cases.
On the basis of this information, in patients with EF ≤35%, in 
sinus rhythm and who are still symptomatic despite the maximum 
tolerated doses of BB, ACEI/ARB, MRA and diuretic treatment, 
it is appropriate to initiate ivabradine primarily if the heart rate 
is ≥70 b.p.m, and digoxin may be chosen in patients with a heart 
rate <70 b.p.m. In patients with a heart rate ≥70 b.p.m and un-
controlled symptoms despite the administration of ivabradine, 
adding digoxin to the treatment should be considered. Ivabradine 
should be the first choice in patients with chronic renal failure 
and a heart rate ≥70 b.p.m. In HF with AF, digoxin can be started 
in symptomatic cases, particularly those with a fast ventricular 
response, regardless of heart rate. However, it should be noted 
that digoxin can reduce heart rate with concurrent use of BBs 
and/or ivabradine in bradycardic patients (heart rate <60 b.p.m.) 
and its use should be avoided in those with a heart rate <50 b.p.m.
9.4 What is the target heart rate for ivabradine? 
The results of the SHIFT Study support the fact that there 
is a 3% increase in the risk of death and HF hospitalization for 
every 1 b.p.m increase in heart rate (23). In cases whose heart 
rate reduces by >10 b.p.m with ivabradine treatment, primary 
outcomes of cardiovascular death or HF hospitalization are ob-
served to reduce significantly compared to the less reduced or 
non-reduced cases. In the same study, optimal heart rate for the 
reduction of primary outcomes was found to be 55-60 b.p.m. (23). 
In the meta-analysis of 23 BB studies, it has been reported that 
mortality benefit was significant in patients whose heart rate 
decreases below 70 b.p.m with BB treatment (73). These results 
support that a heart rate of 55-65 b.p.m. is the ideal target range 
with ivabradine treatment (Table 20).
9.5 Should a loading dose of digoxin be administered? 
When and how should it be given?
There is no rationale for the loading dose of digoxin in pa-
tients who have clinically stable HF. 0.125 or 0.25 mg/day is rec-
ommended as the initial and maintenance doses (4). 0.125 mg/
day or 0.125 mg every other day is recommended in mild-mod-
erate renal dysfunction, advanced age (>70 years) or patients 
with a low body weight. Post-hoc analyses of the DIG Trial sup-
port that there is mortality benefit in patients with plasma digoxin 
levels of 0.5-0.9 ng/mL, there is no effect on mortality in patients 
with levels of 0.9-1.1 ng/mL, and higher plasma levels (≥1.2 ng/
mL) are associated with an increase in death risk (22, 74). There-
fore, if it can be measured, dose adjustment can be performed 
by monitoring the plasma levels of digoxin.
The most important condition for loading dose of digoxin is 
acute HF presenting with rapid ventricular rate response of AF. 
In this case, if there is hemodynamic instability, sinus rhythm 
should be restored with cardioversion. If there is no hemody-
namic instability and the rapid ventricular rate of AF is consid-
ered to be controlled immediately, IV digoxin can be adminis-
tered. The use of BB for rate control in this setting may worsen 
acute HF manifestation. IV digoxin administered as 0.25 mg or 
0.5 mg by considering the patient’s body weight, age, renal func-
tions and whether or not the patient is under digoxin treatment 
can provide rate control within 30-60 minutes and additional oral 
digoxin tablets not exceeding the total dose of 0.75-1.0 mg. can 
be given, if necessary.
9.6 How should the digoxin be administrated according to 
the creatinine level?
Digoxin is mainly excreted by the kidneys. The risk of intoxi-
cation increases in patients with renal dysfunction. Therefore, 
EF ≤35%, sinus rhythm, heart rate >70 b.p.m
Initial Ivabradine Dose 5 mg b.i.d
Resting heart rate after 2 weeks
Ivabradine 7.5 mg b.i.d
Heart rate 55-65 b.p.m
Ivabradine 5 mg b.i.d Ivabradine 2.5 mg b.i
Heart rate ≥65 b.p.m Heart rate ≤55 b.p.m
Table 20. Up-titration of ivabradine according to heart rate* (23)
*Adapted from SHIFT Study (23)
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in patients in which digoxin treatment is considered, the deci-
sion for the initiation of digoxin treatment should be based on 
plasma creatinine levels or GFR and the assessment of the risk/
benefit ratio is required. In assessing the renal functions, GFR 
gives more accurate information. Even though creatinine levels 
are normal, particularly in patients with advanced age, GFR may 
be found to be significantly low. It would therefore be more ap-
propriate to decide on the functions of the kidneys with GFR in 
elderly patients. In patients with mild-moderate renal dysfunc-
tion, it is recommended to reduce the digoxin dose by half or to 
1/4 of the dose and to repeat the measurement of plasma levels 
in intermittently, if possible. Recommended digoxin doses con-
sidering body weight and GFR are given in Table 21 (75). Although 
only 0.25 mg oral formulation is available in our country, 0.125 or 
0.0625 mg formulations are available in some countries for low 
dose convenience.
9.7 Is there a rationale for skipping digoxin doses 2 days a 
week?
Digoxin administration in the DIG Trial is 0.25 mg/day (22). 
There is no rationale for skipping a dose 1 or 2 days a week, 
which is a common clinical practice almost solely in our country. 
In patients who have a concern for the development of digoxin 
intoxication, the ideal approach is to adjust the oral dose by mea-
suring plasma digoxin levels. If there is no opportunity to mea-
sure the plasma digoxin levels, 0.125 mg. or 0.0625 mg. every day 
or every other day can be given in patients with mild-moderate 
renal dysfunction, low body weight or advanced age (>70 years).
9.8 Do hydralazine and/or nitrate provide clinical benefit in 
Whites?
Clinical studies show that H-ISDN combination reduces 
mortality, HF hospitalizations and improves ventricular function, 
symptoms and exercise capacity. There is strong evidence re-
garding the mortality benefit of H-ISDN, particularly in African-
Americans. In the V-HeFT-I Trial (45), improvement was observed 
in exercise capacity, EF and all-cause mortality with H-ISDN 
treatment added to the diuretic and digoxin treatment. However, 
in V-HeFT-II (46) with enalapril, all-cause mortality was found to 
be significantly lower than H-ISDN (18% and 25%, p=0.016). The 
A-HeFT Trial (25), including African-American subjects, was ter-
minated early due to a 43% (p<0.02) reduction in mortality and 
33% (p<0.001) reduction in hospitalization when H-ISDN was 
added to the treatment of HF in patients with NYHA Class III-
IV and reduced EF who were receiving diuretics, digoxin, ACEIs 
(ARBs), BBs and spironolactone. V-HeFT-I and V-HeFT-II are tri-
als including African-American and White subjects. Recently 
published studies show that H-ISDN added to the ACEI/ARB 
treatment reduced all-cause mortality by 35% (p=0.04) and all-
cause mortality/HF hospitalization by 28% (p=0.03) and signifi-
cantly improved cardiac index and systemic vascular resistance 
in Whites (76). Although these results strongly support the clini-
cal benefits of H-ISDN, particularly in African-Americans, they 
also support the fact that H-ISDN may provide clinical benefits 
in Whites who are unresponsive to standard treatments or who 
have contraindication/intolerance to standard drugs.
9.9 Can nitrate alone be used instead of hydralazine+nitrate 
combination?
Hydralazine and ISDN are vasodilator agents with arterial va-
sodilator action and venodilator action, respectively. There is no 
H-ISDN combination in our country. In the H-ISDN combination, 
both arterial and venous vascular dilation are achieved. Thus, 
preload and afterload reduce as a result from a decrease in sys-
temic and venous vascular resistance. Although nitrates show 
venodilator effect prominently, they also have arterial vasodila-
tor properties. Although H-ISDN combination has been evaluat-
ed in most of the HF clinical trials and clinical benefits have been 
proven with H-ISDN combination (25, 45, 46), in the absence of 
H-ISDN combination, use of nitrate alone can be considered to 
provide similar clinical benefit, at least partially. Furthermore, 
some of the previously published studies have shown that ad-
ministration of ISDN alone in HF improved symptoms and exer-
cise tolerance (77, 78). Despite the lack of strong evidence, it 
seems reasonable to use nitrate alone when necessary until the 
H-ISDN combination is available in our country.
9.10 Does nitrate tolerance develop in nitrate use? What 
should be done in this case?
One of the most important issues in nitrate use is the devel-
opment of nitrate tolerance. It is observed in all nitrate forms. 
Tolerance disappears after a nitrate-free period of 10-12 hours. 
Nitrate tolerance mainly affects systemic resistant vessels 
rather than large vessels. Development of nitrate tolerance is 
Table 21. Recommended-doses of digoxin according to body weight and 
GFR* (75)
Body Weight - GFR, mL/min Digoxin dose, mg/day
45-50 kg - ≤60 0.0625
45-50 kg - >60 0.125
51-60 kg - ≤45 0.0625
51-60 kg - 46-110 0.125
51-60 kg - >110 0.25
61-70 kg - ≤35 0.0625
61-70 kg - 36-110 0.125
61-70 kg - >110 0.25
71-80 kg - ≤21 0.0625
71-80 kg - 21-80 0.125
71-80 kg - >80 0.25
81-90 kg - ≤10 0.0625
81-90 kg - 11-70 0.125
81-90 kg - >70 0.25
GFR - glomerular filtration rate
*Adapted from DiDomenico RJ et al (75).
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therefore important in HF. Development of partial or full toler-
ance is observed in the use of both ISDN and isosorbide-5-mo-
nonitrate. ISDN is administered as 20-40 mg, 3-4 times daily in 
HF. In clinical practice, a nitrate-free period of 10-12 hours is 
recommended. Therefore, 3-dose administration at 08:00, 13:00 
and 18:00 or 3-dose administration every 6 hours is ideal for pro-
viding a nitrate-free period. Tolerance does not develop in the 
use of isosorbide-5-mononitrate once daily; however, it develops 
if 2 doses are received at 12-hour intervals. Therefore, use of 
extended-release isosorbide-5-mononitrate once daily allows 
for a sufficient nitrate-free period with no tolerance. Generally, 
the ISDN dose used in HF studies is 120-160 mg/day (25, 45, 46).
9.11 How can we overcome the headache problem during 
nitrate use?
One of the common side effects observed with nitrate use 
is headache. Initiating the treatment with a short-acting nitrate 
(ISDN) is therefore recommended. If headache develops, up-
titration to desired doses by starting with a quarter of the dose 
and doubling the dose every 2-3 days result in the development 
of tolerance to headache. In severe cases, powdering the ISDN 
tablet, taking a pinch of the ISDN dose and incrementing the 
amount generally help to overcome headache problem.
10.0 Drug use in pregnant and/or
breastfeeding women – 
Mehdi Zoghi
10.1 Which drugs can be used in pregnant women?
Treatment principles in acute and chronic HF in pregnant 
women are the same as the cases of general HF population 
except for the requirement to be cautious about the drugs with 
teratogenic effects on the fetus. In this context, ACEIs, ARBs and 
MRAs are teratogenic and should not be used during pregnancy. 
Hydralazine and/or nitrates can be used instead of ACEIs/ARBs 
to reduce afterload. If a significant reduction is observed in LVEF 
after the discontinuation of RAAS blockers, the risk of pregnancy 
should be reviewed. If these groups of drugs had been received 
in the first trimester, they should immediately be discontinued, 
and the condition of the fetus should be examined with fetal 
USG. Mechanical left ventricular support devices or heart trans-
plantation (4%) may be required in patients with peripartum car-
diomyopathy resistant to drug treatment (79).
Although our knowledge on BBs use in pregnancy is ob-
tained from evidence in hypertensive pregnant women, beta-1 
selective BBs are recommended. Metoprolol has much more 
evidence in pregnancy compared to any other beta blockers and 
can be used more safely. Atenolol use is not recommended. Al-
though digoxin can also be used in pregnancy safely, it is not 
among the initially preferred drugs, as has been used in general 
HF population. Loop diuretics can be given in pregnant women 
with prominent symptomatic pulmonary edema and peripheral 
edema (79). If indicated, dopamine and levosimendan can also 
be used in pregnant HF women.
10.2 Which drugs can be used in breastfeeding women?
The amount of ACEIs excreted into breast milk is very low. 
However, ACEIs that have been proven to have a safe profile 
in clinical trials in breastfeeding women (enalapril, captopril or 
benazepril) should be preferred (Table 22). There is no enough 
data regarding the safety of ARBs. Furosemide can reduce milk 
production. Metoprolol succinate extended-release is a BB with 
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Table 22. Drugs and their categories in pregnancy and breastfeeding
Drug TGA pregnancy category Compatibility with breastfeeding
Enalapril D Compatible
Ramipril D Caution, insufficient data
Captopril D Compatible
Perindopril D Caution, insufficient data
Candesartan D Avoid, insufficient data
Valsartan D Avoid, insufficient data
Metoprolol C Compatible
Carvedilol C Caution, insufficient data
Nebivolol C Caution, insufficient data
Spironolactone B3 Compatible
Furosemide C Caution, insufficient data
Ivabradine D Caution, insufficient data
Digoxin A Compatible
Nifedipine C Compatible
TGA - therapeutic goods administration 
A: Controlled human studies show no risk; B: No evidence of risk in studies; B3: No evidence of risk in limited number of studies; C: Risk can not be ruled out; D: Positive evidence of risk
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less excretion into breast milk and with more clinical research 
compared to any other BBs. Oral digoxin preparations are among 
the drug groups which can be used safely (79, 80).
11.0 Controversial issues in drug therapy in HF  –
Mehmet Birhan Yılmaz
11.1 Do omega-3 PUFA and statin treatments provide 
clinical benefit?
The efficacy of omega-3 PUFA treatment in chronic HF has 
been evaluated in the GISSI-HF Trial (81). In this trial, 6975 pa-
tients with NYHA Class II-IV symptoms were randomized to 
receive 1 g omega-3 PUFA or placebo. A slight but significant 
reduction was observed in the composite outcome of all-cause 
mortality and death or HF hospitalization (hazard ratio [HR] 0.91 
[95.5% CI 0.833-0.998], p=0.041 for mortality). Additionally, in a 
sub-group analysis, it has been demonstrated that a slight im-
provement was provided in ejection fraction with this treatment 
(82). Omega-3 PUFA treatment can therefore be recommended in 
patients with chronic HF.
Statin treatment is recommended in the guidelines as Class I 
indication in patients with a history of previous acute myocardial 
infarction (AMI) or ACS (Stage A) in order to prevent the devel-
opment of symptomatic HF and CV events. This indication is a 
prophylactic treatment. In patients with established HF, initiating 
statin for only HF treatment has no benefit. Despite the favorable 
findings in observational studies and post-hoc analyses, in two 
major trials conducted with rosuvastatin, the efficacy of statin 
treatment in patients with HF-REF has been demonstrated to be 
neutral. The guidelines therefore clearly state that adding statin 
to the standard treatment has no benefit on Stage B and C chron-
ic HF and it is recommended as Class III indication with level of 
evidence “A” with the exception of the indications where its use 
is mandatory.
11.2 Do statins have a benefit in HF patients with 
hyperlipidemia and CAD?
Atherosclerotic disease is known to be an important and 
common factor in the development of HF. Aggressive treatment of 
hyperlipidemia with statins reduces the risk of HF development 
in high-risk patients. Statin treatment should therefore be initi-
ated in the presence of compelling indications in Stage A patients 
defined as a group with a high risk for HF development in whom 
the symptomatic HF clinic has not yet developed (4). It should be 
kept in mind that this is a prophylactic treatment for the develop-
ment of HF. As a treatment solely for HF, statins have no benefit in 
Stage C and D patients with symptomatic HF (particularly HF-REF) 
(83). On the other hand, a recent meta-analysis evaluating the 
results of CORONA and GISSI-HF trials reported that rosuvastatin 
therapy might have a slight favorable effect regarding the preven-
tion of MI in ischemic HF (84). However, in HF patients with CAD, 
statins should not be discontinued except significant side effects.
11.3 Does ASA reduce the benefit of HF-specific drug 
therapy?
Aspirin (or OAC) therapy (even in low doses) has no benefit 
in patients with HF, particularly HF-REF. Furthermore, due to a 
high risk of bleeding, their use can be restricted except for com-
pelling indications. On the other hand, because of the pharma-
cokinetic pathway, it may limit the nephroprotective effects of 
ACEIs and BBs (the effect of urodilatin is included). However, it 
should be kept in mind that other NSAIDs except Aspirin (includ-
ing COX-2 inhibitors) have unfavorable effects in patients with HF 
via the abovementioned action, which is also emphasized in the 
guidelines (4). Despite the belief that ASA might limit the effects 
of HF-specific drug therapy, this has not been confirmed in the 
analyses of major HF trials. ASA use should be limited to compel-
ling indications, and liberal use might be avoided.
11.4 Does warfarin therapy have a place in patients with 
HF in sinus rhythm?
In a randomized trial conducted in patients with HF-REF in 
sinus rhythm comparing warfarin and aspirin therapy, no differ-
ence has been observed regarding efficacy; however, bleeding 
has been reported more frequently in the warfarin arm. There-
fore, warfarin therapy has no benefit in patients with HF-REF in 
sinus rhythm (patients should be closely monitored regarding 
paroxysmal AF). On the other hand, in a study examining the re-
cent CORONA and GISSI-HF collective dataset, it was suggested 
that a subgroup could be determined in which anticoagulant 
treatment might have been beneficial even if there was no AF in 
the high-risk patients with HF-REF (85). This expectation is being 
tested in the ongoing COMMANDER-HF Trial regarding the pos-
sible positive effect of NOAC therapy (69).
11.5 Should warfarin be administered in case of severe 
ventricular dysfunction?
The beneficial effect of oral anticoagulant (OAC) therapy 
in severe left ventricular dysfunction is still controversial and 
uncertain. Hypothetically, since there might be a patient group 
which may derive potential benefit from OAC therapy, all antiag-
gregant-anticoagulant discussions are settled to refer to this hy-
pothesis in the literature. It is a subject evaluated within the con-
text of sub-group analysis as evidence. In the sub-group analysis 
of the WARCEF Trial, the risk of new ischemic cerebrovascular 
event has been found to be high in patients with EF <15% com-
pared to other HF-REF patients (86). In an analysis performed re-
cently, the risk of stroke was shown to be 60% higher in HF-REF 
patients in sinus rhythm with NYHA Class III-IV symptoms than 
patients with NYHA Class II symptoms (85). Hence, theoretically, 
anticoagulant therapy may be beneficial in HF-REF patients with 
low EF and high NYHA class. However, in this group with high 
risk of cerebrovascular event, it should be kept in mind that risk 
of bleeding is high in particular considering the age of the patient 
(87). It is therefore not possible to make a clear and general rec-
ommendation in this regard.
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12.0 New drugs in heart failure
12.1 ARNI (LCZ696) – Mehmet Birhan Yılmaz
Angiotensin receptor neprilysin inhibitor is a molecule which 
ends the reign of invincible ACEI (enalapril) therapy regarded as 
the backbone of chronic HF-REF treatment (17). ARNI (LZC696) 
is a chemical compound of valsartan/sacubitril salt. In this mol-
ecule, valsartan is an ARB and sacubitril is a neprilysin inhibitor. 
Neprilysin inhibitors are drugs inhibiting the enzyme responsi-
ble for the degradation of some vasoactive molecules (includ-
ing bradykinin, angiotensin-2) mainly atrial natriuretic peptide 
(ANP). Angiotensin-2 levels increase with their single use (88). 
Therefore, by combining with ARBs or ACEIs, the effects of an-
giotensin-2 should be inhibited. Since their combination with 
ACEIs has been observed to increase the risk of angioedema 
significantly in the previous studies, their use with ACEIs has 
been abandoned. Their concurrent use with ARBs is the safest 
combination possible. Thus, while ARNI blocks the unfavorable 
effects of RAAS axis on one hand, it provides a double benefit 
with the prolonged effect of molecules with favorable effects 
generated by neprilysin inhibition on the other hand. Therefore 
in the PARADIGM-HF Trial, ARNI reduced CV mortality or HF hos-
pitalizations by 20%, CV mortality alone by 20%, HF hospitaliza-
tions alone by 21% and all-cause mortality alone by 16% in HF-
REF patients with NYHA Class II-IV (NYHA IV was represented in 
a very low number) compared to high dose enalapril treatment 
(17). Angioedema, the greatest concern, was reported anecdot-
ally. It is noteworthy that substitution therapy was shown to be 
effective in HF-REF instead of usual add-on therapy. According 
to the results of the PARADIGM Trial, in HF-REF patients with ap-
propriate indication, it seems that ARNI therapy instead of ACEI 
(or ARB) will be strongly recommended in guidelines. However, 
there are matters that still need clarification. For example, ARNI 
has not been tested yet in post-MI patients. Furthermore, its use 
in patients who are ACEI/ARB-naïve or with Stage B asymp-
tomatic HF is not clear regarding evidence-based medicine. Its 
possible use in patients with HF-PEF is still under investigation 
(PARAGON-HF).
12.2 Tolvaptan – Yüksel Çavuşoğlu
Vasopressin (antidiuretic hormone) levels increase in HF. 
This increase is much more significant in HF patients with NYHA 
Class III-IV (89). Non-osmotic vasopressin release caused by an 
increase in angiotensin II levels and baroreceptor activation, and 
also reduction in vasopressin degradation due to liver/kidney 
dysfunction are the mechanisms responsible for the increase in 
vasopressin levels in HF (90). Vasopressin causes free water re-
tention via V2 receptors in renal collecting ducts. It also causes 
vasoconstriction, inotropy and hypertrophy via V1a receptors 
found in vascular smooth muscle and myocardium. Excessive 
water retention increases intravascular and extravascular con-
gestion. This worsens hypervolemic hyponatremia particularly in 
hyponatremic cases. When the hyponatremia limit is considered 
<135 mEq/L, it is reported that 8-27% of the cases admitted to the 
hospital with HF have hyponatremia. Hyponatremia, especially 
plasma sodium level <130 mEq/L, is associated with mortality, re-
hospitalization, longer hospital stay and higher cost (91).
Vaptans are agents exerting effect by increasing free water 
elimination from kidneys. The vaptans used currently are tolvap-
tan and conivaptan. Tolvaptan is an oral V2 selective vasopres-
sin receptor blocker and conivaptan is an IV V1a and V2 non-se-
lective vasopressin receptor blocker. Tolvaptan is commercially 
available in our country and its main indication is hypervolemic 
hyponatremia. The EVEREST Study showed that in hospitalized 
patients for acute decompensated HF with or without hypona-
tremia, adding tolvaptan to the standard therapy has no effect on 
mortality or HF hospitalizations; however, it provided significant 
improvement in dyspnea, edema, body weight and hyponatre-
mia compared to the standard treatment (92). Recent subgroup 
analyses supported that it has a significant benefit in reduc-
ing mortality or cardiovascular hospitalization in hyponatremic 
cases (93). There are randomized, double-blind trials showing 
that tolvaptan increases the amount of urine output and im-
proves congestion in cases resistant to diuretic treatment (93). 
Studies show that the need for high dose diuretic use reduces 
with tolvaptan use and kidney functions are maintained. In car-
diorenal syndrome, it is reported to be beneficial by increasing 
the urine output without worsening renal functions. Therefore, 
tolvaptan has an indication in the treatment of HF associated 
with congestion in Japan. It is indicated in the treatment of hy-
pervolemic hyponatremia in many countries, including Turkey as 
well. However, besides hyponatremia, tolvaptan should be con-
sidered in cardiorenal syndrome and severe congestion resis-
tant to diuretics and can decrease the need for ultrafiltration.
12.3 Aliskiren – İbrahim Sarı
ACEIs (or ARBs), BBs and MRAs which are used as standard 
drugs of HF suppress neurohormonal overactivity by blocking the 
final steps of RAAS. However, they cause an increase in com-
pensatory renin secretion. Renin inhibitors prevent angiotensin-
I formation from angiotensinogen by binding to the active site 
of renin molecule thereby showing its effect in the first step of 
RAAS cascade. It is therefore believed that renin inhibition may 
have an additional benefit in the treatment of HF. Aliskiren is an 
orally active direct renin inhibitor with a non-peptide structure.
To date, there are three trials examining the use of aliskiren 
in the treatment of HF (Table 23). In the ALOFT Trial which is the 
first of these trials, it has been shown that aliskiren, a direct re-
nin inhibitor, added to the therapy of NYHA Class II-IV HF patients 
who are treated with ACEIs (or ARBs) and BBs provided signifi-
cant additional neurohormonal benefits by reducing N-terminal 
pro-brain natriuretic peptide (NT-proBNP) and urinary aldoste-
rone levels (94). In the ASTRONAUT Trial, adding aliskiren in the 
median 5th day to the current therapies of hospitalized patients 
due to worsening chronic HF (85% of the patients were on ACEI 
and/or ARB) revealed similar results with the placebo concern-
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ing primary end-point (95). Finally, the ongoing ATMOSPHERE 
Trial, the results of which are expected to be announced soon, 
aims to evaluate the effects of enalapril alone, aliskiren alone or 
the combination of these drugs on cardiovascular (CV) mortality 
and CV hospitalizations in 7000 patients with systolic HF (96).
Aliskiren is mentioned neither in ESC guidelines 2012 nor 
ACCF/AHA guidelines 2013 for the treatment of HF. In conclusion, 
in the light of current knowledge, aliskiren has no place in the 
treatment of HF as an alternative or additional therapy to ACEIs 
(or ARBs). However, the ATMOSPHERE Trial, the largest trial in 
this regard, will elucidate this matter.
12.4 Non-steroidal MRAs – Ahmet Ekmekçi
Mineralocorticoid receptors (MR) are mineralocorticoid and 
glucocorticoid dependent intracellular steroid receptors. MRs 
are localized in a number of tissues, mainly in the kidneys and 
heart. Eplerenone and spironolactone (and its metabolite potas-
sium canrenoate) are MR antagonists (MRA) which are used in 
current clinical practice. Spironolactone is a non-specific MRA 
but show high-affinity for MR and because of structural similar-
ity with progesterone, it has also a weak interaction with pro-
gesterone, androgen, and glucocorticoid receptors. Eplerenone 
also comprises a steroid component, show high affinity for MR 
and, although minimal, it can also act on progesterone and an-
drogen receptors. There are also non-steroidal MRAs such as Fi-
nerenone and BR4628 which are still under investigation. These 
drugs have similar effects on MR but due to their non-steroidal 
structures, side effects such as impotence, gynecomastia and 
menstrual irregularity are either not present or extremely low. 
Furthermore, since their affinity on cardiac MR is much higher 
than that of kidneys, general and significant side effects of 
MRAs such as hyperkalemia are also low. In a study, fineronone 
reduced hemodynamic stress biomarkers similarly to spirono-
lactone, however, caused less hyperkalemia in patients with re-
duced LVEF and moderate renal dysfunction (97, 98). Comparison 
of available MRAs and fineronone, a promising molecule subject 
to ongoing clinical trials, is given in the Table 24.
13.0 What is the role of natriuretic peptides in the 
management of heart failure therapy? –
Mehmet Birhan Yılmaz
The fact that natriuretic peptides are quantitative biomarkers 
of myocardial wall stress leads to the consideration of the place 
of these biomarkers in disease management. Primarily, there are 
at least two published evidences on the prevention of HF devel-
opment and its treatment. As shown in both PONTIAC (99) and 
STOP-HF (100) Trials, identification, close monitoring and treat-
ment of asymptomatic patients in high-risk population whose 
natriuretic peptide levels are slightly above the limit will improve 
the results. Therefore, natriuretic peptides can find a place in 
the diagnosis and treatment of HF. On the other hand, studies 
performed regarding the role of HF treatment managed with the 
guidance of natriuretic peptides in Stage C and D patients have 
given different and inconsistent results. Therefore, chronic HF 
treatment with the guidance of natriuretic peptides is shown as 
Table 23. Clinical trials examining aliskiren in HF
 ALOFT ASTRONAUT ATMOSPHERE
Patient characteristics Chronic HF During acute HF hospitalization,  Chronic HF, EF <35% and 
  EF <40%, BNP ≥400 or  increased BNP
  NT-proBNP ≥1600 pg/mL
Number of patients 302 1639 7041
Mean age 55 65 ?
Functional class II-IV II-IV II-IV
Trial duration 3 months 12 months 1 year and longer
Treatment arms Aliskiren or placebo (1:1) Aliskiren or placebo (1:1) Aliskiren or enalapril or 
   aliskiren+enalapril (1:1:1)
Primary end-point Change in the NT-proBNP level CV mortality or HF hospitalization  CV mortality or HF  
  in months 6 and 12 hospitalization
Result/comment Significant reduction is observed in Similar to placebo.  Patient enrollment is over. 
 NT-proBNP, BNP and urinary aldosterone While placebo is better in   The results are expected  
 levels in the aliskiren group. Plasma renin 12-month follow-up in diabetics,  to be announced 
 activity demonstrated more reduction aliskiren is better in non-diabetics; at the end of 2015
 in the aliskiren group hypotension and impairment in 
  renalfunctionoccur more frequently 
  in the aliskiren group
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Class IIa indication in the guidelines.
In a recent meta-analysis (101), natriuretic peptide guidance 
has been found to be effective in reducing all-cause mortality in 
patients younger than 75 years of age [hazard ratio = 0.62 (0.45–
0.86); P = 0.004] in the outpatient management of chronic HF. This 
effect is not the same in patients above 75 years of age. On the 
other hand, natriuretic peptide guidance has been found to be 
effective independent of age in terms of reducing HF hospital-
izations. Current problems are the use of either absolute rank 
or percentile rank, the sensitivity and precision of the method 
used in evaluating the reference peptide, lack of clarity of what 
will change in a patient receiving the highest-dose of prognosis-
modifying therapy, other confounding factors (obesity, etc.) and 
accompanying diseases. Solving all of these problems at once 
does not seem to be possible. However, it should be kept in mind 
that natriuretic peptide guidance can affect prognosis favorably 
in patients whose drugs such as ACEIs, ARBs, BBs or MRAs 
have not been up-titrated to the highest dose yet.
14.0 Which drugs adversely affect the clinical
picture and should be avoided? – Ahmet Ekmekçi
Care should be taken regarding three main groups of drugs in 
patients with HF including drugs with negative inotropic effect, 
drugs causing sodium retention and drugs with directly cardio-
toxic effects (102).
Non-steroidal anti-inflammatory drugs — The use of non-
steroidal anti-inflammatory drugs are recommended to be 
avoided in HF due to causing the worsening of HF independent 
of ejection fraction and causing renal dysfunction as well as re-
ducing the beneficial effects of angiotensin-converting enzyme 
inhibitors (ACEIs) and diuretics. Observational data indicates 
that NSAID use increases mortality. This is also true for COX-
2 selective inhibitors. Although aspirin is indicated and provide 
clear clinical benefit in patients with cardiovascular disease, 
there is not enough data regarding benefit-risk ratio in patients 
with HF not accompanied by cardiovascular disease (103). 
Calcium channel blockers (CCBs) — Due to their negative 
inotropic effect, the use of CCBs, particularly the non-dihydro-
pyridine group of CCBs (verapamil, diltiazem), should be accept-
ed as contraindicated in patients with HF. However, in clinical 
trials conducted with amlodipine, a vasoselective agent in the 
dihydropyridine group, it has been observed that amlodipine has 
neutral effect in mortality and morbidity. Therefore, when CCBs 
should be used in other indications such as angina or hyperten-
sion, only amlodipine and felodipine can be used in patients with 
HF (102, 104).
Antidepressants — Depression is associated with poor clini-
cal outcomes including an increase in mortality in patients with 
HF. Therefore, it should be treated. Tricyclic antidepressant (TCA) 
drugs are not recommended due to poor end-points in patients 
with systolic HF. However, in an analysis of randomized, con-
trolled trials, it has been observed that there was no difference 
in terms of HF, myocardial infarction, stroke or cardiovascular 
mortality between TCAs and selective serotonin reuptake inhibi-
tors, but other cardiovascular side effects such as palpitation 
were higher with TCAs (105).
Oral hypoglycemic agents — Thiazolidinediones including 
pioglitazone should not be used as they cause fluid retention. 
Although metformin is a less preferred agent by clinicians due 
to causing lactic acidosis, it can be used in clinically stable HF 
patients (106).
Antiarrhythmic agents — Some of antiarrhythmic drugs 
are not preferred due to their negative inotropic effects, Class 
I and III agents (such as ibutilide and sotalol) due to their proar-
rhythmic effects and again ibutilide, sotalol, and dofetilide due to 
causing QT prolongation and torsades de pointes (102).
Chemotherapeutic agents — Cardiotoxic drugs such as an-
Table 24. Comparison of available MRAs and fineronone
 Finerenone (BAY94-8862) Spironolactone Eplerenone
Chemical group Non-Steroidal Steroidal Steroidal
Mechanism of action Competitive MRA Competitive MRA Competitive MRA
MR affinity +++ +++ +
MR selectivity +++ + +++
Inhibition of nongenomic MR effect Unknown No Yes
Initiation of activation and loss of effect Unknown Slow Rapid
Bioavailability Unknown in humans,  60-90% Absolute bioavailability 
 94% in rats  is not known
Binding to proteins Unknown Binding by 90% Binding by 50%
Metabolism Unknown Hepatic, active   Hepatic, inactive metabolites 
  metabolite by CYP3A4
Half-life Unknown 1-2 hours 4-6 hours
Elimination time of the drug and its metabolites Unknown 10-35  4-6 hours
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thracyclines, high-dose cyclophosphamide, trastuzumab, beva-
cizumab, paclitaxel and interferon should be used under close 
follow-up.
15.0 Which drugs should be used with caution to 
avoid drug-drug interaction? – Ahmet Ekmekçi
Drug-drug interaction is an important cause for morbidity 
and mortality in patients with HF. Generally, drugs can be af-
fected by pharmacodynamic drug interactions (Table 25). For ex-
ample, digoxin, amiodarone, warfarin and BBs are metabolized 
by CYP 2D6. The risk of severe hyperpotassemia increases with 
concurrent use of ACEIs, ARBs, MRAs and BBs (107). The risk 
of digoxin toxicity increases in the presence of hypokalemia. 
The risk of bleeding increases with concurrent use of warfarin, 
aspirin, clopidogrel, ticagrelor, and prasugrel. With the use of 
some antiarrhythmics in combination, QT prolongation and life-
threatening arrhythmias can be observed. Some diuretics used 
in combination cause electrolyte imbalance. Concurrent use of 
nitrates, alpha-blockers, BBs, ACEIs, diuretics, sildenafil, and 
CCBs increases the risk of hypotension. Concurrent use of amio-
darone, BBs, digoxin, verapamil, diltiazem, sotalol, and propafe-
none is associated with the risk of bradycardia (107, 108).
In patients with volume overload; drug absorption, distribu-
tion and clearance may change due to intestinal edema, hepatic 
congestion, and renal failure. The effect of warfarin may increase 
in acute conditions. The digoxin clearance reduces in the setting 
of acute decompensation and requires close monitorization. The 
effect of digoxin is increased by amiodarone, verapamil, diltia-
zem, propafenone, captopril, carvedilol, spironolactone, macro-
lides, and triamterene and decreased by salbutamol, sucralfate 
and rifampin. It is well-known that more than 70 drugs change 
the efficacy of warfarin. The effect of warfarin is increased by 
amiodarone, quinidine, cimetidine, allopurinol, cephalosporins, 
and metronidazole and decreased by cholestyramine, barbi-
turates, and phenytoin. In patients receiving PDE-5 inhibitors, 
regular or even intermittent use of nitrates may cause severe 
and lethal hypotension. In patients who will receive nitrates, 
sildenafil and tadalafil should be discontinued prior to 24 and 48 
hours, respectively (109).
16.0 Drug therapy in atrial fibrillation – 
Ahmet Ekmekçi
16.1 Does rhythm control provide clinical benefit in HF? 
Atrial fibrillation is observed in 13-27% of patients with HF 
depending on the severity of HF (110). In AF trials regardless of 
HF, no clear beneficial effect of pharmacological rhythm con-
trol has been demonstrated on survival. In the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management (AFFIRM) and 
RAte Control vs Electrical Cardioversion for Persistent Atrial Fi-
brillation (RACE) Trials, no superiority of rhythm control over rate 
control in terms of cardiovascular mortality and morbidity has 
been found (111, 112). 
In the Atrial Fibrillation and Congestive Heart Failure (AF-
CHF) Trial including HF patients with AF, rate or rhythm control 
have been observed to cause no difference regarding cardio-
vascular mortality or any cause mortality, worsening of HF or 
stroke in patients with congestive HF symptoms, AF, and LVEF 
≤ 35% in a 37-month follow-up (113). Rhythm control is recom-
mended only in patients who are symptomatic despite sufficient 
rate control (114, 115). Results of an analysis from the AFFIRM 
Trial have suggested that unfavorable effects of antiarrhythmic 
drugs used in rhythm control reduce the benefits provided by 
sinus rhythm (116).
16.2 What should the drug selection be in rate control? 
Ensuring rate control in patients with AF requires adjusting 
the dosing frequency of the drugs, use of various drug combina-
tions and frequent medication changes (117-119).
Commonly used drugs for rate control are BBs, non-dihy-
dropyridine calcium channel antagonists, digoxin, and amioda-
rone. These drugs are used alone or in combination as needed. 
Table 25. Possible adverse effects which can be observed with concurrent use of common drugs in HF are given in the table below
Drug-drug combination Severity Potential adverse effect
ACEI + Diuretic (loop or thiazide)  Moderate  Postural hypotension 
ACEI + Potassium-Sparing diuretic  Major  Hyperkalemia 
Phenprocoumon + Spironolactone  Moderate  Decreased anticoagulant effectiveness 
Aspirin (acetylsalicylic acid) [low dose] + LMWH  Moderate  Increased risk of bleeding 
Antidiabetic agent +β-Adrenoceptor Antagonist  Moderate  Decreased diabetic control 
Aspirin (low dose) + Clopidogrel  Minor  Increased risk of bleeding 
Clopidogrel + Torasemide  Moderate  Torasemide toxicity 
LMWH + Phenprocoumon  Major  Increased risk of bleeding 
ACEI + Potassium  Major  Hyperkalemia 
Amiodarone + Phenprocoumon  Moderate  Increased risk of bleeding
ACEI – angiotensin-converting enzyme inhibitor; LMWH – low molecular weight heparin
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BBs are the most effective agents for rate control (113). BBs are 
known to reduce mortality and morbidity in patients with HF and 
therefore their use is recommended as Class IA indication in HF 
guidelines (120). Another advantage of BBs is that they can con-
trol heart rate during both rest and exercise (121).
In AF patients with chronic systolic HF, digoxin can also be 
preferred for rate control. However, while digoxin reduces ven-
tricular rate during rest, it is not effective on rate control during 
exercise (121, 122). Use of digoxin is difficult due to its narrow 
therapeutic range and high drug interaction. The most common 
side effects are ventricular arrhythmia, atrioventricular block 
and sinus pause and they are all dose-dependent. Concurrent 
use of BBs and digoxin provides better results than their single 
use in terms of providing rate control, reducing symptoms and 
improving ventricular functions (123).
Amiodarone is a less effective antiarrhythmic agent in rate 
control. It is recommended in cases where ventricular rate 
control cannot be provided by BBs and digoxin in patients with 
chronic HF (122). However, it can be used to ensure acute ven-
tricular rate control intravenously or in high doses orally (124). 
Non-dihydropyridine calcium channel antagonists (vera-
pamil, diltiazem) should not be used in patients with systolic HF 
due to their negative inotropic effects. However, they can be 
used in HF-PEF with AF for rate control (125).
16.3 Does beta-adrenoceptor gene polymorphism have an 
effect on rate control? 
Beta-blocker response varies from patient to patient. The 
treatment should therefore be planned individually. One of the 
reasons why efficacy of BBs varies from patient to patient is β1 
adrenoceptor Arg389Gly gene polymorphism. Cyclic adenosine 
monophosphate synthesis reduces with substitution of argi-
nine for glycine at position 389 in β1 adrenoceptor (Arg389Gly) 
polymorphism (126, 127). In Europe, heterozygote genotype fre-
quency and homozygote genotype frequency are 40% and 7%, 
respectively. In the Vanderbil AF Trial conducted by Parvez et 
al. including 543 patients with AF, the patient group having ho-
mozygote Arg389 genotype has been determined to be more 
resistant to pharmacologic rate control (with various BBs) than 
the patient group having Gly389 genotype. However, in this trial, 
only 11% of the patient had HF.
The effect of this genetic polymorphism on rate control in 
patients with AF has been investigated in the Cardiac Insuf-
ficiency Bisoprolol Study in Elderly (CIBIS-ELD) Trial. In this 
trial, 528 patients with chronic HF (412 in sinus rhythm, 107 
with AF) were randomized to bisoprolol and carvedilol groups. 
The patient group in sinus rhythm had the same response to 
carvedilol and bisoprolol, independent of genotype. However, 
patients with AF having homozygote Arg389 genotype have 
been shown to respond 12 beats less to carvedilol (not biso-
prolol) compared to the patient group with at least one Gly389 
allele (128).
16.4 What precautions should be taken in risk stratification 
and warfarin indication? 
Atrial fibrillation is a strong risk factor for stroke and throm-
boembolism (129). It is known that other comorbid conditions 
(HF, hypertension, age, diabetes, stroke, or history of transient 
ischemic attack) along with AF increase the risk. CHADS2 and 
CHA2DS2VASc scoring systems are used to stratify the risk in 
patients as low, moderate and high. Previous trials have demon-
stated that HF carries a higher risk for thromboembolism com-
pared to other risk factors in these scoring systems (130-133). 
Therefore, CHADS2 and CHA2DS2VASc scores may underesti-
mate the real risk in patients with HF. According to these scor-
ing systems, a patient who has only HF is stratified into moder-
ate-risk group and in such a patient, initiation of anticoagulant 
therapy remains uncertain. In the high-risk patient group (score 
≥2), anticoagulants are definitely recommended; however, in 
patients who have ≤1 point, decision for antiplatelet or antico-
agulant therapy is not clear. In a study conducted by Lee et al. 
(134) comparing anticoagulants and aspirin, no difference was 
observed in the rates of major bleeding. In another study, it has 
been reported that the frequency of cerebrovascular events was 
lower in the group receiving vitamin K antagonist compared to 
the group not receiving vitamin K antagonist (135). Considering 
all these facts, in AF patients with HF, it has been observed that 
vitamin K antagonists are superior to antiplatelet agents in the 
moderate-risk group. The ESC AF guidelines recommend OAC 
use in moderate-risk group whose CHA2DS2VASc score is 1; 
whereas, they do not recommend anticoagulant or antiplatelet 
use in the low-risk group (score: 0). The ESC recommends anti-
platelet use in patients with a CHADS score ≥1 only if the patient 
refuses anticoagulant therapy.
It makes sense to initiate OAC therapy if the risk of bleeding is 
not very high in AF patients with HF. The HAS-BLED scoring sys-
tem (hypertension, hepatic and renal dysfunction, stroke, history 
of bleeding, labile INR, age (≥65 years), drug and alcohol use) 
can be used to determine the risk of bleeding (136).
16.5 Should new oral anticoagulant agents be preferred 
over warfarin?
In patients with HF, vitamin K metabolism is highly variable 
and this makes it difficult for INR values to remain in the thera-
peutic range. HF is one of the factors that increase bleeding risk 
in patients who receive vitamin K antagonists.
The use of new OACs (NOACs) is approved for non-valvular 
AF. In the RE-LY (Randomized Evaluation of Long Term Antico-
agulation Therapy) and ARISTOTLE (Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fibrillation) 
Trials, it has been shown that dabigatran and apixaban were su-
perior to vitamin K antagonists in terms of reducing adverse clin-
ical outcomes. In the ROCKET-AF (Rivaroxaban Once Daily Oral 
Direct Factor Xa Inhibition Compared with Vitamin K Antagonism 
for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) 
Trial, it has been demonstrated that rivaroxaban was not infe-
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rior to vitamin K antagonists (137-139). In a recent meta-analysis, 
new OACs and warfarin were compared in terms of preventing 
both systemic embolic event and stroke and causing bleeding in 
AF patients with HF. It has been reported that new OACs reduced 
systemic embolic event and stroke more than warfarin and that 
major bleeding and intracranial bleeding occurred less in the 
NOAC group. Total bleeding rates were similar in NOAC and war-
farin groups. This meta-analysis showed that NOACs may be a 
good alternative for warfarin in patients with HF.
17.0 Drug treatment in hypertension –
Timur Selçuk
17.1 What should the blood pressure target be in HF? 
In the treatment of hypertension in HF, the type of HF is im-
portant. In HF-PEF in which the systolic functions of the heart is 
normal and diastolic functions are impaired, the blood pressure 
target should be within the limits recommended by the current 
hypertension guidelines. Particularly in HF-REF in which systolic 
functions are impaired, an increase in blood pressure causes 
an increase in afterload and also causes an increase in pre-
load with an increase in the filling pressures of the heart. This 
may lead to acute HF manifestation by worsening of the clini-
cal condition of patient. Although target blood pressure has not 
been stated in current hypertension guidelines for HF, it seems 
reasonable to keep systolic BP at around 100-120 mm Hg and 
diastolic BP at around 60-80 mm Hg, which are optimal blood 
pressures to minimize unfavorable hemodynamic effects gen-
erated by high blood pressure. Particularly in the treatment of 
HF-REF, it should be considered that most of the drugs used by 
the patients have hypotensive effects and that their hypotensive 
effects will be potentiated while incrementing the target doses 
of these drugs and combining them with each other.
17.2 Which antihypertensives can be added to ACEIs/ARBs, 
Beta-blockers and MRAs? 
In patients receiving combination therapy such as with ACEIs/
ARBs, BBs and MRAs due to chronic HF-REF, adding diuretics 
to the combination therapy in order to benefit from their antihy-
pertensive properties is quite favorable in the case of hyperten-
sion. Loop diuretics are frequently used in patients with HF in 
whom fluid overload is significant. Thiazides can be used as the 
first-line antihypertensive drugs in addition to loop diuretics. In 
patients with HF-REF, dihydropyridine group of calcium-channel 
blockers (such as amlodipine, felodipine, nifedipine) with vasodi-
latation properties and a neutral effect on mortality can be used 
in the treatment of hypertension accompanied by HF. Isosorbide 
dinitrate- hydralazine combination is included in the category of 
drugs that can be effective in mortality in the treatment of HF and 
it can also be used as an antihypertensive due to its vasodilation 
properties. Drugs that are effective on the central nervous sys-
tem (clonidine, moxonidine) and also alpha-adrenergic blockers 
(prazosin) are not recommended in the treatment of hyperten-
sion associated with HF (3). Recommendations for the treatment 
of hypertension in patients with left ventricular systolic dysfunc-
tion and symptomatic HF (NHYA Functional Class II-IV) are given 
in Table 26 (3).
17.3 Why are Alpha-Blockers and Moxonidine not 
recommended in hypertension in HF? 
Alpha-blockers are agents used in the treatment of hyperten-
sion due to their vasodilator properties. The vasodilation proper-
ties of alpha-blockers have generated the idea that they can be 
used in the treatment of HF as well. However, in small-scale pilot 
trials, it has been observed that risk of HF increased with alpha-
blocker therapy. In a double-blind study evaluating the effect of 
isosorbide dinitrate and ISDN-H combination and prazosin on 
mortality, ISDN-H combination has been demonstrated to be ben-
eficial on mortality in patients with HF compared to placebo and 
prazosin has been shown to have no effect on mortality in patients 
with HF compared to placebo. The ratio of worsening HF was the 
highest with 8.5% in the prazosin group and it has been found to 
be 7.5% and 5.5% in ISDN-H and placebo groups, respectively (45). 
In the ALLHAT Trial, decompensated HF has been observed to be 
higher in the alpha-blocker group than the diuretic group. There-
fore, use of alpha-adrenoceptor antagonists is not recommended 
in hypertension accompanied by HF because of safety concerns 
(neurohumoral activation, fluid retention, worsening HF) (140).
Moxonidine is an agent with an inhibition property on cen-
tral nervous system and is a receptor agonist of imidazole. In the 
MOXCON Trial where the effect of moxonidine in patients with 
HF was evaluated, it has been observed to increase mortality 
and hospitalizations compared to placebo and its use in HF was 
not recommended by the current guidelines (141).
18.0 Drug treatment in coronary artery disease –
Mehdi Zoghi
18.1 Which anti-anginal drugs can be added to beta-
blockers?
The ESC Guidelines for HF recommend BB treatment as 
the first-line therapy in the presence of angina. In patients with 
contraindication or intolerance to BBs, ivabradine, nitrate, am-
lodipine, nicorandil or ranolazine can be used instead of BB 
treatment. In patients in which angina cannot be controlled with 
BB treatment, one of ivabradine, nitrate, amlodipine, nicorandil 
or ranolazine can be added to the BB treatment. In systolic HF 
patients with anginal pain, amlodipine, ivabradine and nitrates 
can be used safely. The efficacy of nicorandil and ranolazine is 
controversial in this group of patients. A meta-analysis of 15 ran-
domized clinical trials, where trimetazidine added to the conven-
tional treatment in HF was evaluated, showed that trimetazidine 
improved NYHA functional class (−0.57, p=0.0003), increased ex-
ercise duration (63.75 min., p<0.0001), improved left ventricular 
EF (6.46%, p<0.0001) and reduced the frequency of hospitaliza-
tion (RR: 0.43, p=0.03) (3, 142).
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18.2 How effective are nicorandil, ivabradine and 
ranolazine in angina control? 
Although a meta-analysis of 20 trials evaluating the efficacy 
of nicorandil reported favorable outcomes, most of the trials in-
volved in this meta-analysis were observational, included very 
heterogeneous HF patient population and the inclusion criteria 
for each trial varied significantly (3, 143).
Ivabradine is recommended by the ESC HF guidelines as an 
anti-anginal agent in patients who have CAD with systolic HF in 
sinus rhythm (3). However, a recently published SIGNIFY trial, in 
almost 20,000 patients who have CAD with a heart rate >70 b.p.m 
and without HF, indicated that ivabradine did not reduce cardio-
vascular death or nonfatal MI, cardiovascular death alone and 
non-fatal MI alone. Furthermore, SIGNIFY trial pointed out that 
in patients with angina limiting daily activity, ivabradine may be 
able to increase cardiovascular death or non-fatal MI (144).
In RALI-DHF (RAnoLazIne for the Treatment of Diastolic Heart 
Failure) Trial, in HFpEF patients, ranolazine has been shown to 
provide an improvement in hemodynamic measurements (left 
ventricular end-diastolic pressure and PCWP) whereas no sig-
nificant beneficial effect has been found in diastolic echocardio-
graphic or cardiopulmonary exercise parameters. On the other 
hand, in HFpEF cases with CAD (EF: 58%±10), after 2 months ra-
nolazine use, significant improvements in deceleration time, iso-
volumetric contraction time and myocardial performance index 
were reported (145).
These findings suggest that there is no enough data for the 
efficacy and safety of nicorandil and ranolazine use in angina 
control in HF. Ivabradine is a drug the efficacy of which has been 
proven in the treatment of HF-REF. However, more data is required 
regarding efficacy and safety in patients with CAD and angina. 
19.0 Drug treatment in chronic renal disease – 
Ahmet Temizhan
19.1 Which should be preferred in the management of drug 
therapy: serum creatinine level or eGFR? 
Glomerular filtration rate is usually estimated by serum cre-
atinine concentration. In elderly and very sick patients, since 
creatinine production will decrease due to a reduction in muscle 
mass, GFR may be significantly low in these patients even if se-
rum creatinine levels are within normal range or slightly elevat-
ed. Therefore, while evaluating the renal functions, estimated 
GFR adjusted to race, age, weight and gender is recommended 
to be used instead of serum creatinine. For the correct GFR es-
timation, the serum creatinine levels should be stable. GFR cal-
culation should not be used in patients whose serum creatinine 
values increase gradually or are highly variable. Patients with 
decompensated HF, particularly those receiving intensive diuret-
ic therapy are typical examples in this regard. Therefore, when 
managing drug therapy in patients with HF, GFR should be used 
in stable outpatients and creatinine value in decompensated pa-
tients receiving diuretics.
19.2 How should drug therapy and monitoring be performed 
in hyperpotassemia? 
Almost all of the drugs that are used in the treatment of 
chronic HF (RAAS blockers, MRAs, BBs and diuretics) affect se-
rum potassium levels. The risk of hyperpotassemia is very low in 
patients with normal renal functions; whereas in patients with 
renal dysfunction, which is frequently accompanied with HF, the 
risk of hyperpotassemia is higher. However, “patients with re-
nal dysfunction who are very likely to develop hyperpotassemia 
Table 26. Recommendations for the treatment of hypertension in patients with HF-REF (3)
Recommendations Class Level
Step I  
One or more of an ACEI (or ARB), BB and MRA is recommended as first-, second-, and third-line therapy, respectively I A
Step 2  
A thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended I C
when hypertension persists despite treatment with a combination of as many as possible of an ACEI (or ARB),
BB, and MRA
Step 3  
Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as I A
possible of an ACEI (or ARB), BB, MRA, and diuretic
Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as I A
possible of an ACEI (or ARB), BB, MRA, and diuretic
Felodipine should be considered when hypertension persists despite treatment with a combination of as many IIa B
as possible of an ACEI (or ARB), BB, MRA, and diuretic
Moxonidine is not recommended because of safety concerns (increased mortality). III B
Alpha-adrenoceptor antagonists are not recommended because of safety concerns III A
(neurohumoral activation, fluid retention, worsening HF)
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are the patients who will receive the most cardiovascular ben-
efit from the treatment”. Therefore, evidence-based HF therapy 
should be implemented insistently by close monitoring of potas-
sium levels in patients who have HF and renal dysfunction.
Cautions for serum potassium levels in the management of 
chronic HF should be taken. First of all, it should be ensured that 
serum potassium measurement is correct and also it should be 
kept in mind that hypopotassemia is as dangerous as hyperpo-
tassemia. Serum potassium level should be kept above 4 mEq/L. 
Optimal serum potassium value is between 4–5 mEq/L. Howev-
er, the values between 5–5.5 mEq/L are considered safe (146). 
Drugs can be continued as long as serum potassium levels are 
within the 4.0–5.5 mEq/L range. Close monitoring is mandatory 
particularly in patients with serum potassium levels between 5 
to 5.5 mEq/L, renal dysfunction and/or diabetes (147). If NSAIDs, 
potassium sparing diuretics and salt equivalents are used, they 
should be discontinued. Potassium-rich foods should be re-
duced. The risk of severe hyperpotassemia reduces in patients 
who are regularly monitored (148, 149). It is not known whether 
serum potassium levels within a range of 5.5 - 6.5 mEq/L without 
an ECG change are dangerous or not. However, it is very impor-
tant to know that severe hyperpotassemia may develop rapidly in 
these patients (Table 27, Figure 2).
19.3 How should diuretic therapy strategies be arranged in 
congestion treatment? 
There is no absolute diuretic strategy recommended since 
the dose-response curve of diuretics in patients with congestion 
varies significantly in each patient and there are no significant 
differences in the benefit-risk ratio among parenteral routes of 
administration (3, 4). Individual administration of furosemide and 
thiazide group of diuretics, the most commonly used diuretics in 
in-patients and outpatients under monitorization, is as follows:
In-patients: Whether the patient used diuretic previously and 
the patient’s response to the drug should be evaluated. If the pa-
tient is diuretic-naïve, i.v. low dose (≤1 mg/kg daily) furosemide 
should be initiated and the dose should be adjusted according to 
the response. If the patient had previous diuretic use, i.v. admin-
istration of the previous oral dose of furosemide (represents low 
dose for these kinds of patients), or in case of severe congestion, 
i.v. administration of 2.5 times the oral dose are recemmended 
(represents high dose) and then the dose should be adjested ac-
cording to the response (see Table 28 which helps up-titration of 
the dose).
Intravenous administration can be performed as 24-hour in-
fusion or bolus injection in doses divided into two. The maximum 
daily dose is 600 mg (3, 4). Other loop diuretics can be used in ac-
cordance with doses equivalent to 40 mg of furosemide (torase-
mide 20 mg and bumetanide 1 mg) (3, 4). Thiazide group diuretics 
can be added to the treatment in patients with eGFR ≥30 mL/
min/1.73 m2 (3, 4). Metolazone is approximately a 10 times more 
potent thiazide diuretic than hydrochlorothiazide (HCTZ) (3, 4). 
It can replace HCTZ in resistant patients. Generally, once daily 
dose is enough. The monitorization of the patient should be close 
and individual (Table 29).
Table 27. Initial and maintenance doses of mineralocorticoid receptor antagonists (4)
 eGFR (mL/min/1.73 m2)
 ≥50 30-40
 Initial dose Maintenance dose Initial dose Maintenance dose
 (if K ≤5 mEq/L) (if K is ≤5 mEq/L    (if K is ≤5 mEq/L) (if K is ≤5 mEq/L  
  at the end of 4 weeks)  at the end of 4 weeks)
Eplerenone 25 mg/day 50 mg/day 25 mg, every other day 25 mg/day
Spironolactone 12.5-25 mg/day 25-50 mg/day 12.5 mg/day or every other day 12.5-25 mg/day
eGFR – estimated glomerular filtration rate
Table 28. Recommendation for furosemide dose up-titration in patients 
under diuretic therapy* (151)
Previous dose Recommended dose
≤80 mg 40 mg i.v. bolus + 5 mg infusion/hour
81-160 mg 80 mg i.v. bolus + 10 mg infusion/hour
161-240 mg 80 mg i.v. bolus + 20 mg infusion/hour
>240 mg 80 mg i.v. bolus + 30 mg infusion/hour
*Adapted from CARRESS HF study (150)
Table 29. Monitorization of patients receiving diuretics at hospital
1- Daily weight monitorization is safer and easier than monitoring   
 fluid output
2- Urinary catheter should not be routinely placed because of   
 infection risk
3- Daily fluid intake should be monitored (See fluid restriction part)
4- Daily blood pressure monitorization should be performed
5- Monitorization of renal functions and electrolytes should be   
 arranged according to the patient;
	 •	 Frequency	of	monitorization	can	be	decided	according	to	the		 	
  eGFR value at the time of initiation of therapy. It will be enough   
  to measure renal functions every day if eGFR value is <30 and   
  every 3 days if ≥30
	 •	GFR	is	not	reliable	in	patients	receiving	intensive	diuretic		 	
  therapy as creatinine values will show a dynamic change.   
  Therefore, it is more appropriate to monitor renal functions   
  according to creatinine levels
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Evaluation of the diuretic response and dose adjustment: Al-
most 500 gr to 1 kg daily weight loss is expected. I.V. loop diuretic 
is continued until congestion signs disappear (mostly equivalent 
to dry weight). After dry-weight is ensured, the initial high-dose 
is decreased to the dose that can maintain dry-weight accord-
ing to renal functions. It should be switched to oral dose when 
congestion disappeared. Double dose of the last parenteral dose 
is administered orally. The dose is divided into two and must be 
taken before meals. Parenteral diuretics can be given as long as 
systolic blood pressure is ≥90 mm Hg. Serum potassium levels 
should be kept at ≥4 -5.5 mEqL. If serum sodium value is <125 
mEq/L despite high-dose treatment, tolvaptan should be added.
Outpatients: Whether the patient used diuretic previously 
and the patient’s response to the drug should be evaluated. If 
the patient is diuretic-naïve, 40 mg/day furosemide is initiated. 
The dose is divided into two and should be given before meals. 
If the patient had previous diuretic use, a double dose of the 
previous furosemide dose is given. The dose is divided into two 
and should be given before meals. Oral furosemide dose adjust-
ment is performed according to weight loss, renal functions and 
electrolyte levels.Frequency of monitorization can be decided 
according to the eGFR value at the time of initiation of therapy. 
It will be enough to measure renal functions after 3 days if eGFR 
value is <30 ml/min and after one week if ≥ 30 ml/min. However, it 
is more appropriate to monitor renal functions according to cre-
atinine levels.Almost 500 gr to 1 kg daily weight loss is expect-
ed. The dose should be up-titrated step by step until desirable 
weight loss is ensured and congestion signs disappear. HCTZ 
may be added to the treatment along with furosemide dose ti-
tration. There is no commercially available single HCTZ prepara-
tion in our country. Therefore, combinations with RAAS blockers 
or spironolactone can be considered. In patients without high 
blood pressure, uptitration to 25 and 50 mg of HCTZ doses with 
spironolactone combination can be preferred for diuretic effi-
cacy and to avoid hypotension. Serum potassium levels should 
be kept at ≥4 -5.5 mEqL. Daily maximum dose should be 600 mg 
for furosemide and 50 mg for HCTZ in compliant patients to the 
treatment (3, 4); if congestion does not improve or renal func-
tions are impaired despite these doses, the patient should be 
hospitalized.
MRA + ACE inhibitor/ARB
Serum K >5-5.5 mEq/L
EGFR ≥50 EGFR ≥50 eGFR 30-40
Diet
SBP <90 mmHg
ACE inhibitor/
ARB
half dose
MRA
half dose
SBP ≥90 mmHg
Diet Diet
SBP <90 mmHg
Discontinue 
ACE inhibitor/
ARB.
MRA
half dose
Discontinue 
MRA. 
ACE inhibitor/
ARB
half dose
SBP <90 mmHg
Discontinue 
ACE inhibitor/
ARB
Discontinue 
MRA
Control every other week. If serum K values
- are the same, continue current therapy
- decrease, uptitrate to the previous dose
- increase, discontinue both drugs
SBP ≥90 mmHg
SBP ≥90 mmHg
eGFR 30-40
Serum K >5.5-6.5 mEq/L (change in ECG+)
Discontinue both drugs
Serum K >5.5-6.5 mEq/L (no change in ECG)
Figure 2. Drug management according to the serum potassium levels during follow-up in patients receiving ACEIs/ARBs and MRAs
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General precautions: Weight monitorization (see Weight 
Monitorization part), blood pressure monitorization and moni-
torization of daily salt consumption including salt equivalents 
should be implemented. Adherence to drug therapy and discon-
tinuation of NSAIDs should be ensured.
19.4 Can tolvaptan be an alternative to diuretics in 
congestion? 
Tolvaptan is an active vasopressin antagonist that can be 
used orally. With its aquaretic effect, it has an important place 
in the treatment of HF in increasing serum sodium levels in 
euvolemic and particularly in hypervolemic patients with hy-
ponatremia. In HF patients with persisting hyponatremia (<125 
mEq/L) despite the use of high-dose diuretic therapy, tolvaptan 
is an appropriate treatment approach, regardless of presence 
of congestion. However it should be kept in mind that It is not 
alternative, but an adjuvant approach to diuretic therapy and can 
shorten the duration of hospital stay.
Tolvaptan is initiated with 15 mg daily. Caution is required on 
the increase in serum sodium level that should not be exceeded 
>1.0 mmol/L/hour in the first 8 hours (risk of osmotic demyelin-
ation syndrome). After a 2-days treatment, it can be increased 
to 30 mg if enough diuretic efficacy and/or increase in serum 
sodium levels are not ensured.
Although there is not enough published data regarding its 
safe and effective long-term use (>30 days) (151, 152), if hypo-
natremia persists when the drug is discontinued, it can be ad-
ministered for a longer period of time. However, if serum sodium 
level is under control with other diuretics after hyponatremia is 
corrected, long-term use of tolvaptan is not necessary.
19.5 Does torasemide provide any advantage over 
furosemide? 
Although open-label, observational Torasemide in Chronic 
Heart Failure (TORIC) Trial has not been designed for mortality, 
total and cardiovascular mortality have been found to be lower in 
patients treated with torasemide than the patients receiving furo-
semide (and other diuretics) (153). Further improvement in func-
tional capacity and less abnormality in serum potassium levels in 
patients receiving torasemide are considered related to the drug’s 
high bioavailability (154) and anti-aldosteronergic effect (155).
If we consider that furosemide as the most commonly used 
diuretic in patients with HF does not provide same level of ef-
ficacy in each patient, we can say that torasemide present an 
advantage over furosemide. Oral initial dose of torasemide is 10-
20 mg o.d. and can be increased up to 200 mg.
19.6 How can we realize whether the worsening renal 
functions are related to RAAS blockers or renal failure? 
In patients with HF in whom serum creatinine levels are el-
evated and/or GFR reduced, it is important to differentiate car-
diorenal syndrome and drug-related changes from each other. 
However, it is not always possible to differentiate. In some pa-
tients all can co-exist (156). Marked proteinuria (generally >1000 
mg), urinary sediment changes concurrent with hematuria, small 
size of kidneys in radiological evaluation should suggest under-
lying renal disease. Normal urinalysis is typical in cardiorenal 
syndrome and drug-dependent changes; however, it should be 
kept in mind that in case of nephrosclerosis and obstructive ne-
phropathy, urinalysis is normal as well.
There may be a 30% elevation in serum creatinine levels with 
RAAS blockers. This elevation is mostly a reflection of angio-
tensin II inhibition rather than impairment in renal dysfunction 
(157, 158). However, RAAS blockers can also be nephrotoxic so 
as to cause severe impairment in renal functions. Drug-related 
changes in renal functions are observed 3-5 days after the drug 
is initiated and become stable in 7 days unless it is nephrotox-
icity (159). If the patient’s serum creatinine value increases by 
≥50% or 1.5 times of basal value in 48 hours and urine output 
decreases (urine output <0.5 mL/kg/hour for longer than 6 hours) 
Table 30. KDIGO classification for acute kidney injury (160)
Stage Serum creatinine Urine output (UO)*
1  An increase of 1.5-1.9 times the basal value   UO <0.5 mL/kg/hour (for 6-12 hours)
 or
 0.3 ≥ mg/dL increase
2  An increase of 2.0-2.9 times the basal value UO <0.5 mL/kg/hour (for ≥12 hours)
3  An increase of 3.0 times the basal value UO <0.3 mL/kg/hour (for ≥24 hours)
 or or
 creatinine being ≥ 4.0 mg/dL anuria for ≥12 hours
 or
 dialysis requirement
 or
 eGFR being <35 mL/min/1.72 m2 in patients <18 years of age
*Reduction in urine output is a fairly sensitive marker of renal dysfunction. It occurs usually before an elevation in creatinine. It should be kept in mind that urine output can be affected 
by diuretic use
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dependent on the drugs, it can be concluded that acute kidney 
injury is about to start (Table 30). If renal dysfunction persists and 
gradually progresses in patients with chronic HF receiving RAAS 
blockers, patients should be closely monitored and investigated 
(Figure 3). Information on renal functions of the patient before 
treatment or in stable periods helps making a differential diag-
nosis of renal dysfunction that develops later (Table 31). There-
fore, the most important examination to be performed in routine 
follow-up of patients with chronic HF is renal functions.
19.7 How can we optimize drug therapy in pre-dialysis and 
dialysis patients? 
Since patients with chronic renal disease are not included in 
most of the major HF trials, there is not enough evidence regard-
ing the use of RAAS blockers and their possible clinical outcomes 
in pre-dialysis patients and patients who undergo regular dialysis 
program. HF treatment guidelines recommend that RAAS block-
ers should be cautiously used in the presence of chronic renal 
disease (CRD) and although there is not a clear contraindication, 
they restrict the use of these drugs in patients with eGFR value 
<30 mL/min/1.73 m2 (3, 4). In fact, it makes sense to be expected 
that RAAS blockers, which are the cornerstones of treatment in 
HF, affect prognosis favorably in patients who have HF in associa-
tion with CRD. Based on the results of retrospective studies (163, 
164), expert opinions (165) and KDIGO recommendations (166), it 
has been pointed out that these patients may benefit from RAAS 
blockers with appropriate follow-up. In a recent prospective co-
hort analysis, it has been reported that in HF patients with severe 
renal disease (creatinine clearance <30 mL/min, Stage 4-5 CRD), 
RAAS blockers reduced all-cause mortality (167). We are look-
Progressive increase in blood urea nitrogen 
and creatinine levels After the first 7 days
Is there oliguria?
Yes
Prerenal diseases
Urine sediment? Renal parenchymal disease
Chronic renal
disease
Bilateral small
kidneys
Kidneys in
normal size
Volume
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(Congestion)
No
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*:BUN/Cre?
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Consider diuretic use
Figure 3. Approach to patients with chronic HF whose renal functions impair in the course of the therapy (162, 163) 
*Blood urea nitrogen/creatinine ratio (BUN/Cre) is commonly used to differentiate pre-renal failure from the underlying renal disease. Increased BUN/Cre ratio (if there is no increase in urea 
production) typically indicates pre-renal etiology; **FENa: fractional excretion of sodium (162)
FENa = 100 x (urine sodium x serum creatinine)/(serum sodium x urine creatinine)
If FENa is <1%, pre-renal possibility is high (can be acute glomerulonephritis, contrast nephropathy, rhabdomyolysis, urinary obstruction)
If FENa is >2% it is very likely to be kidney-related
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ing forward to hearing about the results of trials conducted with 
drugs such as RAAS blockers (for example, selective non-steroi-
dal aldosterone blockers) and better-tolerated potassium binding 
polymers that are currently under investigation. In the light of this 
information, basic drug recommendations in dialysis and pre-
dialysis patients with HF are summarized in Table 32 and Table 33.
When interpreting the recommendations concerning the use 
of drugs, the followings should be considered: These basic drugs 
are beneficial in HF patients with CRD. We should try to use them 
as much as possible. It is appropriate neither to use them in ev-
ery patient nor to restrict with the side effect concerns. There-
fore, considering the evidence and general aspects (Table 33), 
prioritizing safety when using RAAS blockers and individualizing 
the treatment are the most accurate approaches in this patient 
group in whom cardiovascular mortality is high.
20.0 Drug treatment in diabetes mellitus –
İbrahim Sarı
20.1 Which antidiabetics should be used? Which should be 
avoided? 
Metformin is the first choice drug as monotherapy or in com-
bination in the treatment of diabetes (Table 34). It reduces hepat-
ic glycogenesis, increases insulin sensitivity, peripheral glucose 
uptake, and reduces glucose absorption from the intestine. Since 
metformin was believed to increase the risk of lactic acidosis, it 
has been considered as contraindicated in HF for a long time. 
However, it was demonstrated that this risk was actually much 
lower and not more than other anti-diabetics. Furthermore, when 
used alone or in combination with sulphonylureas in HF, metfor-
min reduced mortality compared to sulphonylureas alone in ob-
servational studies. Therefore, in 2007 FDA removed the warning 
that metformin was contraindicated in HF. To summarize, regard-
less of the presence or absence of HF metformin is the first-line 
treatment in all diabetics unless there is a contraindication.
Sulphonylureas increase insulin secretion from pancreatic 
beta-cells. There is no prospective study regarding its use in HF. 
Observational studies show that sulphonylureas are not associ-
ated with worse outcome in patients with HF. End-points with 
metformin are better in studies comparing sulphonylureas with 
metformin in patients with HF. Due to its risk of hypoglycemia 
and weight gain, it is recommended that patients with HF should 
be careful about these effects of sulphonylureas. In summary, it 
seems rational that they should be used in addition to metformin 
or in whom metformin is contraindicated, rather than as a first-
line therapy (Table 34).
Table 31. Possible AKI, ARD and CRD diagnoses (160) according to GFR and serum creatinine
Patients with basal GFR value ≥60 mL/min/1.73 m2
Increase in serum creatinine (for 7 days) GFR (for 3 months) Diagnosis
>1.5 folds Unchanged AKI
<1.5 folds <60 ARD (no AKI)
<1.5 folds >60 No known renal disease
Patients with basal GFR value <60 mL/min/1.73 m2 
Increase in serum creatinine (for 7 days) GFR (for 3 months) Diagnosis
>1.5 folds Unchanged AKI+CRD
<1.5 folds >35% reduction ARD (no AKI) +CRD
<1.5 folds <35% reduction CRD
AKI – acute kidney injury; ARD – acute renal disease; CRD – chronic renal disease; GFR – glomerular filtration rate
Table 32. Basic drug recommendations in HF patients with CRD
Drug  Stage 3 CRD Stage 4–5 CRD
 (eGFR 30–59 mL/min/1.73 m2) (eGFR <30 mL/min/1.73 m2)
ACEIs Recommended in all HF patients with LVEF ≤40% (31, 169, 170). They can be used, however renal functions and electrolytes  
  should be closely monitored (31, 169, 170).
ARBs Recommended in all HF patients with LVEF ≤40%; if there They can be used, however renal functions and electrolytes
 is ACEI intolerance or if symptoms persist despite ACEI should be closely monitored (173).
 and BB therapy but there is MRA intolerance (171, 172).
MRAs Recommended in all HF patients with LVEF ≤35%; Not recommended - no evidence
 if symptoms persist despite ACEI and BB therapy (15, 16, 174).
BBs Recommended in all HF patients with Recommended in all HF patients with LVEF ≤40% (175-179)
 LVEF ≤40% (31, 170, 171) (175-178)
CRD – chronic renal disease; eGFR – estimated glomerular filtration rate; ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid 
receptor antagonist; BB – beta-blocker; EF – ejection fraction
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Glitazones (Thiazolidinediones) improve the presentation and 
function of glucose transporters in adipose tissue, muscle and 
heart by increasing insulin sensitivity. They decrease unesteri-
fied fatty acid use by myocardium. While they have favorable ef-
fects on lipid profile, they can worsen HF due to fluid retention. 
This worsening is more marked in concurrent insulin users. FDA 
emphasizes that glitazones are contraindicated in patients with 
NYHA functional capacity III-IV and that they should be used with 
caution in NYHA functional capacity I-II patients. The ESC HF 
guideline state that glitazones should not be used in HF patients.
Insulin: Most of the patients require insulin as monotherapy 
or in combination. Although there are no trials investigating the 
effect of insulin primarily in HF patients, it appears to be safe. It 
has (+) inotropic effect on myocardial tissue and improves hemo-
dynamics in HF. However, sodium retention and weight gain are 
among its adverse effects. The end-points of studies regarding 
insulin use in HF are controversial. If it is used, patients should 
be monitored regularly, particularly regarding hypoglycemia and 
fluid retention (Table 34).
Incretin Secretion Modulators contain a group of gastroin-
testinal proteins regulating the glucose metabolism with more 
than one mechanism. They contain glucagon-like peptide ago-
nists (GLP-1) (exenatide, albiglutide, lixisenatide, and liraglutide) 
and dipeptidyl peptidase–4 inhibitors (DPP-4) (sitagliptin, saxa-
gliptin, vildagliptin, alogliptin, and linagliptin). Since they are ac-
tivated by food, they are particularly effective in the treatment 
of postprandial hyperglycemia. They appear to be attractive 
alternatives since hypoglycemia and other side effects are ob-
served less. Preclinical and small scale studies have shown that 
they have favorable effects on cardiac hemodynamics. There 
are controversial publications that sitagliptin and saxagliptin 
increase HF hospitalizations. Ongoing major trials will provide 
clearer information regarding the efficacy and safety of this 
group of drugs in patients with HF. 
Table 33. General matters that should be known in patients receiving RAAS blockers
– Primarily, we should try to administer ACEI (ARB) and MRA combination. If the patient cannot tolerate (hyperkalemia, hypotension,   
 progression in renal dysfunction) and we have to give only one RAAS blocker, ACEIs (ARB) should be preferred (180)
	 	 •	 In	clinical	trials,	MRA	was	used	as	an	add-on	therapy	to	ACEI	(ARB).	The	results	are	not	known	if	MRA	is	given	alone
	 	 •	 We	have	evidence	that	ACEIs	(ARB)	are	beneficial	without	MRAs
– High-dose RAAS blockers reduce cardiovascular end-points more than their low doses. However, considering that renal dysfunction,   
 hyperkalemia and hypotension are less in low doses, we can say that although the benefit reduces, even low doses are better than not taking  
 them at all
				 	 •	 In	the	subgroup	analyses	of	randomized	trials,	in	HF	patients	with	reduced	GFR,	it	has	been	determined	that	relative	risk	reduction	with		
   ACEI/ARB, BB and MRA therapy is similar in patients with normal renal functions (even more absolute risk reduction) (166)
– Benefit-risk balance should be carefully assessed when initiating RAAS blockers in Stage 4-5 CRD (eGFR value <30 mL/min/1.73 m2), although  
 they affect prognosis favorably
– Close monitorization of renal functions and serum potassium level is essential after initiating the drugs. Although there is no standard   
 monitorization method, methods used in randomized clinical trials can be used
	 	 •	 For	example,	in	EMPHASIS-HF	Trial,	dose	was	reduced	if	serum	potassium	level	was	5.5-5.9	mmol/L,	discontinued	if	≥6.0	mmol/L.	The		
   drug was restarted when the potassium level returned to ≤5.0 mmol/L after 72 hours (16)
	 	 •	 In	the	dose	adjustment	of	RAAS	blockers,	blood	pressure	should	be	considered	as	well	as	basal	renal	functions	and	individual	approach		
   should be implemented (See How should treatment be arranged and monitorization be performed in hyperpotassemia?)
ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; CRD – chronic renal disease; eGFR – estimated glomerular filtration rate; RAAS 
– renin angiotensin aldosterone system; MRA – mineralocorticoid receptor antagonist 
Table 34. Recommendation on the use of antidiabetic agents in heart failure
Drug/Group Use/Comment
Metformin First choice
  Contraindications: eGFR <30 mL/min, shock, sepsis
Sulphonylureas (Glipizide, Gliclazide, Glibenclamide, (Glyburide), Can be used in addition to metformin or in patients in whom metformin
Glimepiride, Gliquidone) is contraindicated. Caution for hypoglycemia and weight gain
Sulphonylurea-like Group, Glinides (Repaglinide, Nateglinide) 
Glitazones (pioglitazone, rosiglitazone) Contraindicated in HF because of fluid retention risk
Insulin End-point data is controversial. It may cause sodium retention and   
  weight gain
Incretin Secretion Modulators They mostly prevent postprandial hyperglycemia, risk of hypoglycemia  
  is low, data concerning their efficacy and safety in patients with HF is  
  controversial, major trials are ongoing
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20.2 Does diabetes affect choice of beta-blocker? 
Historically, BBs were avoided in diabetic patients. The main 
reasons for this are their potential to suppress the response of 
the body to hypoglycemia (palpitation and tremor) and the con-
sideration that recovery from hypoglycemic status is longer in 
patients on BBs (the suppression of glucose production in the 
liver due to beta2 receptor blockade). However, most clinical 
studies have shown that this unfavorable effect is no more than 
a placebo.
Currently, BBs are one of the key molecules in the treatment 
of HF. A meta-analysis including major trials conducted with BBs 
(1883 diabetic and 7042 non-diabetic patients) has shown that 
survival advantage provided by BBs were present in both diabet-
ic and non-diabetic group (relative risk 0.77 in diabetics, 0.65 in 
non-diabetics). There was no statistically significant difference 
regarding the risk reduction between diabetic and non-diabetic 
patients (180).
Therefore, the recommendations of both ESC and ACCF/AHA 
guidelines concerning BBs are similar for diabetic and non-di-
abetic patients. Moreover, it is emphasized that the ratio of BB 
use is lower in diabetic patients. In clinical practice, almost one 
third of HF patients are diabetic. There is no recommendation in 
guidelines regarding BB selection in HF patients with diabetes.
In the GEMINI Trial including diabetic hypertensive patients, 
while metoprolol tartrate worsened insulin resistance, carvedilol 
had a neutral effect (181). Carvedilol was also superior in terms 
of the effects on lipid profile. In the COMET Trial, the ratio of 
new-onset diabetes was 22% less in the carvedilol group when 
compared with the metoprolol group (p=0.039) (182).
In conclusion, although there are no end-point trials compar-
ing the BBs with each other in HF patients with diabetes, it can 
be suggested that carvedilol has more favorable metabolic ef-
fects than metoprolol, but we cannot make any comparison with 
bisoprolol and nebivolol.
20.3 Does diabetes affect choice of diuretic?
The effect of diuretics on mortality is not known in HF; 
whereas they reduce edema and improve shortness of breath. 
Therefore, in patients with signs and symptoms of congestion, 
they are recommended by the guidelines regardless of EF. 
Diuretics should be used in the lowest possible dose to ob-
tain the dry weight of the patient. The reason for this is the po-
tential adverse effects, such as hypotension, worsening renal 
function, electrolyte imbalance, hyperuricemia and overactiva-
tion of the sympathetic and renin angiotensin aldosterone sys-
tems. Other than these, diuretics have unfavorable effects on 
the glucose metabolism. They may trigger hyperglycemia and 
cause insulin resistance. Their unfavorable effects on glucose 
levels are dose-related, and the dose relationship is more sig-
nificant with thiazide diuretics. Since there is a predisposition 
to the above mentioned impairments in diabetic patients, keep-
ing the diuretic dose as low as possible is even more important 
in these patients.
There is not enough data to evaluate whether the effects of 
diuretics are the same in diabetic or non-diabetic patients with 
HF. However, it may be considered that the general criteria con-
cerning diuretic use in diabetic patients are the same as in non-
diabetics (183). 
20.4 What are the important points in insulin use? 
Insulin is necessary in the majority of diabetic patients either 
as monotherapy or in combination. Insulin has a (+) inotropic 
effect on myocardial tissue and improves hemodynamics in HF. 
Although there is no major trial investigating the effect of insulin 
primarily in HF patients, it appears to be safe. However, sodium 
retention and weight gain are among its adverse effects. Since 
insulin-dependent fluid retention is central rather than a periph-
eral edema (pretibial edema), it can be overlooked. In order to 
deal with this condition, patients can be educated about salt 
restriction, and/or the diuretic dose can be increased. Another 
important side effect of insulin is hypoglycemia. Patients with HF 
should be more careful about hypoglycemia because majority of 
the patients are using BBs.
The end-points of studies regarding insulin use in HF are 
controversial. In the CHARM trial, primary end-point was worse 
in diabetic patients using insulin than the patients not using in-
sulin (184). It can be suggested that worse outcome in the group 
receiving insulin was related to longer period of diabetes and 
more advanced stage of the disease in the group using insulin.
To summarize, a substantial number of patients need insulin; 
however, if it is used patients should be monitored regularly with 
particular attention to hypoglycemia and fluid retention.
21.0 Drug treatment in chronic obstructive 
pulmonary disease (COPD) –
İbrahim Sarı
21.1 Which beta-blocker to choose and at what dose in 
COPD? 
The concern that BBs may trigger bronchospasm in patients 
with HF accompanied by chronic obstructive pulmonary disease 
(COPD) causes the use of BBs to a lesser extent than neces-
sary in this group of patients. Investigations reveal that the most 
important reason for not using BBs or using them less than nec-
essary in patients with HF is the presence of COPD. However, 
according to current data and guideline information, the pres-
ence of COPD does not constitute a contraindication for BB use 
alone (185).
With the exception of advanced stage COPD, beta-1 selec-
tive agents (bisoprolol, metoprolol succinate, nebivolol) can be 
safely used in COPD. In a study including 35 patients with con-
current HF and COPD (186), the effects of BBs on lung functions 
were investigated. The FEV1 value (forced expiratory volume in 1 
second) was lowest with carvedilol and highest with bisoprolol 
(carvedilol 1.85 [95% CI, 1.67-2.03]; metoprolol 1.94 [95% CI, 1.73-
2.14]; bisoprolol 2.0 [95% CI, 1.79-2.22]).
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The most important matter in the use of BBs is that the start-
ing dose should be kept lower and dose incrementing be done 
more gradually than patients without COPD. It is better to be 
cautious about the use of carvedilol, a non-selective BB, in pa-
tients with COPD since it has a higher risk of causing broncho-
spasm and can prevent the bronchodilator response to beta-2 
agonists (187).
21.2 ACE inhibitor or ARB use in case of frequent cough in 
patients with COPD? 
The guidelines emphasize that ACEIs should be used in all 
patients with HF-REF unless there is a contraindication and 
ARBs in patients who cannot tolerate ACEIs.
The prevalence of COPD is approximately 20-30% in patients 
with chronic HF. The additional potential benefits of ACEIs in HF 
patients with accompanying COPD can be explained as follows: 
Angiotensin II is a potent constrictor for airways. ACEIs relieve 
the obstruction in the airways by lowering the level of angioten-
sin II. They reduce pulmonary inflammation and pulmonary vas-
cular constriction. They have favorable effects on gas exchange 
from alveolar membrane.
However, because by ACEIs might cause cough it can be 
confusing in patients with accompanying COPD. The following 
should be considered in cough complaints of HF patients with 
accompanying COPD who receive ACEIs: (1) Cough is one of 
the main symptoms of COPD. Therefore, it may be related to 
the nature of COPD, worsening of COPD or concurrent lung 
infection. It is important to know that in general COPD-related 
cough contains secretion and is productive. In this case, COPD 
treatment should be re-evaluated. There is no need to switch 
from ACEIs to ARBs. (2) Cough may be related to worsening 
of HF i.e. increased pulmonary congestion. The cause may be 
found by history, physical examination and laboratory exami-
nations (such as NT-proBNP). Initially the cough may be dry 
but by time it might become productive. In this case, the HF 
treatment should be intensified (such as increasing the diuret-
ic dose). There is no need to switch from ACEIs to ARBs. (3) In 
patients receiving ACEIs, a dry persistent cough may occur. 
Although its mechanism is not known completely, it is consid-
ered to be related to bradykinin accumulation resulting from 
slowing of the bradykinin degradation by ACEIs. Incidence of 
ACE inhibitor related cough varies from 0.5% to 25% and is 
higher in women. If the patient’s cough is considered to be 
associated with ACEIs, they should be changed with one of 
the guidelines-recommended ARBs (valsartan, candesartan or 
losartan).
The only way to understand whether the cough is associated 
with ACEI is to monitor the course of cough after discontinuation 
of the drug. In clinical practice, it may not always be easy to dif-
ferentiate which one of the abovementioned three conditions is 
associated with cough. In this case, the course of the cough can 
be monitored by switching from ACEIs to ARBs.
21.3 Which inhaled bronchodilators should be chosen in HF 
accompanied by COPD? 
COPD is a disease characterized by progressive airflow re-
striction which is not entirely reversible. Inhaled bronchodilators 
constitute the basis of treatment in symptomatic COPD patients. 
Inhaled bronchodilators are basically comprised of beta-2 ago-
nists and anticholinergics. 
Beta-2 Agonists are divided into two groups as short-acting 
(salbutamol [Ventolin] and terbutaline) and long-acting beta-2 
agonists (salmeterol [Serevent] and formoterol [Foradil, Venta-
for]). Beta-2 agonists cause bronchial smooth muscle relaxation 
by stimulating intracellular cAMP. Beta-2 agonists improve lung 
functions, reduce symptoms, increase exercise capacity, re-
duce exacerbations and improve quality of life in COPD. How-
ever, beta-2 agonists cause an increase in myocardial oxygen 
consumption by increasing the heart rate. They might cause 
hyperglycemia, hypokalemia, hypomagnesemia and QT pro-
longation. These adverse effects are more marked particularly 
with short-acting beta-2 agonists and cause more problems in 
patients with accompanying HF. Beta-2 receptors are preserved 
in number and function whereas there is reduced beta-1 recep-
tor number and activity in HF. Therefore, risk of adverse effects 
increase in patients with HF associated with the excessive car-
diovascular sympathetic response to short-acting beta-2 ago-
nists (185). The abovementioned adverse effects are observed 
much less with long-acting beta-2 agonists and long-acting 
beta-2 agonists are safer in patients with HF. Consequently, if 
a beta-2 agonist will be used in concurrent COPD and HF, long-
acting beta-2 agonists should be preferred (186).
Anticholinergics are divided into two groups as short-acting 
(ipratropium bromide) and long-acting anticholinergics (tiotro-
pium [Spriva] and aclidinium). Anticholinergics ensure bron-
chodilation by blocking muscarinic receptors. Inhaled anticho-
linergics are at least as effective as beta-2 agonists and safer 
than beta-2 agonists in terms of cardiovascular adverse effect 
profile. Therefore, they are the primarily preferred inhaled bron-
chodilators in concurrent COPD and HF (187).
There is not enough data regarding whether to use long-act-
ing beta-2 agonists or anticholinergics as first choice in concur-
rent COPD and HF. There are concerns about possible interac-
tion of beta-2 agonists with BBs used in HF, and it is known that 
the cardiovascular adverse effects of anticholinergics are less 
than beta-2 agonists. Within this context, it can be suggested 
that, at least theoretically, anticholinergics may be preferred 
over beta-2 agonists. However, it should be kept in mind that 
most of the patients require combination of these two agents.
21.4 What to do when corticosteroid is required in COPD? 
Corticosteroids are the main elements of pharmacological 
therapy in patients with COPD. Corticosteroids are frequently 
used both during and in preventing attacks in COPD. Cortico-
steroids can be used through IV or oral route or as an inhaler, 
depending on the stage and presentation of the disease. Cortico-
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steroids should be used cautiously in patients with accompany-
ing HF. Since steroids cause fluid and salt retention, they may 
cause congestion in HF patients. They should therefore be used 
for the shortest time possible. When used, inhaled forms should 
be preferred, if possible, to minimize systemic side effects.
22.0 Treatment in pulmonary hypertension
associated with left heart failure (Group-2 PH) –
Mehmet Serdar Küçükoğlu
22.1 Can PAH-specific treatment be used in severe PH 
associated with left heart disease?
Pulmonary hypertension (PH) associated with left heart dis-
ease (PH-LHD) is considered Group II PH (188) (Table 35). For 
years, valve diseases, particularly mitral stenosis, have been the 
frequent cause of PH-LHD (189). PH is detected in 15% of pa-
tients with mitral regurgitation during rest and in 46% during ex-
ercise (190). PH incidence in aortic stenosis has been reported 
as 30% (191).
Recently, Heart Failure with Preserved Ejection Fraction (HF-
PEF) has been the most frequently reported PH-LHD cause. In 
patients with HF-PEF, PH frequency and clinical properties have 
been investigated with observational studies (192). It has been 
reported that PH was observed more in patients with HF-PEF 
who have comorbidities such as advanced age, obesity, DM, 
COPD, hypertension, CAD and atrial arrhythmias.
In Heart Failure with Reduced Ejection Fraction (HF-REF), PH 
frequency varies depending on the severity of disease, PH defi-
nition used and group of patients investigated in HF-REF (193).
In PH-LHD, the treatment is intended to treat the underlying 
disease. PH regresses with surgical correction of valves and 
optimization of HF treatment. In both precapillary and postcapil-
lary PH patients with increased pulmonary vascular resistance, 
which cannot be corrected with medical and/or surgical meth-
ods, no significant benefit was observed in the trials conducted 
to investigate whether PAH-specific drugs might be beneficial 
(Table 36). The RELAX Trial conducted with sildenafil which was 
the most promising agent among current PAH-specific treat-
ments resulted in disappointment (193). In the light of current 
data, the ESC Guidelines do not recommend the use of PAH-
specific treatment in PH associated with left heart (Class III in-
dication).
22.2 Is high-dose nitrate beneficial in the presence of 
severe PH due to left heart disease? 
The physiopathology of PH comprises pulmonary vasocon-
striction, intimal and smooth muscle proliferation, in situ throm-
bosis and, pathological remodeling processes of pulmonary 
arteries. Although PH formation is accepted as being multifacto-
rial, it starts with impairments in vasodilator (NO and prostaglan-
din pathways) and vasoconstrictor (endothelin-1, angiotensin II) 
Table 36. Trials conducted with PAH-specific treatments in HF
Drug Study acronym Patient population PH as inclusion criteria Outcome
Epoprostenol FIRST HF low EF No Trial terminated early because of
   NYHA III-IV (n=471; 2y)  strong trend toward increased   
     mortality
Bosentan ENABLE HF low EF No No improvement in clinical status; 
   NYHA III-IV (n- 1613; 1.5 y)  increased risk of fluid retention
Bosentan Kaluski HF low EF Yes No difference in hemodynamic or
   NYHA III-IV (m = 94; 20 wk)  echocardiographic parameters; more  
     serious adverse events
Darusentan EARTH NYHA II-IV (n=642) No No change in cardiac remodeling or  
     outcome
Tezosentan RITZ-5 Acute pulmonary edema No No change in oxygen saturation;   
     Outcome worse with higher dose
Sildenafil Observational study HF, 6 mo (n=40) No Improved heart rate recovery with  
     sildenafil
Sildenafil Randomized study HF low EF, NYHA  Yes Reduction in PAP, peak VO2, 6-min  
   II -IV (n=34)  walk distance and fewer   
     hospitalizations
Sildenafil Observational study HF, 6 mo (n=46) No Reduction in PAP, peak VO2, and   
     ventilatory efficiency
Table 35. Current PH Clinical Classification. 2015 ESC/ERS Pulmonary 
Hypertension Guidelines (188)
Group 1 Pulmonary Arterial Hypertension (PAH)
Group 2 Pulmonary Hypertension Associated with Left Heart   
 Disease
Group 3 Pulmonary Hypertension Associated with Lung   
 Diseases and/or Hypoxia
Group 4 Chronic Thromboembolic Pulmonary Hypertension
Group 5 Pulmonary Hypertension with Unknown and/or   
 Multifactorial Mechanism
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pathways. On the basis of this information, drugs affecting the 
NO pathway (phosphodiesterase 5 inhibitors, guanylate cyclase 
stimulants), prostanoids and endothelin receptor antagonists 
have been accepted as PAH-specific treatments.
Although nitrates are used with hydralazine in special 
groups of patients in chronic HF and intravenously in acute de-
compensated HF, there is very limited information about their 
use in patients who have developed PH. Systemic hypotension 
limits their use in this group of patients. Concurrent oral nitrate 
use with sildenafil in 3 patients in one publication has given fa-
vorable results (194). Their use reduced vascular resistance and 
pulmonary pressure and did not cause systemic hypotension. 
However, it should be kept in mind that sildenafil and nitrate 
combination is contraindicated due to severe systemic hypo-
tension risk.
22.3 Can sildenafil be used in the case of severe PH 
associated with left heart disease? 
In a meta-analysis combining trials conducted in the recent 
years, it has been reported that sildenafil improved pulmonary 
hemodynamics especially in the HF-REF group and did not show 
the feared side effects (195). This meta-analysis included 6 HF-
PEF trials and 3 HF-REF trials. Evidence showed that oxygen con-
sumption and EF increased significantly in the HF-REF group and 
no clinical worsening was observed. New trials are required in 
the HF-REF group since there is no result concerning mortality in 
this meta-analysis.
Basic treatment in HF-PEF is intended to improve left ventric-
ular diastolic functions and to reduce pulmonary venous pres-
sure. However, although we have evidence that pulmonary vas-
cular disease may be the primary treatment target, this evidence 
is very limited. Endothelin receptor antagonists and prostanoid 
trials have given either neutral or unfavorable results (196). In 
two ongoing trials, ambrisentan (The Safety and Efficacy Tri-
als to Treat Diastolic Heart Failure Using Ambrisentan) and 
bosentan (The Safety and Efficacy of Bosentan in Patients with 
Diastolic Heart Failure and Secondary Pulmonary Hypertension 
(BADDHY)) are being investigated in the HF-PEF group.
Recently, much evidence has been published concerning the 
fact that prevention of cyclic GMP degradation with PDE-5 in-
hibition may be beneficial by targeting the right ventricle (RV) 
and pulmonary vessels in patients with PH associated with left 
heart disease (196). This benefit is due to PDE-5 inhibition found 
in large amounts in pulmonary arteries and intrapulmonary cir-
culation. Thus, systemic vasodilation is less.
Despite favorable studies, use of sildenafil 60 mg t.i.d has not 
shown any benefit in the RELAX (Evaluating the Effectiveness of 
Sildenafil at Improving Health Outcomes and Exercise Ability in 
People With Diastolic Heart Failure) Trial. However, pulmonary 
hemodynamics and right ventricular functions have not been 
evaluated in this trial (196). Well-planned mortality and morbidity 
trials are required to elucidate this subject.
22.4 Do beta-blockers or digoxin affect PH associated with 
left heart disease? – Mehmet Serdar Küçükoğlu
Beta-blocker therapy is one of the basic treatment options in 
left HF. However, evidence concerning their use in right HF is not 
very clear. Beyond that, their use is not recommended because 
of their possible unfavorable effects on hemodynamics and ex-
ercise capacity. There are studies reporting that discontinuing 
propranolol has favorable effects in 10 patients with portopul-
monary hypertension (197). Nevertheless, new data has shown 
that these drugs can be used safely in right HF and may prevent 
remodeling that may form in the right heart (198, 199). However, 
more trials are required about this subject.
It has been demonstrated that digoxin increased cardiac 
output in acute use. However, the efficacy of this treatment is not 
known in chronic administration. Digoxin can be administered 
to slow ventricular rate in PH with atrial tachyarrhythmia (200).
23.0 Treatment in isolated right HF –
Mehmet Serdar Küçükoğlu
23.1 Should ACEIs/ARBs, beta-blockers, or MRAs be 
administered to patients with normal left ventricular 
ejection fraction? 
The sympathetic nervous system and RAAS are activated 
in HF to compensate for cardiac output. However, chronic ac-
tivation of these systems causes HF to progress by causing 
pathological remodeling of the heart (120, 201). Therefore, ACEI 
(or ARB), BB or MRA combination blocking neurohormonal and 
sympathetic activation constitutes the basis of HF treatment. It 
is known that these systems are activated in right HF as well 
(202). For example, it has been observed that plasma epinephrine 
levels were elevated, beta-1 adrenergic receptors were “down-
regulated” in RV and heart rate variation was reduced in right 
HF (203-206). There are also trials demonstrating that RAAS is 
similarly activated (207, 208). However, there are very few trials 
that are conducted regarding the effect of treatments in right 
HF targeting these systems. For example, So et al. demonstrated 
that BB use did not cause any side effects in patients with PAH 
(199). The results of ongoing trials with bisoprolol and carvedilol 
in patients with PAH are expected to have an answer on this 
issue (209). There are trials showing that aldosterone levels are 
also increased in patients with PAH (210). In the ARIES Trials in-
vestigating the efficacy of ambrisentan in PAH, it has been re-
ported that a more favorable improvement was observed in the 
group of patients receiving spironolactone with no deaths (211). 
There is need for more prospective randomized trials in this re-
gard as well.
Consequently, it may be considered that sympathetic system 
and RAAS are activated in isolated right HF. And although there 
are limited trials concerning the benefit of suppression of these 
systems with ACEIs (or ARBs), BBs and MRAs, they may be used 
in treatment considering that the benefits received in left HF can 
be achieved in this regard as well.
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23.2 How should diuretics and nitrates be used? 
Following fluid retention in decompensated right HF, eleva-
tion in central venous pressure, enlargement in liver due to 
congestion, ascites and peripheral edema may develop. There 
are no randomized clinical trials evaluating diuretics in isolated 
right HF as in left HF. Our clinical observations show that diuretic 
therapy provides significant symptomatic benefit in patients with 
congestion. Diuretic choice and dose in isolated right HF can be 
similar to those of left HF. However, caution is recommended 
concerning hypotension that may develop due to sudden preload 
reduction. Dose up-titration is recommended according to the 
diuresis response received with lower doses. In order to pre-
vent the intravascular volume reduction that may cause prerenal 
failure, the monitorization of blood pressure, renal functions and 
blood chemistry is important (200).
There is no requirement, or enough evidence for, nitrate use. 
If it is to be used, caution is recommended due to hypotension 
and output reduction developed following preload reduction. 
Again, it should be kept in mind that concurrent use of these 
drugs with PDE-5 inhibitors may increase the risk of hypoten-
sion.
23.3 Does the treatment of isolated right HF associated 
with PH differ from left HF?
The treatment target in isolated right HF associated with PH 
is to reduce right ventricular afterload by reducing pulmonary 
pressure and pulmonary resistance. For this, the treatment of 
the cause leading to PH should be the basic target in treat-
ment. Unfortunately, for now, we do not have enough evidence 
regarding which drugs will be beneficial in right HF associated 
with PH.
23.4 What should PAH-specific treatment be in right HF 
associated with PAH (Group-1 PH)?
In right HF associated with PAH, PAH-specific treatment is 
applied as recommended in the PH guidelines (200). PAH-spe-
cific drugs are successfully used in patients with right HF with 
their RV afterload reducing effects. Although all of PAH-specific 
drugs are pulmonary vasodilators, only the effect of PDE-5 in-
hibitors have been shown on RV. Nagendran et al. demonstrated 
that PDE-5 expression increased in the myocardium of patients 
with right ventricular hypertrophy (RVH) and in the experiments 
of mice with RVH (212). It has been reported that PDE-5 inhibi-
tion caused an increase in RV contractility and a reduction in 
RV afterload in patients with RVH (200). Intranuclear receptors 
which are gene expression modulators in prostacyclin, another 
drug used in PAH treatment, can act as a ligand to PPARβ/δ. The 
protective effect of PPARγ agonists has been observed in mice 
monocrotaline and chronic hypoxic PH models by reducing pul-
monary vascular remodeling. It has been observed that PPARβ/δ 
agonists reduced RVH and RV systolic pressure in hypoxia-re-
lated PH mice models with no effect on vascular remodeling in 
this model (213).
24.0 Drug treatment in anemia – Timur Selçuk
24.1 What are the differences between Anemia and Iron 
Deficiency in HF?
The incidence of anemia in HF reported to be 17% to 22% ac-
cording to various studies. The incidence increases up to 40% in 
the registry studies. Incidence of anemia shows an increase in 
line with the worsening NYHA functional class as well (214-216). 
The prevalence of iron deficiency in HF has been detected to 
be between 5-21% in various studies (216-218). In 43% of ane-
mic patients, serum iron or ferritin levels were low; whereas the 
ratio of microcytic anemia was only 6% (219). In a small study 
conducted in 73% of the advanced HF patients with anemia and 
normal serum iron, ferritin, and erythropoietin levels, iron defi-
ciency has been demonstrated in the bone marrow (220). Serum 
ferritin levels are low in only a small number of HF patients with 
iron deficiency (221). It can be explained with the fact that iron is 
not sufficiently presented to the bone marrow in HF, hence accu-
mulates in the reticuloendothelial system and although iron and 
ferritin levels in blood are in normal or high levels, iron deficiency 
is observed more frequently in patients with HF accompanied by 
anemia.
24.2 Should Anemia/Iron Deficiency be treated with drug 
therapy in HF? 
The European Society of Cardiology Guidelines for the Diag-
nosis and Treatment of Acute and Chronic 2012 state that iron 
deficiency is a frequent comorbidity and iron deficiency may 
cause muscle dysfunction and anemia in patients with HF. The 
guidelines recommend that in the evaluation of patients with 
suspected HF, iron deficiency should be investigated by mea-
suring ferritin and transferrin saturation levels (Figure 4). How-
ever, these measurements have not been accepted as a stan-
Exclude other causes for 
anemia (GI bleeding, renal, other 
deficiencies (folic acid, vitamin 
B12 hemoglobinopatiler vs) 
If no other causes, iron treatment
Iron treatment
Yes No
Anemia
Male Hb<13g/dl
Female Hb<12g/dl
Chronic HF+Iron deficiency
(ferritin <100ng/ml or ferritin 100-299 ng/ml 
ve transferrin saturation <%20)
Figure 4. Management of anemia/iron deficiency in HF
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dard procedure yet. Iron therapy should be initiated regardless 
of presence of anemia if there is iron deficiency in patients with 
HF. If erythropoietin treatment is indicated in patients with HF, 
particularly in patients with renal dysfunction, concurrent iron 
therapy may be important due to increased iron need. In anemia 
not caused by iron deficiency, treatment strategy may change 
according to the etiology of anemia.
24.3 What are the agents that can be used in the treatment 
and what are the routes of administration?
Current data does not support the use of agents which stimu-
late erythropoiesis in the treatment of mild and moderate ane-
mia observed in patients with HF. In the studies conducted up to 
now, it has been demonstrated that, in patients with HF, use of 
agents which stimulate erythropoiesis does not provide any clini-
cal benefit, in contrast, they increased thromboembolic adverse 
events (222).
It is essential to determine the cause of anemia in HF (e.g. 
iron deficiency, vitamin B12 deficiency, folic acid, bleeding, re-
nal failure, etc.) and provide etiology-specific treatment. Iron 
absorption is generally poor in oral iron treatment. Furthermore, 
gastrointestinal side effects are observed in 60% of the patients 
receiving oral iron therapy. These problems further increase 
due to a reduction in gastrointestinal absorption in HF. There 
is lack of evidence regarding the clinical benefit of oral iron 
administration in the treatment of iron deficiency. In addition, 
it has been shown that IV iron administration improved exer-
cise capacity, cardiac functions, symptoms and quality of life 
(223, 224). Therefore, IV administration of iron in iron deficiency 
seems to be more rational in HF. However, risk of allergy and 
infection should be considered in IV iron therapy.
Blood transfusion is not recommended in HF with the excep-
tion of acute and symptomatic anemia. Blood transfusion has a 
very limited use due to its risks and its limited beneficial effect. If 
necessary, the volume status of the patient should be monitored 
carefully during blood transfusion.
25.0 Treatment in HF-PEF – Dilek Ural
25.1 Do ACEIs/ARBs have a place in the treatment of
HF-PEF? 
On the contrary to HF-REF, the role of ACEIs or ARBs in HF-
PEF patients is not clear. Major randomized, controlled clinical 
trials conducted with ACEIs and ARBs to date and their results 
are summarized in the Table 37. Although the favorable effects of 
ACEIs and ARBs on mortality in HF-PEF have been noted in obser-
vational studies, meta-analyses of randomized, controlled trials 
did not reveal any effect on all-cause mortality or other cardio-
vascular events (225-227). However, hospitalization due to HF re-
duced slightly (RR 0.88, 95% CI 0.80-0.97). The Swedish Heart Fail-
ure Registry data (228), which was published in 2012 and included 
>16,000 patients with diastolic HF, indicated that mortality benefit 
could be achieved in patients receiving >50% of the target dose of 
ACEIs or ARBs. On the basis of these evidences, main indication 
for using ACEIs or ARBs in HF-PEF is the treatment of comorbid 
conditions such as hypertension, diabetes, proteinuria, etc.
25.2 How should diuretics be used in HF-PEF?
Congestion in HF-PEF develops due to increase in pulmo-
nary capillary wedge pressure (PCWP) and subsequent PH and 
right HF, regardless of an increase in PCWP. Therefore, diuretic 
therapy is used to control fluid and sodium retention and to re-
lieve shortness of breath and edema, as in patients with HF-REF. 
Randomized, controlled trials cannot be conducted with diuret-
ics since they do not have an alternative to improve congestion. 
In the Hong Kong Diastolic Heart Failure Study, which investi-
gated the effect of diuretics alone or combined with irbesartan 
or ramipril in HF-PEF, symptoms and exercise capacity improved 
in all three treatment groups and no further benefit was shown 
with the addition of ACEI or ARB (229). Nevertheless, after one 
year treatment, both left ventricular function and NT-proBNP 
values improved in patients using diuretics with ACEI or ARB.
In ACCF/AHA guidelines, diuretic therapy is recommended 
as Class I indication in patients with HF-PEF who have symp-
Table 37. Major randomized, controlled clinical trials with ACEIs and ARBs in HF-PEF
  Trial drug Number of  Follow-up  Result
   patients (n) time (year)
Trials with ACEIs 
PEP-CHF Perindopril 4 mg o.d. 850 2.1 Perindopril did not reduce cardiovascular death in  
     elderly patients with chronic HF, however, reduced HF  
     hospitalization and increased exercise capacity
Trials with ARBs
CHARM Candesartan 32 mg o.d. 3023 3.1 Candesartan did not reduce cardiovascular death,  
     however, a slight reduction was detected in HF   
     hospitalization
I-PRESERVE Irbesartan 300 mg o.d. 4128 4.1 No reduction was detected in death or cardiovascular  
     hospitalization
ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; HF-PEF – heart failure with preserved ejection fraction
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toms due to congestion. Aggressive and long-term diuretic ther-
apy may cause postprandial or orthostatic hypotension or even 
syncope, particularly in elderly patients with HF-PEF. Therefore, 
discontinuation of diuretic treatment in patients without overt 
clinical congestion and close monitoring of symptoms may af-
fect hemodynamics more favorably by preserving intravascular 
volume and preload (230, 231).
25.3 Is beta-blocker treatment beneficial in HF-PEF? 
There is no consensus on the effect of BBs in HF-PEF pa-
tients. Theoretically, tachycardia may cause an increase in HF 
symptoms by leading to shortening of diastolic time. However, if 
there is no tachycardia, reducing the heart rate may cause pro-
longation of diastasis by leading to chronotropic incompetence. 
In this circumstance, it is wiser not to use BBs. 
Due to impairment of diastolic function in HF-PEF, increase 
in cardiac output during exercise becomes largely dependent 
on heart rate in these patients. BBs may inhibit cardiac output 
elevation by preventing physiological heart rate increase during 
exercise. Therefore, in patients with symptomatic worsening af-
ter BB initiation, it may be necessary to discontinue BBs. 
Although some observational studies, registries and their 
meta-analyses, have shown a reduction in all-cause mortal-
ity with BBs, such an effect was not detected in two relevant 
randomized, controlled trials (subgroup analysis of the SENIORS 
and J-DHF trials) (Table 38) (13, 232-234). Similarly, symptoms or 
exercise capacity have not improved in the ELANDD Trial con-
ducted with nebivolol. Therefore, the main indications of BBs in 
HF-PEF can be summarized as management of accompanying 
hypertension, ischemia, and arrhythmias.
25.4 Should MRAs be used in HF-PEF? 
In HF-PEF pathogenesis, MRs activated by aldosterone in-
volve in the formation of cardiac remodeling via sympathetic ac-
tivation, cardiac and vascular fibrosis, endothelial dysfunction, 
sodium retention and potassium loss and diastolic dysfunction. 
Therefore, the opinion that MRAs may have a favorable effect 
on HF-PEF is commonly accepted. The general conclusion of 
randomized, controlled trials conducted to test this hypothesis 
is that although MRAs did not have any effect on mortality, they 
reduced HF hospitalization, improved quality of life and, partially, 
cardiac remodeling as well as diastolic dysfunction. Recently, 
a meta-analysis that evaluated 14 randomized, controlled trials 
including Aldo-DHF (235) and TOPCAT (236) studies, no reduction 
has been demonstrated in all-cause mortality, (237) but the ratio 
of hospitalization reduced significantly (RR 0.83; p = 0.03). How-
ever, when the results from Russia and Georgia were excluded 
from the TOPCAT Trial, a significant reduction has been detected 
in the combined end-point comprised of hospitalization related 
to cardiovascular mortality, cardiac arrest or HF (RR 0.85; 95% CI 
0.74-0.96; p = 0.01).
Among current therapies, MRAs appear to be the most pref-
erable agents in patients with HF-PEF. Spironolactone 25-50 mg 
daily or eplerenone 25 mg daily were widely used in the trials. If 
MRAs are to be preferred, caution is recommended against cre-
atinine and potassium elevations, particularly in elderly patients. 
Incidence of renal failure is 1.91% and increase in potassium 
level >5.5 mmol/L is 12.15% in the meta-analyses of trials. Fur-
thermore, gynecomastia that may develop due to spironolactone 
(2.8%) may be disturbing for patients. 
25.5 Can digoxin be beneficial in HF-PEF? 
The major studies investigating the role of digoxin in HF-PEF 
are the subgroup analysis of Digitalis Investigation Group (DIG) 
Trial (DIG-PEF) (238). In this trial, digoxin did not change mortal-
ity in patients with preserved EF (EF >45%), slightly reduced HF 
hospitalization (HR 0.79; 95% CI, 0.59-1.04; p=0.094), however, in-
creased unstable angina-related hospitalization (HR 1.37; %95 CI 
0.99-1.91; p=0.061). In another subanalysis of the trial, 30-day all-
cause hospitalization increased significantly in elderly patients 
(≥65 years) using digoxin (HR 2.46, 95% CI 1.25-4.83; p=0.026) 
(239).
For now, the only indication for using digoxin in HF-PEF is to 
control ventricular rate of AF.
25.6 Can calcium channel blockers be used in HF-PEF? 
Calcium is the major electrolyte that contributes to the ac-
tive relaxation phase of diastole. Therefore, CCBs have been 
considered as favorable drugs in diastolic HF in the past years. 
In two small scale studies, the rate-limiting CCB verapamil could 
improve exercise capacity and symptoms (240, 241). Despite 
the lack of major randomized clinical trials relating this topic, 
a large registry study performed in hospitalized elderly patients 
was not able to show a change in total mortality or rate of HF 
hospitalization with prescriptions of CCBs, regardless the type 
of the CCB (242). Currently, the main indications of use for CCBs 
Table 38. Main randomized, controlled clinical trials conducted with beta-blockers in HF-PEF
  Trial drug Number of  Follow-up  Result
   patients (n) time (year)
SENIORS Nebivolol 1.25-10 mg o.d. 643 1.75 No reduction was observed in all-cause mortality or  
     cardiovascular hospitalization
J-DHF Carvedilol 2.5-20 mg o.d. 245 3.2 No reduction was observed in cardiovascular mortality  
     or hospitalization, however, in patients receiving the  
     drug above the median dose (>7.5 mg daily), the time to  
     initial occurrence of events prolonged
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in HF-PEF patients is rate control in AF (rate-limiting CCBs), 
treatment of hypertension and myocardial ischemia.
25.7 Which drugs are effective in symptom control in 
patients with HF-PEF?
The HF-PEF patients represent a quite heterogeneous group. 
The treatment should therefore be individualized according to 
each patient. The main treatment that has been shown to re-
duce symptoms is exercise (243). In a recent meta-analysis of 
6 randomized, controlled trials, it has been demonstrated that 
exercise did not have a significant effect on echocardiographic 
variables, whereas, increased cardiorespiratory fitness and 
quality of life significantly (244). Therefore, exercise/rehabilita-
tion programs should be recommended to all patients who are 
clinically eligible.
Major pharmacological agents which have been shown to 
improve quality of life are MRAs. Diuretics are used to control 
fluid and sodium retention and to relieve shortness of breath and 
edema. Efficient treatment of hypertension, myocardial isch-
emia, and ventricular rate control in AF patients are considered 
important.
25.8 Which drugs are effective in reducing 
re-hospitalization in HF-PEF? 
The major pharmacological agents that can reduce re-hos-
pitalization due to HF in patients with HF-PEF are renin-angio-
tensin-aldosterone system blockers and MRAs. In the PEP-CHF 
Trial, it has been reported that significant improvement was 
achieved in 1-year HF hospitalization and 6-min walk test with 
perindopril; however, it has been reported that these improve-
ments lost their significance at the end of 3 years due to po-
tential treatment discontinuation and substantial cross-over. In 
the CHARM-Preserved Trial, there was a significant reduction 
in HF hospitalization and the ratio of patients hospitalized alone 
with candesartan. Although the results of the TOPCAT Trial have 
suggested that spironolactone was not different from placebo 
regarding primary end-points (cardiovascular mortality, HF hos-
pitalization and resuscitated cardiac arrest), they have shown 
that it improved HF hospitalization alone significantly. 
Administering diuretics at a dose which will keep the patient in 
dry weight may also be beneficial in reducing re-hospitalization.
25.9 How important is the control of comorbid conditions in 
HF-PEF? 
Since HF-PEF patients are generally at advanced age, almost 
every patient has at least one accompanying disease and most 
of them have multiple co-morbidities (Figure 5) (245, 246). These 
diseases are important as they have to be considered in the dif-
ferential diagnosis of HF-PEF, increase mortality and morbidity of 
HF, interfere with the treatment, and cause recurrent hospitaliza-
tions if diagnosis cannot be established (247). Therefore, the pa-
tient should be considered as a whole, accompanying patholo-
gies should be detected and managed (248). The ideal solution 
for elderly patients with HF-PEF appears to be following of the 
patients by multidisciplinary geriatric clinics offering rehabilita-
tion programs.
25.10 Are there any promising novel drugs in the treatment 
of HF-PEF?
Although HF-PEF is a complicated disease with concurrent 
pathologies of different phenotypes, the basic problem is consid-
ered to be in the structure of extracellular matrix of myocardium. 
In many studies, disorders in fibrosis, collagen-I/III, titin, matrix 
metalloproteinases, TIMPs, fibrillin, fibronectin, vitronectin, cy-
tokines, and galectin-3, etc. were examined and new treatment 
targets were investigated. Recently, the importance of endothelial 
dysfunction has become more prominent. However, the absence 
of a generally accepted definition for HF-PEF and inability to con-
stitute a clear experimental model make drug researches difficult.
Novel drugs under investigation and drugs with ongoing 
clinical trials are listed in the Table 39 (249). Interventional treat-
ments other than pharmaceutical therapies may also be effec-
tive in improving the HF-PEF symptoms. Recently, attempts were 
made to reduce left atrial pressure by forming a small interatrial 
shunt through a catheter and as a result of favorable findings in 
preliminary studies, long-term follow-up studies were initiated 
(250). Atrial pacing and renal denervation are other intervention-
al treatment methods under investigation.
26.0 Heart failure therapy in patients with
advanced heart failure –
Jean Marc Weinstein
26.1 Intermittent inotropic support in symptomatic HF 
patients with severely depressed LV function: Is it helpful 
or harmful? 
Fifty per cent of patients with advanced HF will die within a 
year. Many attempts have been made to improve the survival of 
this group of patients, amongst them inotropic agents. 
These drugs, when used intravenously, (such as dobutamine, 
dopamine, milrinone, levosimendan) are generally used in the 
context of an acute decompensation of HF in patients with re-
duced ejection fraction (HFrEF), in whom haemodynamic com-
promise accompanies the congestion (251). Inotropic therapy 
has class IIa,C recommendation according to the ESC guide-
lines, (3), class I, C recommendation according to ACCF/AHA 
guidelines (4), “May be considered”, C recommendation ac-
cording to HFSA guidelines (252). Under these circumstances, 
the treatment is limited to a few days only.
Patients with severe HF awaiting heart transplantation or 
definitive mechanical support (such as left ventricular assist 
devices, LVADs), may need to be maintained on longer-term ino-
tropic support with one or more of these agents (IIa, B recom-
mendation according to ACCF/AHA guidelines (4). In addition, 
these inotropic drugs can be used as short-term haemodynamic 
support in hypotensive HFrEF patients, or long-term use as pal-
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liative care in patients not eligible for transplantation or LVAD 
(IIb, B recommendation according to ACCF/AHA guidelines (4).
The long-term intermittent use of IV inotropes is not recom-
mended, from a safety and an efficacy point of view (III-Harm-, B 
recommendation according to ACCF/AHA guidelines (4), if used 
for reasons other than palliative care.
On the other hand, evidence is accumulating of safety and 
efficacy in using these powerful agents, when lower doses are 
used, with careful monitoring.
Freimark et al. (253) presented a single-center 5-year follow-
up of patients with severe HF in a dedicated HF day-care setting. 
The patients were treated with IV diuretic combinations together 
with intermittent low dose (≤5 µg/kg/min) dobutamine, and/or 
low dose (≤3 µg/kg/min) dopamine, as well as other agents. The 
observed 29% annual mortality rate was significantly lower than 
that reported in the literature (50%). Similarly, the hospital admis-
sion rate was also remarkably low (0.6 hospitalizations/patient/
year) compared to that reported in the literature.
Several small studies have been performed, using intermit-
tent infusions of inotropes such as dobutamine or milrinone. 
However, no conclusions on mortality are possible as patient se-
lection and infusion drugs, as well as protocols, were not stan-
dardized (254). In Guglin & Kaufman’s review (254) of parenteral 
inotropic studies, they propose that the excess mortality dem-
Figure 5. Major co-morbidities in heart failure with preserved ejection fraction
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onstrated in some of the trials, results from certain common fea-
tures: they were performed with inotropic agents not currently 
in use; they were performed before automated cardioverter-de-
fibrillators were standard care for primary prevention; and they 
were performed on patients without evidence of low output HF 
and without indications for inotropes. As a result, these studies 
may not be applicable to current practice.
Recently, a panel of experts has reviewed the use of inter-
mittent levosimendan therapy (255). Over 500 patients have been 
included in studies with repetitive use of this drug in patients 
with chronic advanced HF. There were disparities in patient se-
lection, in study design and in follow-up, so that comparison be-
tween the trials and definite conclusions are difficult. However, 
the benefits of the repetitive use of levosimendan have been 
demonstrated, including improved haemodynamics, symptoms, 
rehospitalisation rates, and biomarkers. The issue of mortality, 
however, is unresolved, and requires further studies.
26.2 Is there any role for pharmacological therapy in 
reducing the severity of mitral regurgitation?
In patients with acute mitral regurgitation (MR), filling pres-
sures can be reduced with nitrates and diuretics. Reduction in 
afterload and in regurgitant fraction can be obtained with so-
dium nitroprusside or an intra-aortic balloon pump. Inotropic 
drugs and an intra-aortic balloon pump should be added in case 
of hypotension (256).
As vasodilator therapy helps in acute severe MR, intuitively 
it seems reasonable to use afterload reduction in chronic as-
ymptomatic MR with normal left ventricular (LV) function in an 
attempt to delay the need for surgery. However, the few trials 
investigating this therapy have demonstrated little or no clini-
cal benefit. Thus, in asymptomatic, normotensive patients with 
chronic significant MR and normal ejection fraction (EF), there is 
no evidence to support the use of vasodilators, including ACEIs, 
and they are therefore not recommended in these patients (256, 
Table 39. Novel drugs in heart failure with preserved ejection fraction
  Drug Trials (Phase) Results
RAAS antagonists
Direct renin inhibitors Aliskiren ALLAY Left ventricular hypertrophy reduced in
    a ratio similar to that of losartan
AT1 and neprilysin inhibitor (ARNI) LCZ696 PARAMOUNT II (Phase II) There was more reduction in NT-pro BNP
    than valsartan alone
   PARAGON (Phase III) Ongoing
cGMP-PKG pathway   
Selective PDE inhibitor Sildenafil SIDAMI There was no change in the left and right
    ventricular hemodynamics with sildenafil
    after AMI
   RELAX Effort capacity did not change after
    24 weeks
Soluble cGMP stimulation Vericiguat SOCRATES (Phase III) Ongoing
  Riociguat DILATE (Phase IIb) Favorable hemodynamic effects were
    observed
If channel blocker           Ivabradine EDIFY Ongoing
Endothelin receptor blockade
  Bosentan BADDHY (Phase III) 
Ca2+ cycle   
NCX reverse mode blocker SEA0400 Experimental 
RyR2 stabilization K201 (JTV519)  
SERCA2-mediated Ca2+ sequestration BH4 Experimental 
NO pathway   
NOS coupling BH4 Experimental 
Nitrates Isosorbide-mononitrate NEAT Ongoing
Cytokines   
Recombinant IL-1 receptor antagonist Anakinra D-HART Favorable improvement was observed in
    aerobic exercise capacity
AT1 – angiotensin 1 receptor; BH4 – tetrahydrobiopterin; cGMP – cyclic guanosine monophosphate; IL-1 – interleukin-1; NCX – sodium-calcium exchanger; NO – nitric oxide; PKG – 
protein kinase G; RAA – renin angiotensin aldosterone; RyR2 – Ryanodine receptor 2
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257). Indeed, as vasodilators decrease LV size and mitral closing 
force, they may worsen MR rather than improving it. In patients 
with hypertension, on the other hand, the hypertension must be 
controlled because of its associated morbidity and mortality and 
also because it increases LV systolic pressure and worsens MR.
AHA/ACC 2014 guidelines: CLASS III, No benefit, vasodilator 
therapy is not indicated for normotensive asymptomatic patients 
with chronic primary MR (stages B & C1) and normal systolic LV 
function, (Level of Evidence: B)
Patients with MR may eventually develop myocardial dam-
age, LV dysfunction and HF. Surgery is usually indicated once this 
stage is reached. However, in patients in whom surgery is not 
performed or is delayed, medical therapy for systolic dysfunction 
should be commenced. There is little evidence available specifi-
cally for patients with MR and LV dysfunction, but the accepted 
treatment for HF is recommended, including beta blockers, ACEIs 
or angiotensin receptor blockers (ARBs), and MRAs. Beta block-
ers have been shown to reverse LV dysfunction in experimental 
MR, and patients receiving theses agents may have better sur-
gical outcomes and delayed onset of LV dysfunction compared 
with those not taking them (3, 256, 257).
AHA/ACC 2014 guidelines: CLASS IIa, medical therapy for 
systolic dysfunction is reasonable in symptomatic patients with 
chronic primary MR (stage D) and LVEF less than 60% in whom 
surgery is not contemplated (Level of Evidence: B).
Chronic MR commonly develops as a result of severe LV dys-
function, especially when accompanied by LV dilation. In these 
patients, standard HF therapy is called for, including diuretics, 
beta blockers, ACEIs or ARBs, and MRAs. These drugs improve 
prognosis and/or symptoms in HF and probably when HF is also 
complicated by chronic secondary MR (3, 257).
AHA/ACC 2014 guidelines: CLASS I, patients with chronic 
secondary MR (stages B to D) and HF with reduced LVEF should 
receive standard GDMT therapy for HF, including ACEIs, ARBs, 
beta blockers, and/or aldosterone antagonists as indicated (Lev-
el of Evidence: A).
26.3 How to manage evidence-based therapy in hypotensive 
advanced heart failure patients 
Hypotension in occasionally seen in patients with advanced 
heart failure with reduced ejection fraction (HFrEF) and is es-
timated to be present in 5-10% of chronic HF patients. It may 
be the result of pump failure itself, or due to drug side-effects, 
since most of the evidence-based drug therapy (EBDT) involves 
agents that may lower blood pressure (BP), such as ACEI, ARBs, 
or beta-adrenoceptor blockers (BB). The finding of significant 
hypotension is very often an ominous sign, portending a poorer 
prognosis. Several questions arise when dealing with such pa-
tients (258).
1. First of all, can a reversible cause be identified and cor-
rected? Several situations may result in hypotension in HF pa-
tients, such as non-cardiac problems, including gastrointes-
tinal bleeding, sepsis, autonomic dysfunction, dehydration or 
concomitant treatment with medications that may lower blood 
pressure. Cardiac problems causing hypotension include isch-
aemic episodes or arrhythmias. All of these need to be excluded 
or treated before changing HF treatment regimens. Medications 
that may exacerbate hypotension include nitrates, CCBs, alpha-
adrenoceptor antagonists, PDEI-5 inhibitors and certain psychi-
atric agents. If possible, these drugs should be stopped.
2. Secondly, can EBDT be commenced (if the patient is not 
yet receiving it)? It should be stressed that in patients with ad-
vanced HF, low BP (as long as systolic BP remains over 80 mm 
Hg), is not a contraindication to commencing or uptitrating EBDT. 
It is often the case that on initiating therapy or on increasing the 
doses, patients may experience some lightheadedness or diz-
ziness during the first couple of days, but this almost invariably 
resolves. Once the patient’s BP stabilizes, further uptitration is 
usually continued, albeit usually at a slower rate and with small-
er increments than used in patients with a higher BP. 
3. Once EBDT is started, in order for titration to be performed, 
which drugs should be given, in which order, and at what dos-
ages? It is generally recommended to start therapy with ACEI 
before BB (3), although it also acceptable to commence in re-
verse order (59). The decision as to which drug to initiate first in 
hypotensive HF patients may be made on an individual basis. For 
example, in patients with significant tachycardia, or with a basis 
of ischaemia, it may be more appropriate to start a BB and then 
add ACEI. In addition, thought should be given to the BB used, 
thus beta-1 selective antagonists such as metoprolol may have a 
less marked hypotensive effect than carvedilol, which also has 
alpha-adrenoceptor antagonist activity.
When commencing treatment with ACEI in hypotensive pa-
tients, it may be appropriate to use a short-acting drug such as 
captopril, which could enable more flexibility with uptitration. 
EBDT stresses reaching evidence-based doses, although in 
the real world, this is often impossible to achieve for various rea-
sons (such as low BP or significant bradycardia). The question 
also arises as to whether to increase the dose of the first drug to 
recommended target levels before starting the next drug. In gen-
eral, whichever agent is chosen first, it is gradually increased and 
then the next drug is commenced, with a continual increase in 
parallel to reasonable intermediate doses. In these patients, usu-
ally the maximal doses attained are lower than the recommended 
targets. Some practical points may help, for example titrating at 
longer intervals and in smaller doses than usually accepted. An-
other useful tip is to advise the patient to take the medications 
separately and not together, and also separately from diuretics.
In asymptomatic patients with significant hypotension, the 
low BP itself is not an indication to discontinue or reduce doses of 
the important drugs such as ACEI or BB. Only in patients develop-
ing shock or signs of end-organ damage do these drugs may need 
to be temporarily stopped or their doses reduced, bearing in mind 
that this in itself may cause a deterioration in the patient’s state. 
A possible solution?
A recent study described a small group of patients with 
HFrEF and symptomatic hypotension precluding optimal medical 
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therapy, who were started on midodrine, a peripheral alpha-1 
adrenergic agonist. More patients on this drug reached higher 
doses of EBDT, resulting in greater improvements in EF and clini-
cal outcomes, such as reduction in hospital admissions, com-
pared to patients not receiving it (259). 
26.4 How to Treat Hyponatraemia in patients with 
refractory congestion
Hyponatraemia has been recognized for many years as a 
powerful adverse prognostic factor in heart failure (HF) pa-
tients. For example, in the Organized Program To Initiate Life-
Saving Treatment In Hospitalized Patients With Heart Failure 
(OPTIMIZE-HF) study, which included data on 47 647 admissions 
for acute decompensated HF (ADHF), almost 20% of the pa-
tients presented with hyponatremia, defined as a serum sodium 
level<135 mEq/L (260). These patients had significantly worse 
outcomes and were more likely to require dialysis or inotropic 
drugs. Their in-hospital mortality was also significantly higher 
compared with patients with normal serum sodium levels (6% 
vs 3.2%, p < 0.0001). Almost half of the study population had pre-
served LVEF, implying that hyponatremia is an independent pre-
dictor of outcomes in HF patients with both preserved, as well as 
reduced, LVEF (261).
Causes of hyponatraemia in HF
Dilutional: In patients with HF, the reduced cardiac output 
and blood pressure result in a drop in perfusion pressure, sensed 
by the carotid sinus baroreceptors and the afferent renal arteri-
oles. This causes the release of hormones, all of which attempt 
to correct the lower perfusion. Thus, renin secretion by the kid-
neys leads to sodium (and therefore water) retention. Renin rise 
also stimulates the increase in angiotensin II and aldosterone 
(the RAAS). Angiotensin II and noradrenaline (secreted by the 
sympathetic nervous system in response to the lowered baro-
receptor perfusion), both reduce renal perfusion which further 
increases sodium and water reabsorption. In parallel, angioten-
sin II stimulates the secretion of antidiuretic hormone (ADH, also 
called arginine vasopressin – AVP) from the posterior pituitary, 
which restricts the kidney’s secretion of free water. The end re-
sult of these interacting mechanisms is salt and fluid retention, 
worsening the oedematous state. Despite this increased volume 
state, reduced perfusion pressure on the baroreceptors and 
kidneys causes the body to perceive volume depletion, thereby 
perpetuating the vicious cycle. In addition, angiotensin II and 
reduced cardiac output both stimulate thirst, causing increased 
water intake. Hyponatraemia associated with HF is generally in 
hypervolemic patients. There is a disproportionate retention of 
both sodium and water, with the increased body fluid volume ex-
ceeding that of total sodium content, resulting in dilutional low 
serum sodium concentration.
Depletional: This situation is more common in acute gastro-
intestinal or third-space losses, clinical signs of hypovolemia, 
and recent use of diuretic agents—especially at high doses or in 
combination therapy (90).
Hyponatraemia often develops insidiously in patients with 
chronic HF, often to mild levels only, unless provoked to much 
lower levels by an additional acute factor such as increased di-
uretic use or diarrhea. Mild hyponatraemia may be asymptom-
atic or cause minimal neurological symptoms. The development 
of severe hyponatraemia (<125 meq/l), in contrast, is extremely 
dangerous, resulting in severe neurological symptoms, particu-
larly when the onset is fast. To compound matters, the correc-
tion of this state has to be managed with extreme caution, as the 
correction itself, if performed too quickly, may also cause irre-
versible brain damage in the form of central pontine myelolinysis. 
Approach to treatment of hyponatraemia
To start with, a careful history, physical examination and 
laboratory tests will aid in excluding non-cardiac causes such 
as diarrhea, drug-induced hyponatraemia or significant hyper-
glycaemia.
Depletional: In cases with a clear history of volume deple-
tion, infusing isotonic saline will raise the serum sodium levels to 
normal. In addition, replenishment of potassium and magnesium 
stores will assist in the correction of hyponatraemia.
Dilutional: Treatment of this state is based on fluid restric-
tion (1.5-2 litres a day, IIa, C recommendation by ACCF/AHA) (4), 
and the use of diuretics together with the simultaneous infusion 
of saline, all under careful clinical and biochemical monitoring. 
In terms of diuretic use, IV loop diuretics are the recommended 
treatment. Acetazolamide may be used instead of, or as well as, 
loop diuretics, but not thiazides or MRAs, which may worsen the 
hyponatraemia (and may have contributed to its onset in the first 
place). In terms of saline use, in general isotonic saline is admin-
istered, although recent reports of the use of hypertonic saline 
seem promising.
Renin angiotensin aldosteron system blockers (ACEI, ARBs) 
increase renal blood flow and decrease proximal tubular sodium 
reabsorption, thus they have an important role in normalizing the 
serum sodium level. 
AVP (ADH) receptor antagonists
There are several AVP receptors, including V1a, V1b and 
V2 receptors. The V2 receptors are mainly responsible for the 
antidiuretic response, while V1a receptors are involved in vaso-
constriction and V1b in release of adrenocorticotropic hormone. 
The AVP receptor antagonists produce a selective free water di-
uresis without affecting sodium and potassium excretion, which 
will tend to correct the hyponatremia. 
Oral AVP antagonists include tolvaptan, satavaptan and lix-
ivaptan, which are V2 selective blockers. Conivaptan is an IV V2 
and V1a blocker. Tolvaptan and conivaptan are approved for use 
in the USA for treating hyponatraemia in HF. One problem with 
these agents is an increase in thirst, and the additional oral fluid 
intake may negate the gains made in water excretion.
In patients with congestive HF, hyponatraemia and significant 
renal dysfunction, renal replacement therapy (such as haemodi-
alysis) may be necessary in removing excess fluid and aiding in 
correcting the hyponatraemia.
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27.0 Drug therapy management in HF: 
Cases from real life clinical practice 
CASE-1
Drug therapy management in a HF patient with renal 
dysfunction and anemia – Sinan Aydoğdu
Summary: Drug therapy management in a patient with newly 
diagnosed HF who is symptomatic with BP 135/85 mm Hg, heart 
rate 86 b.p.m. in sinus rhythm, in NYHA Class III, with LVEF 22%, 
NT-proBNP 11,200 pg/mL, creatinine 1.9 mg/dL, potassium 4.8 
mEq/L, Hb 10.4 g/dL, and ferritin 80 µ/L. 
Case: A 65-year-old male patient presented to our clinic 
with the complaints of dyspnea on effort which have gradually 
increased for about a month, fatigue and swelling in legs. The 
patient’s history revealed that his dyspnea on effort started ap-
proximately 3 months before; however, for the last one month he 
could not perform activities requiring even a mild effort and had 
difficulty in sleeping (NYHA Class III). The patient had no anginal 
complaints and stated that he had no regular use of drugs, only re-
ceived NSAIDs and vitamins intermittently and he was initiated on 
medical treatment with the diagnosis of HT approximately 5 years 
ago but did not receive his antihypertensive medications. BP was 
135/85 mm Hg and pulse was regular and 86 b.p.m. Cardiac sounds 
were rhythmic, S3+ and systolic 2/6 murmur was heard at mitral 
focus. Crepitant rales were present in the basal and 1/3 mid seg-
ments of lungs bilaterally on respiratory examination. There was 
jugular venous distension and ++ pitting edema in bilateral lower 
extremities. Sinus rhythm was observed in ECG. Hemoglobin (Hb) 
was measured as 10.4 g/dL and ferritin as 80 µ/L and other whole 
blood parameters were within normal limits. Blood chemistry re-
sults were: fasting blood glucose 96 mg/dL, potassium: 4.8 mEq/L, 
sodium: 138 mEq/L, serum creatinine: 1.9 mg/dL and NT-proBNP: 
11.200 pg/L. Transthoracic echo findings were: left ventricular 
end-diastolic diameter (LVEDD): 65 mm, LVEF: 22%, septal / poste-
rior wall thicknesses: 6 mm/7 mm and left atrial diameter: 48 mm. 
Left ventricular wall motion was globally and severely hypokinetic 
and he had moderate mitral regurgitation and mild tricuspid regur-
gitation. Systolic pulmonary arterial pressure (sPAP) estimated by 
tricuspid regurgitant flow was 36 mm Hg.
HF signs and symptoms, reduced LVEF and NT-proBNP of > 
300 pg/L in patient who had not received HF diagnosis allowed us 
to establish the diagnosis of HF. Briefly, according to physical ex-
amination, laboratory and imaging findings, our patient had new-
ly diagnosed HF-REF accompanied by renal failure and anemia.
In the management of drug therapy of such a patient, renal 
dysfunction and anemia should be monitored carefully. The 
causes for renal dysfunction may be renal diseases, renal con-
gestion, use of ACEI/ARB or MRAs, NSAIDs or other nephrotoxic 
drugs or dehydration. Our patient should be evaluated with re-
gard to these factors. Anemia is an unfavorable prognostic mark-
er in patients with HF.
Reducing symptoms, improving quality of life and decreasing 
hospitalization by increasing survival in the long term should be 
the treatment targets for the patient. ACEI (if not tolerated, ARB) 
and BB therapy should be initiated in our patient as with all pa-
tients with LVEF <40%. Absolute contraindications for ACEIs are 
bilateral renal artery stenosis, history of angioedema and preg-
nancy. There is no absolute contraindication in case creatinine is 
>2.5 mg/dL and/or potassium (K) is >5.0 mEq/L; however, caution 
is recommended. Since K was <5 mEq/L and creatinine was <2.5 
mg/dL in our patient, ACEI (if not tolerated, ARB) therapy should 
be initiated. The treatment should be initiated with the lowest 
dose and the dose should be titrated with at least 2 weeks’ inter-
vals and increasing to the maximum dose should be aimed. Blood 
chemistry should be repeated at 1-2 weeks after the initiation, 1-2 
weeks after the last titration and every 4 months subsequently. 
Dose reduction is not necessary until creatinine increases up to 
50% compared to baseline or is <3 mg/dL (the lower one is accept-
ed) and/or serum K level is <5.5 mmol/L (Table 40). Supplemental 
drugs and diuretic therapy that may cause the increase in potas-
sium should be discontinued and the patient should be monitored. 
If the increase in creatinine is persistent, the ACEI dose should be 
reduced and renal functions should be measured 1-2 weeks later. 
ACEI should be discontinued if increases in creatinine and potas-
sium continue. ACEIs/ARBs should be discontinued if creatinine 
increases by 100% compared to baseline or is >3.5 mg/dL and/or 
K is >5.5 mEq/L (Table 40). BBs should be initiated in all HF patients 
with EF <40%. Since our patient had renal dysfunction, one of the 
beta blockers metabolized by liver should be preferred. Adding 
mineralocorticoid receptor antagonists (MRAs) to the treatment 
should be planned if the patient is still in NYHA Class II-IV despite 
ACEI and BB therapy. If creatinine is >2.5 mg/dL and/or K is >5.0 
mmol/L, MRA use is not recommended. If the patient’s baseline 
creatinine values are between 1.5 and 2 mg/dL in females and 
2-2.5 mg/dL in males, MRAs are recommended to be initiated in 
the lowest dose. Therefore, in our patient, when starting MRA, 
daily doses of 12.5 mg for spironolactone and 25 mg for eplere-
none should be initiated. The doses should be increased with 4-8-
week intervals. Measurement of potassium and creatinine levels 
Table 40. Renal Dysfunction-ACEI / ARB Use
ACEIs/ARBs  <50% increase in creatinine 50-99% increase in creatinine  >100% increase in creatinine 
  (<3 mg/dL) and/or K<5.5 mEq/L (<3.5 mg/dL) and/or K <5.5 mEq/L (>3.5 mg/dL) and/or K >5.5 mEq/L
 Maintain the dose, prevent effects Reduce the dose, prevent effects such Discontinue treatment
 such as diuretics, potassium as diuretics, potassium replacement, 
 replacement, etc. that may cause etc. that may cause an increase in potassium
 an increase in potassium
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in blood chemistry in the first and 4th weeks following the MRA 
initiation and/or every dose increase is recommended. Subse-
quently, biochemical tests should be performed at weeks 8 and 
12, at months 6, 9 and 12 and then every 4 months. MRA should be 
discontinued immediately if serum creatinine is >3.5 mg/dL and/or 
K is >6 mEq/L (Table 41). If serum creatinine is 2.5-3.5 and/or K is 
5.5-6 mmol/L, it is recommended that the dose should be reduced 
and renal functions should be monitored closely. In the treatment 
of our patient, due to renal dysfunction, use of NSAIDs should 
be avoided and potassium supplements should be discontinued 
to minimize the potential increases in potassium and creatinine 
levels that may occur due to ACEI/ARB and MRA therapies.
Diuretic therapy should be planned in our patient due to con-
gestion signs. The target of diuretic therapy should be to prevent 
the symptoms and signs of congestion and avoid unnecessarily 
prolonged diuretic use with fluid balance monitorization. Thus, 
worsening of renal dysfunction that may be caused by diuretic 
use can be prevented. Although diuretics ensure symptomatic re-
lief, they do not affect in the rate of mortality and hospitalizations. 
Therefore, they should only be used in the presence of conges-
tion. In cases when diuretic therapy is required to be administered 
due to congestion, if progressive worsening is observed in renal 
functions (creatinine >2.5 mg/dL), MRAs should be discontinued, 
if the loop and thiazide group of diuretics are co-administered, 
the thiazide group of diuretics should be discontinued, ACEI/ARB 
dose should be reduced and if there is no response with these 
precautions, hemofiltration/dialysis should be considered.
Another problem with our patient is anemia. Anemia is as-
sociated with functional worsening, increased risk of hospital-
ization and reduction in survival. Generally, the cause of anemia 
should be investigated even though no etiology could be de-
termined. Treatable causes should be treated with a standard 
therapy. In patients in whom the cause cannot be detected, 
treatment of iron deficiency anemia with i.v. iron preparations 
is recommended. Although it does not take a place in treatment 
guidelines as class recommendation, it has been determined 
that i.v. iron preparations show favorable effects in the prognosis 
of HF in randomized trials. In patients with ferritin <100 µg and/or 
Hb 9-12 mg/L, the favorable effect of i.v. iron treatment has been 
demonstrated. However, results of the trials with erythropoietin 
stimulating agents in the treatment of anemia in HF are negative. 
Therefore, their use is not recommended.
CASE-2 
Management of drug therapy in patients diagnosed with 
HF-PEF – Necla Özer
Summary: Approach for drug therapy in a 78-year-old female 
patient with dyspnea on effort, in NYHA Class II-III, with hyper-
tension (BP 150/95 mm Hg), left ventricular hypertrophy, EF 66%, 
non-dilated LV, AF (ventricular rate 104/min.), diabetes (HbA1c 
7.2%), creatinine 1.4 mg/dL, potassium 4.2 mEq/L, and NT-proB-
NP 2400 ng/mL. 
Case: A 78-year-old female patient presented to the cardi-
ology outpatient clinic with dyspnea on effort which she had 
for a year; however, it had increased significantly in the last 2 
weeks. She had also a chest pain complaint in the form of chest 
discomfort which increases during exercise in addition to short-
ness of breath; however, she expressed that she had undergone 
coronary angiography when she presented with a chest pain 
complaint 3 months previously and her coronary arteries were 
found to be normal. Her medical history revealed that she had 
hypertension (HT), DM and chronic kidney disease (CKD) and 
received ramipril 5 mg daily, metformin 1000 mg b.i.d. In her 
physical examination blood pressure (BP) was 150/95 mm Hg 
and pulse was 98 b.p.m. (irregular) and her functional capac-
ity was in NYHA Class III. Jugular venous distension and first 
degree pitting edema in the pretibial region were detected. No 
rales or rhonchi have heard in the lung examination. Although 
the patient’s whole blood count was within normal limits, blood 
biochemistry values were: HbA1c: 7.2%, potassium: 4.2 mEq/L, 
serum creatinine: 1.4 mg/dL and NT-proBNP: 2400 ng/L. AF with 
a ventricular rate of 104 b.p.m. was detected in electrocardiog-
raphy. Echocardiographic measurements were: left ventricular 
end-diastolic diameter (LVEDD): 46 mm, LVEF: 66%, septal / pos-
terior wall thicknesses: 12 mm/12 mm, left atrial diameter: 4.3 cm, 
left atrial volume index: 36.8mL/m2, left ventricular E/E’ ratio: 9.3. 
Moderate mitral regurgitation and moderate tricuspid regurgita-
tion were detected. There was no left ventricular wall motion 
abnormality. Systolic pulmonary arterial pressure (sPAP) was 
measured as 45 mm Hg.
Increase in myocardial wall thickness, enlarged left atrium, 
increase in E/E’ ratio, elevated Nt-proBNP levels and normal 
LVEF were consistent with HF-pEF manifestation in our patient 
who presented with long-term hypertension and HF symptoms 
and signs. Since correcting conditions that are treatable with in-
terventional/surgical methods and effective medical treatments 
provide significant benefits in the management of these patients, 
the causes that may lead to diastolic dysfunction, such as CAD, 
aortic valve diseases, storage/infiltrative myocardial diseases, 
should be excluded primarily in these types of patients. CAD 
and severe valve diseases were excluded in our patient. Blood 
pressure was measured as 150/95 mm Hg. However, it was un-
derstood from her history that the patient did not receive any 
effective medical treatment. One of the most important causes 
of sudden decompensation in patients with HF-pEF is sudden 
increases in blood pressure causing an increase in afterload. 
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Table 41. Renal dysfunction - Mineralocorticoid receptor antagonists (MRA) use
MRAs Creatinine <2.5-3.5 mg/dL) and/or K=5-5.5 mEq/L Creatinine >3.5 mg/dL) and/or K >6 mEq/L
 Reduce the dose, monitor renal functions closely Discontinue treatment
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In our patient with DM and CKD, the target of blood pressure 
of <150/90 mm Hg seemed to be acceptable in accordance with 
the recently published guidelines. However, one of the important 
problems in this patient was renal dysfunction, which is one of 
the frequently observed conditions in the group of patients with 
advanced age. Before investigating the permanent causes of 
renal dysfunction, the use of both ACEIs or ARBs and hypovo-
lemia, which can be observed commonly in patients in this age 
group, should be reviewed. Moreover, renal parenchymal injury 
associated with hypertension or diabetes, secondary hyperten-
sion that may develop secondary to renal artery stenosis and 
renal dysfunction should be considered. Therefore, eliminating 
renal pathologies is very important with regard to the selection 
of medical treatment.
Based on this information, it is clear that more effective blood 
pressure control is mandatory when exclusion of CAD, elimina-
tion of secondary HT and DM and renal dysfunction develop-
ing secondary to renal dysfunction are considered. Therefore, 
when ACEI or ARB in combination with thiazide is initiated, the 
renal functions of the patient should be monitored closely. One 
of the most important subjects is the monitorization of BP in 
daily life which was controlled in-hospital setting. Considering 
that intensive antihypertensive treatment may cause orthostatic 
hypotension in this group of patients, before being discharged 
from the hospital, blood pressure must be measured in sitting 
and standing positions regarding orthostatic hypotension and, if 
necessary, it should be evaluated with a 24-hour ambulatory BP 
monitorization depending on the efficacy of the treatment and 
complaints of the patient.
Since our patient had HF-PEF, it is quite important to try to 
convert AF to sinus rhythm if possible, and if it is not, to ensure 
rate control. Digoxin use is not suitable for rate control for AF in 
these patients. BBs or CCBs may be preferred in rate control. 
OACs should also be initiated in the patient. One of the impor-
tant issues concerning our patient was that the typical history of 
angina persisting although CAD was excluded by the coronary 
angiography. In this context, third generation BBs or CCBs may 
be given to the patient in addition to the baseline treatment to 
help provide efficient BP control and reduce chest pain. Since 
our patient has AF, it makes sense to select a CCBs from the non-
dihydropyridine group (verapamil-diltiazem). Moreover, it should 
be kept in mind that intensive diuretic therapy particularly in 
HF-PEF may lead to further impairment in renal functions even if 
the patients require to receive diuretic treatment in their decom-
pensated period. Accordingly, overadministration of diuretics to 
these patients in acute decompensation period should be avoid-
ed. Further, since spironolactone administration reduces hospi-
talizations according to the results of the trials conducted with 
spironolactone, it may be considered as an additional choice.
In the light of all this information, the patient underwent 
transesophageal echocardiography (TEE) before cardioversion. 
Thrombus in the left atrial appendix was observed. With these 
findings, cardioversion was given up. Spironolactone 25 mg and 
HCTZ 25 mg combination daily, metoprolol succinate 25 mg b.i.d. 
and warfarin 5 mg o.d were added to the ramipril 5 mg therapy 
for blood pressure control, AF rate control and congestion con-
trol. In her follow-up 5 days later, BP was 145/90 mm Hg, AF rate 
was 94 b.p.m., creatinine was 1.5 mg, and potassium was 4.9 
mEq/L. Metoprolol was increased to 50 mg b.i.d. Verapamil 40 mg 
t.i.d. was added to the therapy for optimal blood pressure and AF 
rate control in the follow-up 7 days later. Dose optimization was 
planned based on the monitoring of blood pressure, AF ventricu-
lar rate and renal functions.
CASE-3
Drug therapy management in a systolic HF patient with 
hyperlipidemia and coronary artery disease – Merih Kutlu
Summary: Additional drug therapy approach in a patient with 
a diagnosis of HF in NYHA Class II, with EF 32%, NT-proBNP 4300 
pg/mL, dilated right and left ventricle, diabetes, diffuse small ves-
sel disease in coronary angiography, not suitable for coronary 
revascularization, creatinine 1.3 mg/dL, potassium 4.9 mEq/L, 
LDL-C 184 mg/dL, TG 320 mg/dL, HDL-C 28 mg/dL, AST 62 U/L, 
ALT 58 U/L who is on ACEI + BB + MRA therapy. 
Case: A 63-year-old male patient with the diagnosis of HF, 
CAD, and DM presented to the hospital with recently increased 
shortness of breath (NYHA Class II) and decrease in effort ca-
pacity. The cardiovascular system examinations were: BP 150/95 
mm Hg, heart rate 85 b.p.m., regular rhythm, normal heart and 
lung sounds. There were no signs of volume overload.
Normal sinus rhythm, R wave loss in precordial leads, non-
specific ST-T changes were detected in ECG. Transthoracic echo 
revealed right and left ventricular dilation, mild mitral insufficien-
cy with a 32% of EF. The biochemical analysis were: fasting blood 
glucose 98 mg/dL, hemoglobin 13.4 gr/dl, creatinine 1.3 mg/dL, 
potassium 4.9 mEq/L, NT-proBNP: 4300 pg/mL, LDL-C 184 mg/dL, 
TG 320 mg/dL, HDL-C 28 mg/dL, AST 62 U/L, ALT 58 U/L, troponin 
normal, uric acid: 5.7 mg/dL, HbA1C: 7% and body mass index: 27.
Coronary angiography showed diffuse CAD that was consid-
ered to be not suitable for revascularization. Patient was receiv-
ing ACEI (ramipril 2.5 mg daily), BB (metoprolol 50 mg daily), MRA 
(spironolactone 25 mg daily), and metformin (750 mg b.i.d) as an 
anti-diabetic drug. The patient stated that although his doctor 
recommended statins and acetylsalicylic acid (ASA 100 mg dai-
ly), he stopped taking them and did not comply with life style 
changes.
In summary, our patient was a HF-REF patient with CAD and 
diabetes representing a NYHA Class II dyspnea but his medica-
tions were not optimal.
The patient has the diagnosis of CAD and DM, however, was 
not receiving ASA. Therefore, ASA 100 mg o.d was initiated. Also 
according to ATP IV and ESC guidelines, the patient must have 
taken statin therapy; however, he did not. The patient whose 
LDL-C was 184 mg/dL was initiated on a high-dose statin (rosu-
vastatin 40 mg daily) in addition to the recommendations for life 
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style changes. Since the ALT and AST values of the patient were 
lower than 3 times higher the upper limit of normal, this hepatic 
abnormality was not a contraindication for statin initiation. Fi-
brate therapy was not considered at this stage because he did 
not comply with life style changes and did not use statin.
Despite the use of ACEI, BB and MRA therapy, patient has 
had dyspnea. His medications were appropriate for CAD, HF and 
DM. However, despite this treatment, BP was still mildly elevat-
ed, his resting heart rate was >70 b.p.m. and he was in NYHA 
functional class II.
In such a patient with DM, target BP should be <140/90 mm 
Hg according to JNC 8 and ASH/ISH 2014 guidelines and <140/85 
mm Hg according to the ESC Hypertension Guidelines. In terms 
of HF, the target heart rate is <70 b.p.m. in patients with sinus 
rhythm. Ramipril dose was increased to 5 mg daily and meto-
prolol dose to 100 mg daily for the goals of BP control, reducing 
heart rate to <70 b.p.m. and up-titrating the HF medications. The 
dose of MRA 25 mg daily was not changed.
The patient has a BMI of 27 and was educated in detail about 
the drugs he has been receiving, newly recommended drugs and 
lifestyle changes (such as daily drug intake, BP monitoring, heart 
rate monitoring, diet, salt restriction, exercise, weight loss). It 
was emphasized strongly that he should not discontinue statin 
and ASA therapy. Loop diuretics were not considered since 
there was no volume load. BB dose was primarily increased to 
reduce heart rate. The patient was given a BP chart and a 10 day 
follow-up was scheduled.
At 10-day follow-up visit, BP was found to be 135/85 mm Hg, 
heart rate was 66 b.p.m. with regular rhythm, creatinine was 1.3 
mg/dL and potassium was 5.1 mEq/L. Patient was recommended 
to continue the current therapy and a one-month follow-up visit 
was scheduled. Considering the drugs recently initiated and that 
the doses of which were increased, a plan was made to evalu-
ate the fasting lipid profile, ALT, AST, creatinine and potassium 
levels.
CASE-4
Management of HF therapy in a patient presenting with low 
cardiac output, borderline hypotension and hyponatremia – 
Mahmut Şahin
Summary: Drug therapy approach in a patient with HF; NYHA 
III, BP 95/70 mm Hg, heart rate 89 b.p.m. in sinus rhythm, EF 16%, 
peripheral +++ edema, NT-proBNP 8600 pg/mL, creatinine 1.4 
mg/dL, sodium 124 mEq/L, potassium 4.7 mEq/L. 
Case: A case of 73-year-old female patient was admitted to 
the hospital with a gradually increasing shortness of breath for 
the last two weeks. The functional capacity was evaluated as 
NYHA Class III. In physical examination, the blood pressure was 
95/70 mm Hg and the heart rate was 89 b.p.m. in sinus rhythm. 
Crepitant rales at the basal segments of the lungs and pretibial 
+++ edema were detected. Her medical history revealed that 
she underwent coronary angiography 7 years ago, had nor-
mal coronary arteries and a CRT-D device had been implanted 
for cardiac resynchronization 3 years ago. The patient was on 
carvedilol 6.25 mg b.i.d., ramipril 2.5 mg daily, furosemide 40 mg 
daily and digoxin 0.125 mg daily. EF was measured to be 16% and 
severe global hypokinesia was detected by transthoracic echo-
cardiography. The laboratory findings were: sodium 124 mEq/L, 
creatinine 1.4 mg/dL, potassium 4.7 mEq/L, NT-proBNP: 8600 pg/
mL. The patient was admitted to the cardiology department with 
the diagnosis of decompensated HF.
Worsening in her symptoms was considered to be due to 
congestion. Borderline hypotensive systolic blood pressure was 
considered as the sign of low cardiac output. Low sodium val-
ues were related to hypervolemic hyponatremia manifestation. 
Fluid intake was restricted to 0.5-1 L per day for the treatment of 
hyponatremia and congestive symptoms. Daily weight and urine 
output monitorization was performed. IV furosemide 40 mg b.i.d. 
was given as a diuretic therapy. Since her systolic blood pres-
sure was <100 mm Hg, IV vasodilator therapy for hemodynamic 
congestion could not have been applied. Her medical treatment 
with carvedilol, ramipril and digoxin was continued. Serum di-
goxin level was measured as 0.9 ng/mL.
Expected increase in diuresis and improvement in hypona-
tremia were not achieved despite diuretic therapy within the 
48-hours follow-up. IV furosemide infusion 10 mg per hour was 
initiated and dopamine infusion at a renal vasodilator dose of 
2 µgr/kg/min was added to increase urinary output. However, 
improvements in diuresis and hyponatremia were not achieved. 
Diuretic dose was not further increased due to the risk of both 
worsening renal functions and reducing blood pressure. Tolvap-
tan 15 mg daily was added to the therapy. Diuretic dose was 
reduced to half dose. Sodium was monitored for 8 hours in the 
first day. Following initiation of tolvaptan therapy, urinary output 
increased without worsening BP and creatinine levels. Invasive 
monitorization was not considered as it was believed to provide 
no further benefit since the clinical signs and monitorization of 
the patient were optimal. Sodium level increased to 133 mEq/L 
in the 5th day. Pretibial edema regressed significantly. Tolvap-
tan was discontinued upon detection of 10% reduction in body 
weight and relief of symptoms. Diuretic therapy continued oral-
ly. Spironolactone 25 mg daily was added to the current therapy. 
Since she could barely tolerate carvedilol 6.25 mg b.i.d. therapy 
and her BP did not allow beta blocker up-titration, she was 
discharged from hospital upon planning to initiate ivabradine 
treatment according to the level of heart rate at 7-day of her 
follow-up.
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28.0 Appendix – Hakan Altay
28.1 Angiotensin-converting enzyme inhibitors/
Angiotensin receptor blockers 
Treatment indications
Should be used in all HF patients with EF <40%. 
First line treatment in New York Heart Association (NYHA) 
Class II-IV patients; treatment should be initiated as soon as 
possible.
Also beneficial in asymptomatic patients with left ventricular 
systolic dysfunction (NYHA Class I).
Should be used in all patients who develop left ventricular 
systolic dysfunction after MI.
ARBs can be used in patients who cannot tolerate ACEIs.
Starting and target doses 
Should be started with the lowest dose and increased to the 
target or tolerated dose.
Double the dose at not less than 2-week intervals.
Starting and target doses of ACEIs/ARBs are shown in Table 
42 and Table 43.
Contraindications 
History of angioedema
Known bilateral renal artery stenosis
Pregnancy/risk of pregnancy
Conditions which require dose reduction or discontinuation 
When significant hyperkalemia (Serum K >5 meq/L) devel-
ops, first of all potassium-sparing diuretics should be discontin-
ued. If it continues, ACEI/ARB dose should be reduced.
When severe hyperkalemia develops (Serum K >5.5 meq/L), 
ACEIs/ARBs should be stopped.
ACEIs/ARBs may continue to be used until an increase in 
creatinine (Cr) of up to 50% above baseline or Cr of 3 mg/dL.
If greater rise in creatinine persists, other nephrotoxic drugs 
should be discontinued first and if there is no congestion, the 
diuretic dose should be decreased.
When there is an increase in creatinine in the range of 50-
100%, the ACEI/ARB dose should be halved and renal functions 
should be rechecked within 1-2 weeks. 
If creatinine increases by >100% or to >3.5 mg/dL or GFR <20 
mL/min/1.73 m2, ACEI/ARB should be stopped.
In case of hypotension, before discontinuing ACEI/ARB dose 
diuretic dose should be optimized and other antihypertensives 
should be discontinued first and then ACEI/ARB dose should be 
reduced.
If there is symptomatic or severe asymptomatic hypotension 
(systolic blood pressure <90 mm Hg) despite above mentioned 
precautions, ACEIs/ARBs should be stopped.
28.2 Beta-blockers
Treatment indications 
Potentially all symptomatic patients with stable systolic HF 
(EF <40%).
All patients who developed left ventricular systolic dysfunc-
tion after MI.
First-line treatment (along with ACEIs/ARBs and MRAs) in 
stable HF patients; start as early as possible in the course of dis-
ease.
Starting and target doses 
Should be started with the lowest dose and tried to increase 
to the target or maximum tolerated dose.
Double the dose at not less than 2-week intervals; slower up-
titration may be needed in some patients.
Starting and target doses of BBs are shown in Table 42 and 
Table 43.
Contraindications 
Asthma (COPD is not a contraindication)
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Table 42. Starting and target doses of drugs recommended in the ESC HF 
2012 guidelines (3)
Drug Starting dose Target dose
Angiotensin converting enzyme inhibitors
Captopril, mg, t.i.d. 6.25 50-100
Enalapril, mg, b.i.d. 2.5 10-20
Lisinopril, mg, o.d. 2.5-5 20-35
Ramipril, mg, o.d. 2.5 5 
Trandolapril, mg, o.d. 0.5 4
Perindopril, mg, o.d. 2.5 10
Angiotensin receptor blockers
Candesartan, mg, o.d. 4-8 32
Valsartan, mg, b.i.d. 40 160
Losartan, mg, o.d. 50 150
Beta-blockers
Bisoprolol, mg, o.d. 1.25 10
Carvedilol, mg, b.i.d. 3.125 25-50
Metoprolol succinate, mg, o.d. 12.5-25 200
Nebivolol, mg, o.d. 1.25 10
Mineralocorticoid receptor antagonists
Spironolactone, mg, o.d. 25 25-50
Eplerenone, mg, o.d. 25 50
Loop diuretics
Furosemide, mg 20-40 240
Bumetanide, mg 0.5-1 5
Torasemide, mg 5-10 20
Ivabradine
Ivabradine, mg, b.i.d. 5 7.5
Digoxin
Digoxin, mg, o.d. 0.125-0.25 0.25
Hydralazine – isosorbide dinitrate (H-ISDN)
H-ISDN, mg, t.i.d. 37.5/20 75/40
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2nd or 3rd degree atrioventricular block (not contraindicated in 
the presence of a pacemaker)
Conditions which require dose reduction or 
discontinuation 
Severe (NYHA Class IV) HF (should be continued as long as 
possible).
Worsening HF currently or recently (<4 weeks) (should be 
continued as long as possible).
Worsening heart block or symptomatic bradycardia (<50/min) 
Hypotension (systolic blood pressure <90 mm Hg) or low out-
put signs.
28.3 Mineralocorticoid receptor antagonists
Treatment indications
Potantially all patients with persisting symptoms (NYHA 
Class II-IV) and an EF <35% despite treatment with ACEIs (or 
ARBs) or BBs.
Patients with symptomatic HF or DM who develop systolic 
dysfunction (EF <40%) after MI.
Starting and target doses 
Should be started with the lowest dose and tried to increase 
to the target or maximum tolerated dose.
The dose should be increased every 4-8 weeks.
Potassium, creatinine and GFR are recommended to be 
checked at 1 and 4 weeks after starting or increasing dose and 
subsequently at 2, 3, 6, 9, 12 months ; 4-monthly thereafter. 
Starting and target doses of MRAs are shown in Table 42 and 
Table 43.
Contraindications 
Serum creatinine level >2.5 mg/dL in males and >2 mg/dL in 
females.
Concurrent with ACEI and ARB combination.
Concurrent with potassium-sparing diuretics.
Concurrent with potassium supplement.
Conditions which require dose reduction or 
discontinuation 
The dose should be halved if serum K rises above >5.5 mEq/ or 
creatinine rises to >2.5 mg/dL, and GFR is reduced to <30 mL/min.
It should be stopped if serum K rises to > 6mEq/L or creati-
nine to >3.5 mg/dL or GFR is reduced to <20 mL/min.
28.4 Diuretics
Treatment indications 
All HF patients with symptoms and signs of congestion inde-
pendent of EF should receive diuretics; diuretics should always 
be used concurrently with ACEIs (or ARBs), BBs and MRAs in 
patients with low EF.
Diuretic choice, dose and administration 
Generally loop diuretics are used; furosemide is the most 
commonly used agent.
If diuretic resistance occurs, it can be switched to other loop 
diuretics (bumetanide or torasemide) or thiazide-type diuretic 
can be added.
Started with a low dose and dose is reduced according to 
the patient’s congestion status, blood pressure and renal func-
tions.
The lowest possible dose that will maintain euvolemia (dry 
weight of the patient) should be used.
In the presence of severe congestion, high dose furosemide 
(oral dose x 2.5) can be administered intravenously or in bolus or 
infusion forms in the hospital setting.
Starting and maximum doses of diuretics are shown in Table 
42 and 43.
Cautions during diuretic therapy 
Severe hypokalemia (potassium <3.5 meq/L) may develop
Renal functions may worsen
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Table 43. Starting and target doses of drugs recommended in the ACC/
AHA HF 2013 guidelines (4)
Drug Starting dose Target dose
Angiotensin converting enzyme inhibitors
Captopril, mg, t.i.d. 6.25 50
Enalapril, mg, b.i.d. 2.5 10-20
Fosinopril, mg/g 5-10 40
Lisinopril, mg/g 2.5-5 20-40
Perindopril, mg/g 2 8-16
Quinapril, mg, b.i.d. 5 20
Ramipril, mg/g 1.25-2.5 10
Trandolapril, mg/g 1 4 
Angiotensin receptor blockers
Candesartan, mg/g 4-8 32
Losartan, mg/g 25-50 50-150
Valsartan, mg, b.i.d. 20-40 160 
Beta-blockers
Bisoprolol, mg/g 1.25 10
Carvedilol, mg, b.i.d. 3.125 50
Carvedilol CR, mg/g 10 80
Metoprolol succinate, mg/g 12.5-25 200
Aldosterone antagonists
Spironolactone, mg/g 12.5-25 25 (or b.i.d.)
Eplerenone, mg/g 25 50
Hydralazine – isosorbide dinitrate (H-ISDN)
Fixed dose combination, mg 37.5 hydralazine + 75 hydralazine +
  20 ISDN t.i.d.  40 ISDN t.i.d.
Hydralazine  25-50 mg, 300 mg/g
  t.i.d./q.i.d. (in divided doses)
  
 Isosorbide dinitrate 20 – 30 mg, 120 mg/g,
  t.i.d./q.i.d. (in divided doses)
+
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Severe hyponatremia (<125 meq/L) may develop when used 
with thiazide diuretics 
Symptomatic and asymptomatic hypotension (systolic blood 
pressure <90 mm Hg) may develop
28.5 Ivabradine, digoxin, hydralazine and/or nitrates 
treatment
Ivabradine 
Treatment indications 
Can be used in symptomatic (NYHA Class II-IV) patients in 
sinus rhythm with systolic HF (EF <35%) and a heart rate >70/min 
despite treatment with ACEI, BB and MRA therapy
Can be used in symptomatic (NYHA Class II-IV) patients in 
sinus rhythm with systolic HF (EF <35%) and a heart rate >70/min 
who cannot tolerate BB therapy.
Starting and target doses
Starting and target doses of ivabradine are shown in Table 42.
Side effects to consider in ivabradine use 
Symptomatic bradycardia
Visual defect (Phosphene)
Digoxin
Treatment indications 
Can be used in patients with systolic HF (EF <45%) and AF 
when rate control cannot be achieved with BBs.
Can be used in patients with systolic HF (EF <45%) in sinus 
rhythm when symptoms persist despite optimal medical treat-
ment with ACEIs/ARBs, BBs and MRAs.
Starting and maintenance doses 
There is no need for digoxin loading dose in patients whose 
clinical condition is stable.
Starting and maintenance doses of digoxin are shown in 
Table 42.
Conditions/side effects to consider in digoxin use 
The dose should be reduced in patients with advanced age, 
renal dysfunction and low muscle mass.
Drugs such as amiodarone, verapamil, diltiazem, and quini-
dine may increase digoxin serum level.
Digoxin may cause arrhythmia and heart block particularly in 
the presence of hypokalemia.
Loss of appetite, nausea, and visual impairment should sug-
gest digoxin intoxication.
Ventricular arrhythmia and advanced AV block may be ob-
served in digoxin intoxication.
Hydralazine and/or nitrates 
Treatment indications 
Hydralazine/isosorbide dinitrate may be considered as an al-
ternative to an ACEIs/ARB if neither is tolerated in systolic HF (EF 
<45%) (In addition to BBs or MRAs). 
If symptoms persist in patients with systolic HF (EF <45%) 
despite ACEI (or ARB), beta-blocker and MRA therapy, H-ISDN 
can be added.
Starting and target doses 
Starting and target doses of H-ISDN are shown in Table 42 
and Table 43.
Can be started with the lowest dose and increased to the 
target or maximum tolerated dose by increasing dose every 2-4 
weeks.
Side effects to consider in hydralazine/isosorbideuse 
May cause headache, hypotension, arthralgia, lupus-like 
syndromes.
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